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ABSTRACT 
Multidrug-resistant Neisseria gonorrhoeae (Ng) is a global health emergency. To stop the spread 
of untreatable gonorrhea, improved molecular diagnostics and characterization of antimicrobial 
resistance (AMR) determinants are crucial. For this research, I developed an RT-PCR based 
molecular diagnostic test to identify Ng as well as a second test, utilizing novel multiplex primers 
for gyrA, to simultaneously identify Ng and predict ciprofloxacin susceptibility. Although 
ciprofloxacin is no longer recommended for the treatment of gonorrhea, susceptible isolates can 
be prevalent in some regions. Thus, if the ciprofloxacin susceptibility of an isolate is known, this 
antibiotic could be used for treatment. Both the Ng diagnostic test and the test for ciprofloxacin 
susceptibility performed with high sensitivity and specificity with DNA from cultures and gave 
more variable results with clinical specimens (i.e. urines and remnant Aptima urine specimens). 
These tests were modified for the incorporation of the primers into a hydrogel-based diagnostic 
platform, for eventual point-of-care applications. The hydrogel platform performed with high 
sensitivity and specificity for Ng diagnosis, depending on the specimen type. Additionally, to 
identify emerging AMR genotypes, various genes implicated in Ng AMR resistance were 
amplified and sequenced from Ng positive remnant Aptima urine specimens (for which AMR 
testing is not possible). Phenotype predictions based on DNA sequence analysis indicated 
emerging azithromycin resistance in Saskatchewan and highlighted the importance of molecular 
AMR surveillance to prevent Ng outbreaks. Finally, the properties of a β-lactamase produced by 
an uncharacterized Ng plasmid was investigated. A novel 6bp deletion in the start codon of 
blaTEM was identified. Due to this deletion, the β-lactamase was truncated and resulted in slow 
ampicillin hydrolysis coupled with a low penicillin MIC (0.125 mg/L). Overall, my research 
produced molecular diagnostic tests for Ng and ciprofloxacin susceptibility prediction and 
characterized and predicted emerging AMR resistance by molecular analysis. 
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CHAPTER 1: INTRODUCTION 
1.1 NEISSERIA GONORRHOEAE 
1.1.1 Gonorrhea Infection 
Gonorrhea, a sexually transmitted infection (STI) caused by the pathogen Neisseria gonorrhoeae 
(the gonococcus), remains an important global public health concern with 86.9 million new 
infections worldwide each year (1). Gonococci, Gram-negative diplococci belonging to the 
Neisseriaceae family, are human restricted and are believed to have co-evolved with their human 
host for centuries (2). N. gonorrhoeae and its closely related opportunistic pathogen, Neisseria 
meningitides, are considered to have evolved from commensal Neisseria species in the pharynx 
(3). In heterosexuals, N. gonorrhoeae primarily causes urogenital tract infections resulting in 
urethritis and cervicitis in women and urethritis in men (4, 5). However, with differing sexual 
practices and norms, especially in men who have sex with men (MSM), gonococcal infections are 
more commonly reported from extragenital sites (i.e. rectum and pharynx; 2). Gonorrhea infections 
in the genital tract are largely symptomatic in men (at least 90%) but are asymptomatic or present 
with non-specific symptoms in women during the primary stages of the infection. As a result, 
gonococcal infections in many women are undiagnosed. If left untreated, ascending gonococcal 
infections can lead to severe reproductive complications such as salpingitis which in turn can result 
in pelvic inflammatory disease, ectopic pregnancy, complicated pregnancy, and infertility (2). 
Additionally, untreated infections can cause epididymitis in men. Gonococcal infections can also 
lead to the acquisition of other STIs such as Chlamydia, Mycoplasma and the Human 
Immunodeficiency Virus (HIV; 2). Furthermore, pregnant women with N. gonorrhoeae can 
transmit the infection to infants during birth resulting in ophthalmia neonatorum, a leading cause 
of blindness in newborns before the introduction of antibiotics (2). 
 
Despite the number of cases reported worldwide, there is still no vaccine to prevent infections 
caused by N. gonorrhoeae. One limitation is the lack of an ethically acceptable animal model of 
challenge. The only functional mouse model to date is female mice treated with 17β-estradiol (6) 
and transgenic mouse models expressing human receptors are currently under study (7, 8). Human 
challenge models have been conducted in men to study the early stages of colonization. This model 
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has limitations in that treatment has to be administered at the onset of first symptoms and testing 
is not permitted in women due to the higher risk of complications (9). Even though primates (i.e. 
chimpanzees) can be used as a challenge model, costs and ethical constraints of using larger 
animals hinders the use of this model. Another reason is that N. gonorrhoeae is antigenically highly 
variable and only two antigens (i.e. purified pilin and killed whole cells) have been tested in clinical 
trials, with no success (10). Third, and owing to antigenic variability, despite repeat infections 
correlates of protection have not been identified in humans (10). Without a vaccine, prevention 
largely relies on testing, especially at the onset of symptoms, partner notification, epidemiological 
surveillance, and education of safer sexual practices. Treatment relies on effective antibiotic 
therapy, where the current standard in North America is co-treatment with 1g azithromycin orally 
and 250 mg ceftriaxone intramuscularly. In the absence of ceftriaxone, 1g Azithromycin orally is 
recommended with 2g spectinomycin intramuscularly (11). In general, Canada, the United States, 
Europe, Australia and Brazil recommend dual treatment with ceftriaxone and azithromycin at 
differing concentrations for gonococcal infections. Brazil is the only nation that still recommends 
ciprofloxacin in combination with azithromycin, primarily due to lower resistance levels to 
ciprofloxacin (12). Strikingly, the United Kingdom’s 2019 STI treatment guidelines no longer 
recommend azithromycin as the first-line treatment of gonorrhea due to the alarmingly high levels 
of azithromycin resistance reported in Europe (13). Rather, the recommended treatment is mono-
therapy with 1g ceftriaxone or ciprofloxacin for susceptible infections (13).  
 
1.1.2 Prevalence of N. gonorrhoeae 
In an era of rising gonorrhea infections, a 67% increase in the number of infections was observed 
in the United States from 2013 to 2017. Similarly, an increase in the number of infections in MSM, 
at 38.5%, was noted in 2017 (14). Gonorrhea statistics from the United States date back to 1919 
(15). The rates are even more striking in Europe, where an over 200% increase was observed from 
2008 to 2017 (2). In Europe, 30% of all reported infections in 2017 stemmed from MSM (14). 
Diagnosis and treatment for gonorrhea have been provided in England and Wales since 1916 (15).  
Gonorrhea has been a notifiable disease in Canada since 1924. In 2017, 29,034 gonorrhea 
infections were reported in Canada, corresponding to a 109% increase from the reported rates in 
2008 (Figure 1.1; 17). From reported gonorrhea infections in 2017, 65% was males and 35% was 
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Figure 1.1 Number of reported gonorrhea infections in Canada from 1924 to 2017. Figure adapted from the ‘Reported cases from 1924 
to 2017 in Canada – Notifiable diseases online’ 2019. Public Health Agency of Canada. https://diseases.canada.ca/ndis/charts.php?c=pl.  
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female (16). The highest rate of infection was reported among 20-24-year-olds. Notably, the 
number of cases reported in men increased with age and the highest rate was reported among men 
over 60 years. Conversely, the number of cases reported decreased among older women (16). The 
rates of gonorrhea vary between Canadian provinces and territories. The highest rates in 2017 were 
reported from Nunavut and Northwest Territories (over 1,000 cases per 100,000 population), while 
the largest increase (610%) since 2013 was noted in the Yukon (Figure 1.2). The lowest rates were 
reported from the Maritime Provinces, followed by Ontario, British Columbia and Quebec (less 
than 100 cases per 100,000 population). Alberta, Saskatchewan and Manitoba observed high 
numbers of cases at 112, 193 and 250 cases per 100,000 population respectively (16). 
 
1.1.3 Costs Associated with N. gonorrhoeae Infection 
The economic burden of N. gonorrhoeae is striking in terms of primary health care costs, 
diagnosis, hospitalizations, long-term disabilities, and lost productivity. This cost would be 
substantially higher in the absence of proper diagnostic measures (17, 18). The estimated cost in 
Canada for hospital care for gonorrhea is CAD $247 per person per visit (19). However, detailed 
information on the economic burden of gonorrhea in Canada is lacking. In the United States, the 
lifetime direct medical costs for gonorrhea was USD $162.1 million (18). The estimated cost per 
single case of gonorrhea was USD $354 for women and USD $79 for men (20). When costs were 
assessed for diagnosis and treatment, the pelvic inflammatory disease was USD $3202 per 
individual while the cost for epididymitis in men was USD $313 per individual (20). It is important 
to note that the total costs reported here do not include costs associated with gonorrhea prevention 
measures, lost productivity and costs associated with personal suffering. Other estimates of 
productivity loss due to STIs have indicated that these costs are equal or in some cases significantly 
higher than the associated direct medical costs (18).  
 
As per estimates by the United Nations Children’s Fund (UNICEF), the costs of therapeutics and 
service delivery combined, average USD $10.71 for treatment of gonorrhea per person (21). In 
Saskatchewan, the combined cost for diagnosis of chlamydia and gonorrhea was CAD $31.50 
including specimen collection (CAD $10.50) and testing (CAD $21) (unpublished information 
from Roy Romanow Provincial Laboratory, Regina, SK). The government of Alberta has  
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Figure 1.2 Rates of reported gonorrhea infections in Canadian provinces and territories in 2017. 
Figure adapted from the ‘Report on sexually transmitted infections in Canada’, 2017. Public Health 
Agency of Canada. 
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estimated that for every dollar spent on early detection and timely treatment of gonorrhea and 
chlamydia, CAD $12 could be saved in the long term costs of delayed or non-treatment (22).  
 
A recent survey estimated the costs associated with the implementation of a national STI program, 
as part of the Global STI control strategy from 2016-2021. Here, it was found that the 
implementation itself will cost USD $18.1 billion in low and middle-income countries (21). The 
associated costs for screening are USD $3.69 billion, while a staggering USD $3 billion is 
associated with the clinical management of urethral discharges, vaginal discharges and genital 
ulcers alone (21). Embedded in this cost is USD $1.4 billion for chlamydia and gonorrhea testing 
and another USD $818 million for service delivery. It is projected that the global costs of treating 
gonorrhea and chlamydia will increase from USD $2.6 billion to over USD $4 billion within this 
5-year time frame. The 5-year cost associated with screening for gonorrhea and chlamydia 
combined is projected at USD $463,132,876 for low and middle-income countries (21). Thus, a 
cost-effective test for N. gonorrhoeae diagnosis would reduce the burden on the health care system 
and allow the implementation in resource-constrained settings. 
 
1.2 ANTIMICROBIAL RESISTANCE 
1.2.1 Overview of Antibiotics for Treating N. gonorrhoeae Infections 
Antimicrobial resistance (AMR) has been identified as a foremost threat to global health by various 
health agencies including the United States Centers for Disease Control and Prevention (CDC) and 
the World Health Organization (WHO). In September 2016, the United Nations (UN) General 
Assembly held a meeting of global leaders to engage them in the fight against AMR and to 
implement the Global action plan on AMR. It was only the 4th time in history that a health topic 
was addressed by the UN General Assembly. The problem of AMR is so severe that antibiotics 
may become ineffective within the next few decades (25). Indeed, the emergence of multidrug-
resistant, untreatable bacteria has already been described foreshadowing a post-antibiotic world. 
The rise in gonorrhea infections is partially attributed to the emergence of isolates with decreased 
susceptibility and resistance to many of the first-line antibiotics used for treatment (26). It was 
reported that 63% of Canadian isolates tested in 2017 were resistant to at least one antibiotic, where 
11.7%, 0.6% and 0.5% were resistant to azithromycin, cefixime and ceftriaxone respectively (27).  
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Extended-spectrum cephalosporins (ESC) cefixime and ceftriaxone were discovered in the latter 
part of the 1940s and introduced for gonorrhea treatment in the early 1980s. The use of ceftriaxone 
increased in response to ciprofloxacin resistance and the withdrawal of this antibiotic from 
treatment guidelines (25, 26). Cefixime was introduced for gonorrhea treatment prior to 
ceftriaxone; however reduced susceptibility was quick to emerge (11) and treatment failures were 
reported in Europe in the early 2000s (27-29) and have continued to emerge in North America, 
South Africa, Japan, Australia, Sweden, and Slovenia (30, 31).  
 
Of concern is that resistance was also reported to ceftriaxone, the last antibiotic recommended for 
monotherapy. The first ceftriaxone resistant isolate was identified in Japan in early 2000, and two 
years later resistance was also reported from Spain and France. Shortly after reports of ceftriaxone 
resistant isolates began to emerge from China, Argentina, and Singapore and treatment failures 
were reported from Australia, Japan and several European countries (32-35). Two instances of 
ceftriaxone resistant N. gonorrhoeae have been reported in Canada from 2017-2018 (36, 37). 
Despite the reported treatment failures, ceftriaxone remains the last antibiotic recommended for 
monotherapy of gonorrhea (30, 31). 
 
Azithromycin, a macrolide, was first introduced for gonorrhea treatment in the 1980s (38). The 
first resistant isolates were from Latin America in the 1990s (38, 39) and the first report of high-
level azithromycin resistance was reported in Argentina (40) These reports were soon followed by 
resistance reports of azithromycin from the Latin America, United States, China, Canada, Scotland 
and Italy, where between 2014 and 2015 even isolates with azithromycin MIC over 256 g/mL were 
reported from England (Figure 1.3; 41-44). Regina, Saskatchewan has also observed over 5% 
azithromycin resistant gonococcal isolates in 2010. However, the overall prevalence of 
azithromycin resistance in the province, and in Canada, was well below the WHO recommended 
5% cut-off limit (45); which states if more than 5% of isolates tested are resistant to a given 
antibiotic, the antibiotic should be discontinued from treatment (45). 2014 marked the first report 
of dual treatment failure (azithromycin and ceftriaxone) in the United Kingdom (46). Additionally, 
isolates with high-level azithromycin and ceftriaxone resistance were also isolated from Australia  
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Figure 1.3 Emergence of gonococcal resistance to various antibiotics for nearly 90 years. The length of the bar represents the time since 
the introduction of the antibiotic to the emergence of resistance to the given antibiotic. Figure adapted with modifications from Unemo 
et al., 2019. Gonorrhoea. Nat Rev Dis Primers. 5:79. The figure is reproduced with permission from Nat Rev Dis Primers. 
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and the United Kingdom (35, 47, 48). Consequently, azithromycin is no longer recommended as 
a first-line treatment for gonorrhea in the United Kingdom (13). Highlighting the graveness of this 
finding, a ceftriaxone resistant strain from Japan has been reported in many other countries by 
2015 (49-51). 
 
Ciprofloxacin, a fluoroquinolone antibiotic, was introduced in the late 1980s to replace tetracycline 
due to high levels of tetracycline resistance (52). Despite the observance of reduced susceptibility 
and treatment failures in 1989 and the early 1990s, ciprofloxacin was prescribed as a monotherapy 
for almost two decades and was removed from recommendations in the United States, Canada, 
Europe and Asia only in mid-2000s (38, 53-55). However, isolated communities with 
ciprofloxacin susceptible isolates in Canada, the United States, Europe and Australia hold promise 
in re-introducing this antibiotic for treatment (45, 56-58).  
 
First introduced in 1943, resistance to penicillin in N. gonorrhoeae was observed in the early 1950s 
but was prescribed until the 1980s at increasingly higher concentrations (15, 59, 60). In 1950s 
tetracycline was introduced for the treatment of penicillin-allergic individuals (61). However, by 
1985 high-level tetracycline resistance was observed in the United States and was no longer 
recommended for treatment (61, 62). Sulfonamides, the first antibiotic for gonococcal treatment, 
was introduced in the 1930s, and less than 15 years later more than 75% of treatment failures were 
reported (Figure 1.3; 63, 64). Combined sulfonamides and trimethoprim treatment was used until 
the 1970s (65, 66). Even at least one documented gonorrhea treatment failure with doxycycline 
was reported from France in 2017 (67). 
 
1.2.2 Antibiotic Resistance Mechanisms 
Drug resistance in N. gonorrhoeae arises through a multitude of mechanisms including both 
chromosomal and plasmid-mediated. Remarkably, the accumulation of resistance determinants 
does not affect gonococcal fitness (2). Resistance to ESCs can arise through mutations in penA 
(PBP2), penB (PorB), ponA (PBP1) and/or mtrR (MtrR). Furthermore, it is speculated that there 
remain unknown mechanisms of ESC resistance and are termed ‘factor X’ (25, 26). Cefixime 
resistance is primarily driven by substitutions in penA (A501V, I312M, V316T, G545S, A501V 
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and N512Y), while porB (G120K/A121N/S, G120K/A121G) and mtrR (A-, A38T, G45D) 
alterations also play minor roles (11).  
 
As ceftriaxone binds PBP2 with high affinity, penA remains the main resistant determinant (G542S 
and P551S/L) for ceftriaxone (11). Accumulation of mutations in penA alters the structure of PBP2 
and prevents ceftriaxone binding (Figure 1.4). penA mutations arise through single nucleotide 
polymorphisms (SNPs) and genetic recombination between N. gonorrhoeae and other commensal 
Neisseria species, which result in mosaic penA alleles (11, 25, 38, 68). Compared to wild-type, 
mosaic penA alleles encoding PBP2 can contain up to 60 amino acid changes. Two of the well 
known mosaic penA alleles implicated in ESC resistance is penA type X with A311V, A328T, 
T316P and T484S substitutions, and penA type XXXIV with A501P substitution (34, 69, 70). 
Highlighting the gravity of emerging ceftriaxone resistance, recently a Canadian report identified 
a ceftriaxone resistant FC428 N. gonorrhoeae clone, which was originally identified in Japan (71). 
Additionally, ceftriaxone resistance clones F90, GK124 and IR72 have been reported from France, 
Denmark and Ireland respectively (61, 72, 73). 
 
Azithromycin works by preventing the elongation of the peptidyl transferase polypeptide chain 
within the ribosomal subunit (74, 75) and resistance arises through several mechanisms (Figure 
1.4). Primarily resistance is driven by mutations in 23S rRNA, where A2059G and C2599T 
substitutions in 1-4 alleles encoding 23S rRNA result in high-level resistance, while C2611T 
substitution results in low-level resistance (11, 76). Although mutations in single alleles do not 
have a profound effect on azithromycin MICs, high-level resistance was reported when these 
substitutions occur in all four alleles (77-80). Furthermore, low-level resistance to azithromycin is 
mediated by rRNA methylases (ermB, ermC and ermF) that methylate a single adenine at position 
2058 of the 23S rRNA peptidyl transferase domain, preventing macrolide interaction with the 
ribosome (38, 77, 81). Additionally, overexpression of the multiple transferable resistance efflux 
pump (MtrCDE) through mutations in mtrR (A-, A38T, and G45D) repressor can elevate 
azithromycin MIC to 0.5 g/mL (82, 83), and mutations in the L4 ribosomal protein, which comes 
in to contact with the peptidyl transferase of 23S rRNA, can influence the RNA confirmation (83-
86). Although not common, overexpression of MacAB efflux pump and mef encoded efflux pump 
can also decrease susceptibility by exporting azithromycin out of the cell (38, 74).  
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Figure 1.4 Antibiotics and their respective resistance mechanisms in the gonococcus. Figure adapted from Dillon et al., 2015. Culture. 
35:1. The figure is reproduced with permission from Thermo Scientific. 
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Ciprofloxacin influences DNA gyrase and topoisomerase IV activity, which affect DNA 
replication, recombination, transcription and repair mechanisms (11). Ciprofloxacin resistance in 
gonococci is mediated through substitutions in the quinolone resistance determining region 
(QRDR), namely within the nucleotide sequences of DNA gyrase A (gyrA) and topoisomerase IV 
(parC; 87). Substitutions in GyrA S91 (S91F/Y), A92 (A92P) and D95 (D91A/G/N) positions 
alone are associated with resistance (88-90). However, combined GyrA and ParC (D86N, S87R/N, 
S88P, and E91K) substitutions lead to ciprofloxacin MIC over 32 g/mL (74, 91, 92). 
 
Tetracycline binds to the bacterial 30S ribosomal subunit and prevents protein synthesis (93, 94). 
Similar to penicillin resistance, porB (G120K/A121N, A121S, G120N/A121G) and mtrR (A-, 
A38T, G45D) mutations also produce tetracycline resistance (59, 95). An additional substitution 
(V57M) in the 10S ribosomal protein (rpsJ) can elevate tetracycline MICs to over 2 g/mL (Figure 
1.4; 88, 104). In addition to chromosomal resistance, TetM (tetM) produced by conjugative 
plasmids prevents tetracycline from binding to the ribosome and leads to high-level tetracycline 
resistance (38, 59, 61).  
 
Penicillin works in the periplasm and prevents bacterial cell wall synthesis by binding to penicillin-
binding proteins (PBP; transpeptidase enzymes). Resistance to penicillin occurs through mutations 
in penA, ponA, penB, and mtrR. Here penB (porin protein B; PorB) and mtrR (multiple transferable 
resistance transcriptional repressor of MtrCDE efflux pump; MtrR) works by regulating the 
antibiotic concentration in the cell, while penA (penicillin-binding protein 2; PBP2) and ponA 
(penicillin-binding protein 1; PBP1) works by altering the PBP structure (Figure 1.4; 74, 97).  
 
Acquisition of mutations in penA, mtrR, porB and ponA have been associated with stepwise 
increases in MICs to penicillin. The 345D insertion in PBP2, along with an additional 4 to 8 
substitutions (i.e. F504L, A510V, A516G, H541N, P552V, K555Q, I556V, and I557V) in penA 
lead to an intermediate MIC to penicillin (95, 98, 99). The L421P substitution in PBP1 decreases 
the acylation with the β-lactam structure in β-lactam antibiotics, while G120K/N and A121D/G/N 
substitutions in PorB are associated with elevated MICs to penicillin (11, 100, 101). Importantly, 
PorB substitutions and elevated MICs to penicillin were noted only when the MtrCDE efflux pump 
was also overexpressed (102). Overexpression of MtrR elevates MICs not only of penicillin but 
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also of tetracycline and macrolides (103, 104). This is achieved through a single nucleotide 
deletion (A-) or a dinucleotide insertion (AA) in the mtrR promoter and A38T or G45D 
substitutions in MtrR (82, 104, 105).  
 
Chromosomally mediated resistance mechanisms lead to penicillin MICs of up to 4 mg/L. In the 
1970s, penicillin MIC up to 128 g/mL were observed (34, 106) and were attributed to a plasmid-
mediated β-lactamases. Gonococcal isolates with β-lactamase producing plasmids are known as 
penicillinase-producing N. gonorrhoeae (PPNG; 104, 105). Over the years, seven genetically 
related β-lactamase producing plasmids with various insertions and deletions have been identified 
in N. gonorrhoeae and these plasmids were named according to their geographical origin, namely 
Asia, Africa, Toronto/Rio, Nimes, New Zealand, Johannesburg and Australia (106-109).  
 
Sulfonamides act by competing for dihydropteroate synthetase (DHPS), an enzyme in the folic 
acid biosynthesis pathway (Figure 1.4). Gonococci have developed mechanisms to overproduce 
p-aminobenzoic acid, the substrate for DHPS to develop sulfonamide resistance, or to mutate folP 
(dihydropteroate synthase) to synthesize a mutated DHPS that has low affinity to sulfonamides 
(59). Similar to sulfonamides, trimethoprim works on the folic acid synthesis pathway by 
inhibiting the activity of dihydrofolate reductase (DHFR). However, N. gonorrhoeae is less 
sensitive to this antibiotic because gonococcal DHFR has a low affinity for trimethoprim (59, 110, 
111).  
 
1.3 N. GONORRHOEAE SURVEILLANCE  
1.3.1 Typing Methods  
Isolate tracking by using strain differentiation techniques is vital to identify the clonal spread of 
N. gonorrhoeae in a population (112). In response, over the years several typing schemes for N. 
gonorrhoeae, from phenotypic to next-generation sequencing, have emerged (113). Typing 
increases gonococcal surveillance and epidemiological awareness, traces the evolutionary history 
and measures population dynamics of the pathogen, while providing contact tracing and rational 
treatment, and facilitates control and prevention initiatives (112, 114).  
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The N. gonorrhoeae multiantigen sequence typing (NG-MAST) scheme (http://www.ng-
mast.net/) is based on sequence analyses of two highly polymorphic genes, porB and tbpB (115). 
Upon sequence submission of porB and tbpB, sequence types are assigned separately to both of 
these genes and a final NG-MAST number is assigned to the isolate harbouring the given 
porB/tbpB sequencing pattern (115). NG-MAST analysis is useful if a higher discriminatory power 
between the isolates is required, i.e. to differentiate large porB based N. gonorrhoeae clusters 
(115).  
 
In contrast to the NG-MAST, multilocus sequence typing (MLST) scheme for N. gonorrhoeae 
(https://pubmlst.org/neisseria/) is based on sequence analysis of a panel of conserved 
housekeeping genes in N. gonorrhoeae (eg. porA, porB, fetA, fHbp, nadA, and NHBA) and 
represents genetic variation in the N. gonorrhoeae population (112, 116). Due to the presence of 
conserved loci and their slow accumulation of mutations, these genes reflect the spread and the 
natural evolution of gonococci. However, MLST typing schemes are more suitable for the long 
term and large scale global epidemiological analyses, while NG-MAST is more suitable for 
analyzing short term and local outbreaks (114, 115).   
 
Recently, a curated web-based sequence typing scheme, N. gonorrhoeae sequence typing for 
antimicrobial resistance (NG-STAR; https://ngstar.canada.ca/alleles/query?lang=en), was 
introduced (117). Using DNA sequences of seven known AMR determinants (penA, mtrR, porB, 
ponA, gyrA, parC, and 23S rRNA), this scheme identifies specific mutations leading to antibiotic 
resistance in N. gonorrhoeae isolates and assign sequence types (117). Based on the mutations, a 
MIC value for each antibiotic is also predicted. 
 
Although almost every nucleic acid-based typing method is suitable for N. gonorrhoeae molecular 
surveillance, these analyses have been mostly limited to retrospective studies. Sequencing whole 
genomes from N. gonorrhoeae positive clinical specimens or cultures can simultaneously provide 
an in-depth analysis of the prevalence of AMR and strain types. Already a whole-genome 
sequencing (WGS) based platform, Gen2Epi (ftp://www.cs.usask.ca/pub/combi), integrating NG-
MAST, MLST and NG-STAR, has been developed and tested with a large repository of N. 
gonorrhoeae genomes (118). The increase in WGS data allows robust AMR determination from 
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gonococcal isolates, especially because WGS has “superior resolution” in tracking disease 
transmission and outbreak spreading compared with conventional methods such as NG-MAST and 
MLST (119, 120). Furthermore, WGS has facilitated the monitoring of the AMR evolution in N. 
gonorrhoeae and the development of countermeasures to address this by identifying mutations 
leading to drug resistance in N. gonorrhoeae (121). Thus, the development of WGS has 
revolutionized the characterization of microbial isolates such as N. gonorrhoeae and has impacted 
typing methods, genetic analyses, transmission and epidemiological surveillance studies.  
 
1.4 SCREENING AND DIAGNOSIS 
1.4.1 Microscopy 
Despite the availability of more advanced molecular tests, microscopic diagnosis is still used 
(Table 1.1). The hallmark of N. gonorrhoeae is Gram-negative diplococci within 
polymorphonuclear leucocytes under the field of a light microscope. However, the sensitivity and 
specificity of the Gram stain depend on the specimen type, where higher sensitivities are observed 
with urethral swab specimens from symptomatic males (122-125). Lower bacterial load from 
asymptomatic males and endocervical specimens, especially when a large number of other 
bacterial species are also present, makes it challenging for Gram stain-based diagnosis of 
gonorrhea. The Gram stain is not recommended for the diagnosis of rectal specimens due to low 
sensitivity (≤40%) and pharyngeal specimens due to the presence of commensal Neisseria species. 
Alternatively, methylene blue staining, instead of Gram staining, has also been used for the 
diagnosis of gonorrhea (124-127). In instances of obvious symptoms, (i.e. purulent discharge from 
the urethra) a Gram stain is sufficient to confirm N. gonorrhoeae infection. However, culturing 
accompanied by biochemical tests is required for asymptomatic genital infections and extragenital 
infections such as pharyngeal, rectal and ocular sites (2, 128).  
 
1.4.2 Culture 
For decades, culture has been the gold standard for gonococcal diagnosis and remains the only 
means of diagnosis in remote settings where more expensive molecular diagnostic methods are    
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Table 1.1 Comparison of diagnostic methods for N. gonorrhoeae. Table adapted from Unemo et 
al., 2019. Gonorrhoea. Nat Rev Dis Primers. 5:79. The table is reproduced with permission from 
Nat Rev Dis Primers. 
 
Parameter Microscopy Culture NAAT 
Specimen types    
Urine No No Yesa 
Urethral swab Yes Yes Yes 
Rectal swab No Yes Yes/nob 
Pharyngeal swab No Yes Yes/nob 
Conjunctival swab Yes Yes Yes/nob 
Performance    
Sensitivityc Low-high Moderate-high Very high 
Specificityc Moderate-high Very high Moderate-very high 
Cost Low Moderate Moderate-very high 
Instrumentation Microscope Routine microbiology Moderate-large 
footprint 
Technical complexity Low-moderate Moderate Low-high 
Level of laboratory 
infrastructure 
Low Low-intermediate Intermediate-high 
Potential as a POCT Yes No Yes 
aSensitivity of urine specimens can be lower than with other specimen types and a negative result 
does not exclude gonococcal infection.  
bNot all platforms have received FDA approval for the given specimen.  
cSensitivity and specificity depend on the specimen type. 
 
  
17 
unaffordable. Furthermore, culture is required to perform subsequent biochemical characterization 
tests. Culture is still the method recommended for pelvic inflammatory disease, cases of sexual 
abuse, treatment failures and AMR testing (123-125, 129). Specimens for culture should be 
obtained at least two days post-exposure, as samples collected sooner may fail to grow. As with 
Gram staining, the sensitivity of culture depends on a combination of factors (Table 1.1). The 
method of sample collection and transportation is vital for culturing as the viability of the organism 
depends on sample handling and proper transportation. The viability of gonococci can be preserved 
up to 12h at room temperature when transport swab systems (with or without charcoal) are used 
(130). Depending on the size of the inoculation, viability may be prolonged. JEMBEC plates 
containing Martin-Lewis agar and a CO2 generating tablet, as well as chocolate agar slants are also 
acceptable means of transportation (130). 
 
The anatomical site of the specimen, growth media and incubation conditions also play a role in 
the growth of cultured specimens (Table 1.1; 124, 125, 129). Sensitivities of culture also depend 
on the expertise of the laboratory personnel. For example, sensitivities for urogenital specimens 
range from 72-95%, while the same specimen cultured by an experienced technician could give a 
95-100% sensitivity (2, 124, 125). Upon arrival, the specimen should be inoculated on selective 
agar (i.e. Thayer-Martin, New York City, Martin Lewis medium) with antimicrobials (i.e. 
vancomycin, colistin, trimethoprim, nystatin, amphotericin and/or anisomycin) to inhibit the 
growth of commensal bacteria and fungi (130). Following inoculation, plates should be incubated 
at 35-37°C with 5% CO2 in a humid environment for 18 to 24h (38). Subsequent to primary 
isolation on selective media, isolates should be subcultured on non-selective media (i.e. 
gonococcal (GC) medium base or chocolate agar supplemented with 1% Kellogg’s defined 
supplement) prior to being used for additional confirmatory tests (38, 130). 
 
From cultured bacteria, it is important to distinguish between N. gonorrhoeae and other 
commensal Neisseria species. Thus, the primary selection of cultured isolates is based on colony 
morphology, Gram stain and oxidase testing (125-127). For confirmatory testing, biochemical 
tests, chromogenic enzyme substrates and serological tests are also used. A detailed description of 
these tests is beyond the scope of this discussion (2, 130).  
A significant advantage of culture is that minimum inhibitory concentration (MIC) testing of 
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various antibiotics to N. gonorrhoeae is only possible with culture at present. MIC testing of N. 
gonorrhoeae is performed on GC medium base with additional supplements (i.e. Kellogg’s defined 
supplement). MICs are traditionally determined either with agar dilution or disk diffusion methods 
(25). However, many laboratories now choose to use E-tests due to their ease of use (i.e. less labour 
intensive and faster compared to the Agar dilution method). When testing MICs for new isolates, 
a panel of isolates with well-established MIC values should always be used in parallel for 
comparison (38). Regardless of the method used, results should be evaluated against the Clinical 
and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) breakpoints for each antibiotic (25, 131) 
 
1.4.3 Nucleic Acid Amplification Tests 
In contrast to traditional diagnostic methods for N. gonorrhoeae, nucleic acid amplification tests 
(NAATs) provide superior sensitivity and specificity and are now the first choice for diagnosis in 
most high-income settings (Table 1.1). NAATs are more appealing to clinicians and for laboratory 
personnel due to their ease of specimen handling (i.e. viability of the organism is not a concern), 
non-invasive specimen collection (i.e urine and self-collected vaginal swabs), rapidity, 
simultaneous detection of multiple STI pathogens (i.e. N. gonorrhoeae and C. trachomatis) and a 
non-requirement for highly skilled laboratory technicians such as with culturing (123, 126, 132-
134).  
 
There are also many in-house PCR based molecular tests for gonococcal diagnosis (135-138). 
These tests are widely used in low-income settings and have not been validated by regulatory 
agencies such as the United States Food and Drug Administration (FDA) and the European 
Conformity (CE; 2). Almost all the NAATs used in high-income settings have been validated by 
regulatory agencies for their performance with various clinical specimens (Table 1.2). 
 
NAATs are more sensitive to N. gonorrhoeae diagnosis than cultures. FDA and CE-in-vitro 
diagnostic (CE-IVD) approved NAATs for N. gonorrhoeae are grouped into three categories: 
PCR, strand displacement amplification, and transcription-mediated amplification (Table 1.2).  
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Table 1.2 FDA and CE-IVD approved Nucleic acid amplification tests for the diagnosis of N. gonorrhoeae. Table adapted from Unemo 
et al., 2019. Gonorrhoea. Nat Rev Dis Primers. 5:79. The table is reproduced with permission from Nat Rev Dis Primers. 
 
Test, instrument 
(manufacturer) 
Gonococcal 
target(s) 
Specimen 
Type or 
Cultured 
isolate 
Sensitivity (%) Specificity (%) 
Symptomatic Asymptomatic Symptomatic Asymptomatic 
PCR 
Real-Time 
CT/NGa, m2000b 
(Abbott 
Molecular) 
 
opa  SCVS (F) 96.7-98 95.7 99.7-100 100 
CCVS (F) 96.8 95.7 99.9 99.4 
ECS (F) 87.1 91.3 99.7 100 
FVU (F) 76.9 NA   99.8 NA 
Urine (F) 93.8 87 99.7 99.6 
Urethral (M) 99.2 81.8 99.3 99.8 
Urine (M) 98.8 100 99.5 100 
Urine (M/F) 100 NA 100 NA 
Culture 
 
99.5 NA 100 NA 
Xpert CT/NGa,c,d, 
GeneXpert 
(Cepheid)b 
 
Two (NG2, NG4) 
highly conserved, 
noncontiguous 
unique 
chromosomal 
targets 
VS (F) 100 100 99.8 99.9 
ECS (F) 100 100 100 100 
Urine (F) 100 91.7 100 99.9 
Urine (M) 97.8 100 100 99.9 
Culture 
 
100 NA 100 NA 
Cobas 4800 
CT/NGa, Cobas 
4800b (Roche)  
 
Direct repeat 
region 9 (DR9) 
SCVS (F) 84.6 NA 99.6 NA 
FVU (F) 81.1 NA 100 NA 
Urine (M/F) 92.9 NA 100 NA 
Urogenital 
(F) 
97.5 NA 100 NA 
Urogenital 
(M) 
100 NA 100 NA 
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Nongenital 
(F) 
100 NA 100 NA 
Nongenital 
(M) 
100 NA 99.8 NA 
Culture 100 NA 100 NA 
BD MAXe, BD 
Max System 
(Becton-
Dickinson) 
Chromosomal 
DNA 
VS 96.3 94.1 99.8 99.9 
ECS 96.3 94.1 99.9 100 
Urine (F) 100 88.9 99.9 99.5 
Urine (M) 
 
NA 80 NA 100 
Strand displacement amplification 
Probe Tec ETe, 
Viper XTR 
(Becton-
Dickinson) 
 
Pilin gene-
inverting protein 
homologue 
SCVS (F) 90.6-100 NA 100 NA 
ECS (F) 87.5 91.3 99.6 98.9 
FVU (F) 75.5 NA 100 NA 
Urine (F) 76.7 85.7 95.6 96.9 
Urine (M) 94.9 100 97 95.7 
Urine (M/F) 95.8 NA 100 NA 
SCRS (M) 77.1 NA 99.3 NA 
CCRS (M) 67.5 NA 100 NA 
PS (M) 85.7 NA 100 NA 
Rectal (M) 89.1 NA 99.8 NA 
Culture 
 
100 NA 88.9 NA 
Transcription mediated amplification 
Aptima Combo 
2a,d, Pantherb 
(Hologic (earlier 
Gen-Probe) 
 
16S rRNA SCVS (F) 96.2-100 NA 98.4-100 NA 
CCVS (F) 93.8 95.7 99.3 99.7 
ECS (F) 90.6 90.9 99.4 99.7 
FVU (F) 88 NA 99.4 NA 
Urine (F) 84.4 82.6 99.6 99.4 
Urethral (M) 99.2 81.8 99.2 99.7 
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Urine (M) 97.9 100 99.7 99.5 
Urine (M/F) 100 NA 100 NA 
SCRS (M) 84.3 NA 100 NA 
CCRS (M) 78.3 NA 99.8 NA 
PS (M) 100 NA 99.6 NA 
Rectal (M) 93.5 NA 97.7 NA 
Culture 100 NA 100 NA 
CCRS, clinician-collected rectal swab; CCVS, clinician-collected vaginal swabs; ECS, endocervical swab; FVU, first void urine; PS, 
pharyngeal swabs; SCRS, self-collected rectal swab; SCVS, self-collected vaginal swabs; VS, vaginal swabs; F, female; M, male; NA, 
not applicable. 
aCan also detect Chlamydia trachomatis 
bFully automated 
cCartridge based near-point-of-care test 
dFDA approved for extragenital specimens such as rectal and pharyngeal 
eCan also detect C. trachomatis and Trichomonas vaginalis 
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PCR based NAATs include RealTime CT/NG (Abbott Molecular), Xpert CT/NG (Cepheid), 
Cobas 4800 CT/NG (Roche), and BD MAX (Becton-Dickinson). Strand displacement and 
transcription-mediated NAATs include Probe Tec ET (Becton-Dickinson) and Aptima Combo 2 
(Hologic), respectively. Although many NAATs for N. gonorrhoeae diagnosis use genital 
specimens (Table 1.2), two of the most widely used NAATs (Aptima Combo 2 and Xpert CT/NG) 
have recently received FDA approval for extragenital specimen testing (139). Nonetheless, a 
second confirmatory target or test will be useful for pharyngeal specimens, as many commensal 
Neisseria species residing in the pharynx could provide false-positive results (133, 140).  
 
A significant disadvantage of all the approved commercial NAATs is the inability to characterize 
an isolate’s AMR profile. However, there are NAATs in development that can predict the N. 
gonorrhoeae susceptibility to ciprofloxacin and one such test, Resistance Plus GC (SpeeDx), has 
recently received FDA approval and is currently being used in the United States and Europe (13, 
134). Furthermore, and especially due to the lack of AMR testing by approved NAATs, remnant 
NAAT specimens (i.e. remnant Aptima urine specimens from Hologic Aptima Combo 2 Assay) 
have been used by a few researchers to identify evolving AMR patterns in gonococci (141-146). 
Nonetheless, such testing has been hindered by nucleic acid (i.e. DNA) degradation due to the 
Aptima buffer (143, 147). 
 
With the rise of NAATs, there has also been an increase in the number of gonorrhea infections 
diagnosed. In 2017, the Canadian National Microbiology Laboratory reported that 70% of 
gonorrhea cases in Canada were identified using NAATs (24, 148-150). The rise in gonorrhea 
infections is not only attributed to higher sensitivities of NAATs, but also to the larger number of 
specimens diagnosed per day and varying sexual practices and more patients seeking treatment 
due to more acceptance (especially in high-income settings) of their sexual orientations (i.e. MSM 
and bisexual individuals; 143, 151). 
 
1.4.4 Point-of-Care Tests 
Due to the widespread use of NAATs, AMR testing of N. gonorrhoeae isolates has significantly 
declined in resource-rich countries (6, 152). AMR testing is often beyond the technical capabilities 
of resource-limited settings because this requires expensive reagents and highly skilled personnel. 
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Although several studies have utilized remnant NAAT specimens, the focus was largely on either 
bacterial load detection or only explored a limited number of markers related to ESC or 
ciprofloxacin resistance (7-9). However, due to the lack of AMR surveillance globally, the total 
burden of N. gonorrhoeae AMR remains incomplete (5). A recent study noted ESC resistance in 
9.4% isolates while 18.8% isolates were multidrug-resistant (153). This study highlights the 
importance of continuous surveillance to prevent the spread of AMR among gonococci.  
 
This calls for a near-patient test (i.e. point-of-care tests; POCTs) that can identify an isolate’s 
resistance profile to an antibiotic at local health settings. Rapid (i.e. real-time) determination of 
AMR status will facilitate evidence-based treatment and will fill the knowledge gap in N. 
gonorrhoeae AMR spread. This is especially valuable in low-income settings where treatment is 
largely based on syndromic management and patients may not return for diagnosis results (154-
156). Although any test that provides a rapid diagnosis during a single clinical visit could be 
identified as a POCT (Table 1.3), ideally such tests would be approved by regulatory agencies 
such as the FDA and CE-IVD, such that there is an assurance of the reliability of results. 
Furthermore, the WHO has established that an ideal POCT should meet the ASSURED criteria, 
which states the test should be affordable, sensitive, specific, user-friendly, robust and rapid, 
equipment-free and deliverable to the end-users (155, 157, 158).  
 
POCTs for N. gonorrhoeae diagnosis include optical immunoassays and immunochromatographic 
tests that rely on antigen detection, as well as PCR based tests (134, 158-160), such as the Xpert 
CT/NG assay which has shown promising results from South Africa, Papua New Guinea and 
underprivileged regions in Australia (134, 161-163). Unfortunately, optical immunoassay and 
immunochromatographic POCTs have demonstrated sensitivities and specificities as low as 12.5% 
and 80% respectively (158, 159). As a result, these tests are not recommended for gonococcal 
diagnosis. However, modelling studies have shown that a rapid diagnostic test with a lower 
sensitivity can significantly increase the number of patients treated rather than waiting for a highly 
sensitive, yet slower test or a highly sensitive but expensive test requiring substantial electricity 
such as the Xpert CT/NG assay (164). 
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Table 1.3 Point-of-care tests approved and in development for N. gonorrhoeae. Table adapted from Unemo et al., 2019. Gonorrhoea. 
Nat Rev Dis Primers. 5:79. The table is reproduced with permission from Nat Rev Dis Primers. 
  
Platform GeneXpert 
CT/NG 
Binx io 
CT/NG  
ID NOW CT/NGa Truenat 
CT/NG 
Resistance Plus 
GCb 
Manufacturer Cepheid Atlas Genetics Abbott Molbio SpeeDx 
Instrument; 
health-care 
setting 
Table-top, not 
portable (used in 
mobile clinics); 
Level 2c 
Table-top, portable; 
Level 1c 
Table-top, 
portable; Level 1 
Table-top, 
portable; Level 1-2 
Table-top, not 
portable; Level 2 
Amplification 
technology 
PCR NAAT, immunoassay 
and small molecule 
chemistry 
Isothermal PCR Real-time PCR Real-time PCR 
Specimen Female and male 
urine, endocervical 
swab, patient-
collected vaginal 
swab 
Self-collected and 
clinician-collected 
vaginal swabs from 
symptomatic and 
asymptomatic females, 
and urine from males.  
TBD Female 
endocervical and 
vaginal swabs, 
male urethral 
swab, male and 
female urine 
Male and female 
urine, rectal, 
cervical, vaginal, 
urethral, 
pharyngeal, and 
ocular swabs, 
ocular extracts 
Procedure ~4 steps, sample 
prep automated  
~4 steps, sample prep 
automated  
~6 steps, raw 
sample added to 
the device 
Multiple pipetting 
steps 
~4 steps 
Time to result ~90 minutes 30 minutes 15 minutes ~60 minutes 50 minutes 
Reagent stability 3 years Cartridges with 
reagents stable at 2-
25oC 
>12 months 2 years at 
temperatures 2-
30oC 
18-24 months 
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Energy 
requirements 
Mains power 
required; solar power 
possible and can be 
powered by 12V DC 
or 120V AC 
Mains power required AC mains and DC 
from external 
AC/DC supplied 
plug pack 
Rechargeable 
lithium-ion battery 
Mains power 
required 
Training Less than 0.5 days Less than 1 hour  Less than 0.5 days Less than 0.5 days Less than 0.5 
days 
Connectivity Yes, computer 
required, remote 
calibration 
Yes, via middleware Yes, USB and 
ethernet outlets 
Yes, wireless 
connectivity: Wi-
Fi, Bluetooth, 
SMS 
Yes, computer 
required 
Regulatory 
Compliance 
FDA, CE-IVD CE-IVD, FDA 
approval pending  
N/A CE-IVD approval 
pending 
CE-IVD, FDA 
approval pending 
Tests listed in this table are selected based on the amount of information available and is not a comprehensive list of all the POCTs for 
N. gonorrhoeae in development. TBD – to be determined; NA – not available.  
aPreviously named Alere i CT/NG 
bFirst licensed molecular test for detecting N. gonorrhoeae and its AMS to ciprofloxacin 
cLevel 1 – primary healthcare center; Level 2 – district hospital 
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Although the current POCT platforms for N. gonorrhoeae can provide results within 30-90min, 
their sensitivities and specificities are highly variable between platforms (157), and despite the 
results being available promptly, for many of these tests it could take up to days for the diagnosis 
to be delivered to the patient (165, 166). These POC tests include GeneXpert CT/NG (Cepheid), 
Binx io CT/NG (Atlas Genetics), ID NOW CT/NG (Abbott), Truenat CT/NG (Molbio), and 
Resistance Plus GC (SpeeDx; Table 1.3). Additionally, multiple in-house near-patient POCTs 
have been developed to predict ciprofloxacin susceptibility (141-145, 147, 158, 167-173). 
Although many of these tests have been assessed with clinical specimens (141-146), most in-house 
tests have not been assessed in larger populations.  
 
1.5 COUNTERMEASURES TO ADDRESS AMR IN N. GONORRHOEAE 
The WHO’s 2016-2021 global health sector strategy for STIs has highlighted global targets to 
address the STI epidemic. To this end, the Pan-Canadian Sexually Transmitted and Blood-Borne 
Infections (STBBI) Framework for Action was approved in 2018 (170, 174, 175), and includes 
reducing the cases of STBBIs in Canada, providing improved access and support for testing, 
treatment and care. One of the important strategies outlined in this initiative was the effort to 
reduce discrimination and stigma associated with an STBBI diagnosis (16, 175). Thus, providing 
improved NAATs and POCTs alone will not reduce the number of infections; rather, a collective 
effort to reduce stigma, educate young adults on safer sexual practices, and provide accessible 
testing and affordable treatment, together with isolate tracking and development of novel 
therapeutics and vaccines will contribute to the effective control of rising gonorrhea infections. 
 
The introduction of novel antibiotics to the market is a lengthy process and requires regulatory 
approval at several levels. However, multi-drug resistant N. gonorrhoeae isolates are emerging all 
over the world. Thus, immediate and alternate strategies are critical to controlling the rise of AMR 
in N. gonorrhoeae. One seemingly feasible approach is the re-introduction of older antibiotics, for 
which a given gonococcal isolate is still susceptible. Ciprofloxacin is one prime example of such 
an antibiotic. However, prior to treatment, the susceptibility status of N. gonorrhoeae isolates to 
ciprofloxacin must be established. The FDA approved Resistance Plus GC (SpeeDx) is licensed 
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for use in the United States and Europe (134). However, this test is not accessible to resource-
constrained settings. Therefore, a user-friendly and rapid diagnostic test that can identify N. 
gonorrhoeae infections and determine isolates’ susceptibility to an antibiotic, such as the RT-PCR 
based tests developed during my research to determine N. gonorrhoeae susceptibility to 
ciprofloxacin, would be more applicable in a multitude of settings. Additionally, if such a test (or 
at least a N. gonorrhoeae diagnosis test) can be made portable, it would be highly beneficial for 
the diagnosis and control of drug-resistant N. gonorrhoeae infections.  
 
  
28 
1.6 HYPOTHESIS AND OBJECTIVES 
1.6.1 Hypothesis 
Multidrug-resistant N. gonorrhoeae is a global public health threat and can compromise the control 
and management of gonorrhea. Resistance to the ESCs, the last resort treatment of gonorrhea, was 
reported from high-income global settings. To prevent the onset of an era of untreatable gonorrhea, 
it is a paramount health priority to understand and monitor the spread of AMR. Priorities of the 
WHO global action plan to control the spread and impact of AMR in N. gonorrhoeae indicated 
the need for strengthened AMR surveillance and research into molecular methods for monitoring 
and detecting AMR, especially to develop and update treatment guidelines rapidly. 
 
I hypothesize that real-time molecular diagnostic platforms with specific primers will allow timely 
diagnosis of N. gonorrhoeae and information on its resistance to various antimicrobials used for 
treatment. Furthermore, molecular characterization of resistant determinants will provide a 
perspective of the spread of AMR and the emergence of resistance in gonococci in local 
communities (i.e. Saskatchewan).  
 
1.6.2 Objectives 
The specific objectives of my thesis are: 
1) To develop a multiplex real-time PCR assay for simultaneous identification of N. gonorrhoeae 
and its ciprofloxacin susceptibility status.  
2) To evaluate a commercial hydrogel platform for the diagnosis of N. gonorrhoeae by, using N. 
gonorrhoeae specific diagnostic primers, and then using multiplex primers capable of 
discriminating between ciprofloxacin susceptible and resistant isolates.  
3) To use molecular techniques and predict trends of antimicrobial resistance in N. gonorrhoeae 
isolates from Saskatchewan.  
4) To characterize a potential novel resistance-conferring mutation in an N. gonorrhoeae isolate 
leading to slow β-lactamase production.  
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2.0 INTERFACE 
At present, there are several in-house and commercial diagnostic tests for N. gonorrhoeae. 
However, none of these tests are portable and even require a DNA extraction step prior to 
diagnosis. Many high gonorrhea burden communities are in resource-constrained settings and 
could benefit from a portable point-of-care test requiring minimal training. The portable and 
commercial hydrogel system used in this research has worked well for the diagnosis of multiple 
pathogens directly from clinical specimens, without a DNA extraction step. In this research, we 
assess the feasibility of using the hydrogel platform for N. gonorrhoeae diagnosis. Importantly, 
the primers used in this research are unique to N. gonorrhoeae and have not reported cross-reaction 
with any other Neisseria species or non-Neisseria species tested. This chapter was previously 
published in Antibiotics, 7(3): 70, 2018, and is reprinted here with permission. This work was 
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presented at the International Union Against Sexually Transmitted Infections (IUSTI) World + 
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2.1 ABSTRACT 
Eleven primer pairs were developed for the identification of N. gonorrhoeae. The sensitivity and 
specificity of these primers were evaluated by Real-Time (RT)-PCR melt curve analyses with 
DNA from 145 N. gonorrhoeae isolates and 40 other Neisseria or non-Neisseria species. Three 
primer pairs were further evaluated in a hydrogel-based RT-PCR detection platform using DNA 
extracted from 50 N. gonorrhoeae cultures. We have observed 100% sensitivity and specificity in 
the hydrogel assay confirming its potential as a point-of-care test (POCT) for N. gonorrhoeae 
diagnosis. 
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2.2 INTRODUCTION 
N. gonorrhoeae, the second most prevalent bacterial sexually transmitted infection (STI) globally, 
causes 78 million new gonorrhea infections annually (1). Rates of antimicrobial-resistant (AMR) 
gonorrhea are rising worldwide (2). Left untreated, gonococcal infections can cause severe and 
potentially life-threatening disease and reproductive complications, especially in women, 
including infertility or involuntary death of the fetus (2, 3). With no immunization available, the 
only way to eliminate the infection is with effective antibiotic therapy (4, 5).  
 
Early diagnosis of infection, preferably at the patient’s first contact with the health care system, is 
vital for proper control of N. gonorrhoeae (6). Traditional diagnosis of gonorrhea largely relied on 
microscopy and or culture of the organism from urogenital specimens. Highly sensitive and 
specific nucleic acid amplification tests (NAATs) have replaced these tests in resource-rich 
settings (7-10). In resource-poor settings, either the appropriate laboratory facilities are not 
available at the primary health care level, or the costs associated with the diagnosis are 
unaffordable. In these instances, patients are treated empirically based on symptoms (i.e. 
syndromic management) (11, 12). Syndromic management often fails to identify asymptomatic 
infections and leaves a large population of people at risk for ongoing transmission and severe 
complications (13, 14). Therefore, it is of the utmost importance to design rapid, easy to perform 
tests that can provide early diagnosis of N. gonorrhoeae even in asymptomatic patients. 
 
An important factor contributing to the rising prevalence of gonorrhea is treatment delay whereby 
a patient may wait for a positive diagnostic test result before treatment is initiated (15). Sometimes, 
despite the availability of laboratory facilities, the delays in reporting results severely hinder timely 
treatment (6). It has been shown by mathematical modelling that a rapid test with a sensitivity as 
low as 63% can drastically increase the number of patients treated, rather than waiting for a highly 
sensitive, yet slower test (16). Likewise, although culture is considered the gold standard for a 
positive diagnosis, the number of infected individuals diagnosed by a rapid test and in turn 
successfully treated can outnumber the number of patients who return for treatment following 
extensive diagnostic procedures such as culturing and more sensitive NAATs (17). Furthermore, 
viable organisms are required for culturing. Improper handling and transportation can reduce the 
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viability of N. gonorrhoeae leading to false-negative results. However, with NAATs, the viability 
of the organism is not a concern (18, 19). 
 
The development of point-of-care tests (POCTs) for an STI such as gonorrhea is recognized as a 
vital approach to improve timely diagnosis (13, 14, 20-22). Although POCTs are commercially 
available for the diagnosis of N. gonorrhoeae, many of these tests do not fit the ASSURED criteria 
important for STI diagnosis tests, such as affordability, sensitivity, specificity, user-friendliness, 
robustness and rapidness, equipment-free, and deliverable to the end-users (13, 21). A reliable and 
rapid diagnostic test for N. gonorrhoeae would be a critical advancement in diagnostic capability.  
 
The portable hydrogel-based RT-PCR method, developed by Aquila Diagnostic Systems Inc. 
Edmonton AB, Canada, is a rapid diagnostic platform utilizing Real-Time Polymerase Chain 
Reaction (RT-PCR) melt curve analysis to amplify nucleic acids directly in clinical specimens and 
report the presence of specific genetic targets (23). This system has successfully detected blood-
borne infectious diseases such as malaria, BK virus, and herpes simplex virus (23-25). We 
developed and evaluated eleven diagnostic primer pairs for the identification of N. gonorrhoeae. 
We then evaluated three of these primers with the hydrogel-based detection method to assess the 
potential of this method for further development as a POCT.  
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2.3 MATERIALS AND METHODS 
2.3.1 Bacterial Strains 
To determine the sensitivity and specificity of primer pairs developed by us for the identification 
of N. gonorrhoeae, DNA from 145 N. gonorrhoeae isolates was obtained from the Dillon Culture 
Collection and represented isolates from diverse geographical areas (26-28) (Table 2.1: Panel 1). 
These isolates included the World Health Organization (WHO) N. gonorrhoeae reference isolates 
M, L, F, B, O, C, P, K, G and N (29). A random collection of 40 other Neisseria and non-Neisseria 
species were obtained from the National Microbiology Laboratory (NML), Winnipeg MB, Canada 
(Table 2.1: Panel 1).  
 
For experiments evaluating the hydrogel platform, DNA from 50 cultured N. gonorrhoeae isolates 
was used (Table 2.1: Panel 2 is a sub-panel of Panel 1). WHO N. gonorrhoeae reference strains 
WHO-F, P, G, K and N were used as positive controls. Five non-N. gonorrhoeae and non-
Neisseria species (E. coli, L. jensenii, N. elongata, N. subflava, and S. enterica serovar 
Typhimurium) were used as negative controls.  
 
2.3.2 DNA Extraction 
The DNA extraction was performed with a QIAamp DNA Mini Kit (#51306 Qiagen Canada) 
according to the manufacturer’s instructions. DNA was quantified using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington DE, USA) and the final 
concentration was adjusted to 50, 70 or 100ng/µL for evaluating the hydrogel method. 
 
2.3.3 Design of Diagnostic Primer Pairs 
Non-homologous sequence regions between N. gonorrhoeae FA1090 and N. meningitidis (MC58, 
FAM18 and Z2491) were extracted from the N. gonorrhoeae FA1090 genome. These sequences 
were then BLAST-ed against 25 in-house sequenced N. gonorrhoeae genomes and 15 N. 
gonorrhoeae genomes available at the Broad Institute database. Sequences that were positive in 
this BLAST search (50 sequences) were then further aligned against the NCBI non-redundant (nr) 
database using the BLAST program. Regions that were only found in N. gonorrhoeae were filtered 
for further analysis. Targets for all primer pairs are present in multiple copies in the N. gonorrhoeae 
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FA1090 genome and in-turn increase the sensitivity of detection even at lower DNA 
concentrations. Based on these findings, eleven primer pairs were designed using Primer-BLAST 
(36) (Table 2.2). Potential cross-reactivity of the primer pairs was evaluated in silico using primer-
BLAST software against the NCBI-nr database. Primer pairs were tested in vitro for their 
sensitivity and specificity with N. gonorrhoeae, non-N. gonorrhoeae and non-Neisseria species. 
 
2.3.4 Limit of Detection of Primers 
RT-PCR reactions contained 5 µl of 2X SYBR-Green master mix (Cat # 4472912, Life 
Technologies Inc.), 0.25 µl of each primer (10µM), 1 µl of DNA (50ng/µl) and 3.5 µl PCR-grade 
water in a total 10 µl reaction volume. Initial holding and activation of DNA polymerase were at 
50°C for 2 minutes. RT-PCR was performed for 40 cycles of 95°C for 20 seconds and 60°C for 
40 seconds. A post PCR melt curve was performed between 60°C to 95°C with 0.3°C temperature 
increments. Limit of detection assays, using serial dilutions (100 ng/µl to 0.00001 ng/µl) of DNA 
from N. gonorrhoeae reference strains WHO F, P, G, K and N, were used to ascertain the 
sensitivity of each primer pair. DNA from 40 non-N. gonorrhoeae and non-Neisseria species was 
also used to test the specificity of each primer pair.  
 
2.3.5 Real-Time PCR and Hydrogel Methods  
To compare hydrogel and RT-PCR methods, DNA was amplified using three N. gonorrhoeae 
diagnostic primer pairs (3, 17-1, and 21-5) and SYBR Select master mix. For the RT-PCR control 
method, each reaction contained 2 µL DNA (50, 70 or 100 ng/µL), 1.5 µL of each primer (10 µM) 
and 5 µl 2X SYBR-Green master mix in a total 10 µl reaction volume. For the hydrogel method, 
each reaction contained 1 µl DNA (50, 70 or 100 ng/µL), 0.38 µL of each primer (10 µM) and 
8.24 µL PCR-grade water. 2X SYBR-Green and primers were pre-mixed with the hydrogel. DNA 
and water were added to the hydrogel immediately before the start of the RT-PCR assay. Initial 
holding and activation of DNA polymerase were at 50°C for 2 minutes. RT-PCR was then 
performed for 30 cycles of 95°C for 20 seconds and 60°C for 40 seconds. A post PCR melt curve 
was performed between 60°C to 95°C with 0.3°C temperature increments. Various RT-PCR 
conditions were tested to optimize the hydrogel method. The final assay conditions included: 30 
PCR cycles, 60oC annealing temperature, 60-95oC melt curve temperature range, 0.3oC image 
taking temperature increments, and 2x SYBR-Green concentration.  
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Table 2.1 N. gonorrhoeae, non-N. gonorrhoeae and non-Neisseria isolates used in this research. 
 
Isolate 
selection 
Organisms Geographic source No  References  
Panel 1 N. gonorrhoeae Saskatchewan 86 26, 27 
USA 13 Dillon Culture 
Collection 
China 8 28 
WHO 10 29 
 South America and the Caribbean 28 Dillon Culture 
Collection 
Non-N. 
gonorrhoeaeb 
Canada 30 NMLa 
Non-Neisseria 
speciesb 
Canada 10 NML 
Panel 2 N. gonorrhoeae Saskatchewan 35 26, 27 
 China 6 28 
 South America and the Caribbean 9 Dillon Culture 
Collection 
 WHO 5 29 
Non-N. 
gonorrhoeaec 
Canada 2 NML 
Non-Neisseria 
speciesc 
Canada 3 NML 
 
aNational Microbiology Laboratory 
bOne isolate of – Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella 
oxytoca, Lactobacillus jensenii, Moxarella catarrhalis, Neisseria animaloris, Neisseria cinerea, 
Neisseria elongata, Neisseria flava, Neisseria lactamica, Neisseria menengitidis, Neisseria 
mucosa, Neisseria perflava, Neisseria polysacchareae, Neisseria sicca, Neisseria subflava, 
Neisseria wadsworthii, Neisseria weaverii, Pseudomonas aeruginosa, Salmonella enterica serovar 
Typhimurium, Staphylococcus aureus, and Staphylococcus epidermis 
cOne isolate of – E. coli, L. jensenii, N. elongata, N. subflava, and S. enterica serovar Typhimurium 
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Table 2.2 Primer sequences used in this research for detection of N. gonorrhoeae, their respective targets and copy numbers present in 
the N. gonorrhoeae genome. 
 
Primer ID  
(product length) 
Sequence (5'->3') Target Geneb No Targets 
in FA1090c 
Similar Targets from 
Commercial NAATs 
Primer 2 (208bp) NGO1620, NGO0469, 
NGO1126 
3 Cobas 4800 CT/NG  
Forward  TCTGCTTTCTTGGTGGGCGA  
Reverse  AGGCGATCCGGAAATGCTGA 
Primer 3 (139bp) NGO05940, NGO06090, 
NGO06650, NGO1642 
4 - 
Forward  TATGGGGGTTCCTTCGCACC  
Reverse  CAGACGGTTGCGGGTTCTTG 
Primer 8-3 (132bp)  NGO0773, NGO1200, 
NGO1703, NGO1137, 
NGO1164, NGO1262, 
NGO1641 
7 BD ProbeTec GC Qx 
Forward  CAGAAGCCTACGGACGAGCA  
Reverse  CGCATATGCTTTGGCCGCTT 
Primer 8-4 (180bp) NGO0773, NGO1200, 
NGO1703, NGO1137, 
NGO1164, NGO1262, 
NGO1641 
7 - 
Forward  TCACGGATGACCGCAGCATA  
Reverse  AGACGCTTCACGCCTTCCTT 
Primer13 (138bp) NGO0773, NGO1137, 
NGO1703, NGO1164, 
NGO1200, NGO1262, 
NGO1641 
7 BD ProbeTec GC Qx 
Forward  GCGTAACGCCGTAGGATTGGA   
Reverse  CCCAAGCTTTTCAACCGGTCC   
Primer16 (93bp) 
 
NGO1131, NGO1209 2 - 
Forward  CGGAACAAGCGTTTTTCAGCG   
Reverse  TCTTTGGCTTGTCCGGGTGT   
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Primer 17-1 (73bp) 
 
NGO1638, NGO0487, 
NGO1108 
3 - 
Forward  TCCGAAACACGCAAACCGAAA   
Reverse  TAGCCCGGGTTGGTATTGCC   
Primer 17-2 (82bp) 
 
NGO1638, NGO0487, 
NGO1108 
3 - 
Forward  ACACGCAAACCGAAACCGTC   
Reverse  GCGCGGTTTTTGTAATAGCCC   
Primer 21-5 (101bp) 
 
NGO1085, NGO1652 2 - 
Forward  GCACGAAACCCGTCCAATCC   
Reverse  CAAGACATGCGGCTATGCGG   
Primer 31-2 (188bp) 
 
NGO0480, NGO1113, 
NGO1631 
3 - 
Forward  AAAATCGCGCCGGGTTTGAA   
Reverse  AGCTTATCCGCAGCGGTTCT   
Primer 31-3 (275bp) 
 
NGO0480, NGO1113, 
NGO1631 
3 - 
Forward  AAAAAGCCCGTCGGGTCAGA   
Reverse  AACCCGAAGAATCGGAGCCA   
 
aThe primer sequences presented in this manuscript are the subject of a United States utility patent (#62/088,332) 
bLocus Tag ID in the NCBI database 
cNumber of targets on N. gonorrhoeae FA1090 genome 
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2.4 RESULTS 
2.4.1 Evaluation of N. gonorrhoeae Diagnostic Primer Pairs 
Nine primer pairs (3, 8-3, 8-4, 13, 16, 17-1, 17-2, 21-5, 31-2) amplified every N. gonorrhoeae 
isolate tested (n=130) (Table 2.3). Primer pair 2 did not amplify one of the 130 N. gonorrhoeae 
isolates. Primer pair 31-3 did not amplify 28 of the 130 N. gonorrhoeae isolates. Primer pairs 2, 3, 
8-4, 16, 17-1, 17-2, 21-5, 31-2, and 31-3 did not amplify any of the non-N. gonorrhoeae or non-
Neisseria species. However, primer pair 8-3 amplified DNA from Neisseria flava, Neisseria 
lactamica, and Neisseria polysacchareae. Primer pair 13 amplified DNA from N. flava, Neisseria 
subflava, Neisseria mucosa, N. lactamica, Neisseria perflava, Neisseria flavescens and N. 
polysacchareae (Table 2.4). The limit of detection of the primers was assessed by serially diluting 
(10 ng/µl to 0.000001 ng/µl) genomic DNA from N. gonorrhoeae strain WHO-M. After 30 cycles 
of PCR, all the primers were able to detect gonococcal concentrations as low as 0.001 ng/µl (data 
not shown).  
 
2.4.2 Optimization of the Hydrogel System and Comparison with RT-PCR Methods 
The ability of primers 3, 17-1 and 21-5 to identify genomic DNA from N. gonorrhoeae strains 
WHO F, WHO P, WHO G, WHO K and WHO N in the hydrogel system were analyzed using RT-
PCR (Table 2.4). To optimize the performance of the hydrogel system for N. gonorrhoeae, 
different parameters for hydrogel and RT-PCR were assessed. In testing for the most effective 
concentration of SYBR-Green, we determined that with 1X SYBR-Green (pre-mixed in the 
desiccated gel), primer pair 3 produced melt curve temperatures (Tm values) similar to previously 
established Tm values (80.5oC) with control methods. However, with primer pairs 17-1 and 21-5, 
2x SYBR-Green was required for established Tm values (85.0oC). Therefore, 2x SYBR-Green was 
chosen for subsequent experiments. Further, with our primer pairs, we determined that optimal 
amplification occurred with 30 PCR cycles, which differs from the hydrogel manufacturer’s 
recommendation of 40 cycles.  
 
The performance of the hydrogel method with increasing concentration of DNA (50, 70 or 
100ng/µL) was assessed using genomic DNA from 50 N. gonorrhoeae positive cultures (Table 
2.1: Panel 2), WHO N. gonorrhoeae reference strains (n=5; positive control) and  
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Table 2.3 Evaluation of eleven primer pairs using N. gonorrhoeae, non-N. gonorrhoeae and non-Neisseria species.  
 
Bacterial species No. of 
isolates 
Positive Amplifications 
2a 3 8-3b 8-4 13b 16 17-1 17-2 21-5 31-2 31-3 
N. gonorrhoeae 130 129 130 130 130 130 130 130 130 130 130 102 
N. flava 2 0 0 1 0 2 0 0 0 0 0 0 
N. subflava 2 0 0 0 0 1 0 0 0 0 0 0 
N. elongata 2 0 0 0 0 0 0 0 0 0 0 0 
N. mucosa 3 0 0 0 0 1 0 0 0 0 0 0 
N. lactamica 4 0 0 2 0 2 0 0 0 0 0 0 
N. perflava/sicca 5 0 0 0 0 3 0 0 0 0 0 0 
N. flavescensc 2 0 0 0 0 1 0 0 0 0 0 0 
N. polysacchareae 4 0 0 1 0 2 0 0 0 0 0 0 
Other Neisseria speciesd 6 0 0 0 0 0 0 0 0 0 0 0 
Non-Neisseria speciese 10 0 0 0 0 0 0 0 0 0 0 0 
 
aPrimers are amplifying regions with partial homology to DR9 repeats used in Cobas 4800 CT/NG Test (Roche Molecular Diagnostics, 
Pleasanton CA, USA) 
bPrimers are amplifying regions with partial homology to targets used in BD ProbeTec GC Qx Amplified DNA Assay (Becton Dickinson 
and Company, Franklin Lakes NJ, USA) 
cNeisseria flavescens 
dNeisseria animaloris (1), Neisseria cinerea (2), Neisseria menengitidis (1), Neisseria wadsworthii (1), Neisseriaweaverii (1)  
eEnterococcus faecalis (1), Enterococcus faecium (1), Escherichia coli (1), lebsiella oxytoca (1), Lactobacillus jensenii (1), Moraxella 
catarrhalis (1), Pseudomonas aeruginosa (1), Salmonella enterica serovar Typhimurium (1), Staphylococcus aureus (1), and 
Staphylococcus epidermis (1) 
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Table 2.4 The effect of SYBR-Green concentration on melt curve temperature (Tm values) of five N. gonorrhoeae strains, with primer 
pairs 3, 17-1 and 21-5. 
 
 
Strain 
Melt Curve Temperature (oC) 
Primer Pair 3a Primer Pair 17-1a Primer Pair 21-5a 
1X SYBR-Green 2X SYBR-Green 1X SYBR-Green 2X SYBR-Green 1X SYBR-Green 2X SYBR-Green 
WHO-F 80.49 81.52 83.90 84.64 84.05 84.84 
WHO-G 80.78 81.82 84.05 84.64 83.90 84.79 
WHO-K 80.49 81.97 84.05 84.49 84.20 84.79 
WHO-N 80.63 81.82 83.90 84.49 84.05 84.79 
WHO-P 80.93 81.97 83.90 84.64 84.05 84.79 
 
aExpected Tm values for primer pair 3 - 80.5oC; primer pair 17-1 - 85.0oC; primer pair 21-5 - 85.0oC  
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non-N. gonorrhoeae strains (n=4; negative control). Based on the melt curve (Tm) temperatures 
(primer pair 3, 80.5oC; primer pairs 17-1 and 21-5, 85.0oC), primer pair 3 with 50 ng/µL DNA 
identified 44 N. gonorrhoeae isolates. Primer pair 3 with 70 ng/µL DNA identified 46 isolates and 
100 ng/µL DNA identified all 50 N. gonorrhoeae isolates (Table 2.5). Thus, primer pair 3 had 
88%, 92% and 100% sensitivity with 50, 70 and 100 ng/µL DNA respectively. The specificity of 
primer pair 3 was 100% with all DNA concentrations tested. Primer pair 17-1, irrespective of the 
DNA concentration tested, identified all 50 N. gonorrhoeae isolates and had 100% sensitivity and 
specificity. Primer pair 21-5 identified 47 N. gonorrhoeae isolates with 50 ng/µL DNA and had a 
sensitivity of 94% and a specificity of 100%. With 70 ng/µL and 100 ng/µL DNA, primer pair 21-
5 identify all 50 isolates and had 100% sensitivity and specificity. Primer pairs 3 and 17-1 in the 
control RT-PCR method, identified all 50 N. gonorrhoeae isolates and had a sensitivity of 100%. 
Primer pair 21-5 identified 48 isolates with a sensitivity of 96%. One non-Neisseria species 
(Escherichia coli) was incorrectly identified as N. gonorrhoeae positive by primer pair 3 in the 
RT-PCR control method, thereby giving a specificity of 67% (Table 2.5). With primer pairs 17-1 
and 21-5, all the negative control isolates (E. coli, Lactobacillus jensenii, Neisseria elongata, 
Neisseria subflava, and Salmonella enterica serovar Typhimurium) were correctly ascertained as 
N. gonorrhoeae negative, giving a specificity of 100%. 
 
With the hydrogel method and primer pair 3, 33 samples had positive threshold cycle (Ct) values 
when using 70 ng/µL DNA. However, with 50 ng/µL and 100 ng/µL DNA, none of the samples 
had positive Ct values. Similarly, with primer pairs 17-1 and 21-5 all 50 samples had negative Ct 
values. In contrast, when using the control RT-PCR method and primer pair 3, all 50 samples had 
positive Ct values. Likewise, with primer pair 17-1 all 50 samples had positive Ct values. With 
primer pair 21-5, 49 samples had positive Ct values. To consider if the hydrogel system was 
interfering with the fluorescence reading, extra, fresh SYBR-Green (commercially made 2X 
SYBR-Green) was added to the reaction mixture of samples with the hydrogel method. These 
reaction mixtures pre-contained 2X SYBR-Green incorporated into the desiccated gel. The 
addition of total 4X and fresh SYBR-Green significantly improved the results from the hydrogel 
method and produced Ct values similar to that obtained with the RT-PCR control method (Table 
2.5). 
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Table 2.5 Evaluation of hydrogel and RT-PCR methods using varying concentrations of N. 
gonorrhoeae DNA (n=50)a and diagnostic primer pairs 3, 17-1 and 21-5. 
 
Primer 
Pair 
Method DNA 
Conc. 
(ng//µL) 
No N. gonorrhoeae 
Isolates Identified 
as per Tm value 
(n=50)b 
Positive 
Ct values 
(n=50)b 
Sensitivity 
(%) 
Specificity 
(%) 
3 Hydrogel 50 44 0 88 100 
3 Hydrogel 70 46 33 92 100 
3 Hydrogel 100 50 0 100 100 
3 Hydrogel+4X 
SYBRd 
100 50 50 100 100 
3 RT-PCR control 70 50 50 100 67c 
17-1 Hydrogel 50 50 0 100 100 
17-1 Hydrogel 70 50 0 100 100 
17-1 Hydrogel 100 50 0 100 100 
17-1 RT-PCR control 70 50 50 100 100 
21-5 Hydrogel 50 47 0 94 100 
21-5 Hydrogel 70 50 0 100 100 
21-5 Hydrogel 100 50 0 100 100 
21-5 RT-PCR control 70 48 49 96 100 
 
aControls - WHO N. gonorrhoeae reference strains (n=5; positive control) and non-N. gonorrhoeae 
and non-Neisseria strains (n=4; negative control) 
bNumber of N. gonorrhoeae isolates identified as per the melt curve temperature (Tm) and 
threshold cycle (Ct) values. Isolates with negative Ct values had a positive melt curve temperature 
(Tm) 
cOne Non-N. gonorrhoeae isolate identified as N. gonorrhoeae positive 
dHydrogel method pre-contained 2X SYBR-Green dye. For this assay, extra, fresh 2X SYBR-
Green dye was added for a final concentration of 4X SYBR-Green dye 
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2.5 DISCUSSION 
We developed and evaluated novel primers in a hydrogel platform as a potential useful POCT for 
N. gonorrhoeae diagnosis. This system is rapid and requires minimal sample preparation. The 
hydrogel system introduces a state-of-the-art portable diagnostic approach to bringing the 
detection platform to clinicians and remote locations, as this system contains desiccated primers, 
polymerases and other PCR components, thereby enabling the delivery of prompt results to 
clinicians. Only the patient sample would need to be added to the system prior to PCR 
amplification. As such, this system does not require a cold chain (i.e. refrigeration) to preserve the 
PCR reagents, a major obstacle to delivering diagnostic tests to remote locations.  
 
A recent review evaluated POCTs for N. gonorrhoeae (13). The tests evaluated include lateral flow 
immunochromatographic test (ICT) formats, i.e. the Binax NOW Gonorrhoea Test (Inverness), the 
GC Check (PATH, Seattle, Washington, USA) and, the ACON format tests (ACON Laboratories, 
San Diego, California, USA); an optical immunoassay test (OIA), the BioStar 
(ThermoFisher/BioStar, Boulder, Colorado, USA); and a nucleic acid amplification test, the 
GeneXpert CT/NG Assay (Cepheid, Sunnyvale, California, USA). The performance of the ICTs 
was variable with sensitivities ranging from 94%, 70% and 12.5% and specificities from 96%, 
97%, and 99.8% for Binax NOW, GC Check and ACON format tests, respectively. The OIA 
BioStar test had a sensitivity of 60% and a specificity of 89%. The ICTs and the OIA had 5 or 
more steps and took 25 to 40 minutes to obtain results (13, 14). These tests generally fail to meet 
the high levels of sensitivity and specificity required for a POCT. The GeneXpert CT/NG Assay 
is the only commercial NAAT-based POCT for N. gonorrhoeae diagnosis and has high sensitivity 
(95.6-98%) and specificity (99.9-100%) which is dependent on the specimen type (13, 30-33). 
This assay requires 3 steps and takes 90 minutes to produce results (31). The limiting factor about 
considering the GeneXpert as a POCT is the affordability and portability of the equipment.  
 
The currently available, United States Food and Drug Administration approved commercial 
NAAT systems for N. gonorrhoeae identification primarily rely on a single target detection 
strategy (34). These tests include the Abbott RealTime CT/NG assay which targets a 48bp 
sequence within the N. gonorrhoeae opa gene (Abbott Laboratories Abbott Park, IL, USA), the 
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Aptima COMBO 2 assay and the Aptima GC assay which target specific regions within N. 
gonorrhoeae 16S rRNA (Hologic/Gene-Probe Inc., San Diego, CA, USA), the BD ProbeTec ET 
CT/GC Amplified DNA assay and BD ProbeTec Qx GC Amplified DNA Assay which target the 
chromosomal pilin gene-inverting protein homologue (Becton Dickinson and Company, Sparks, 
MD, USA), the Cobas 4800 CT/NG which targets the DR-9 region (Roche Diagnostics, 
Indianapolis, IN, USA) and the GeneXpert CT/NG Assay (Cepheid, Sunnyvale, CA, USA) which 
uses two non-contiguous chromosomal targets (NG2 and NG4) of N. gonorrhoeae  (7, 30, 31, 34, 
35).  
 
The hydrogel method we evaluated had 100% sensitivity and specificity using DNA from N. 
gonorrhoeae cultures. The system remains to be tested using clinical specimens of N. gonorrhoeae 
such as urines or self-collected vaginal or rectal swabs. One complication that arose with the 
hydrogel method was that, despite having a positive N. gonorrhoeae diagnosis by melt curve (Tm) 
analysis, most samples contained negative threshold cycle (Ct) values. Therefore, we considered 
that the hydrogel system was interfering with the fluorescence reading, thereby giving Ct values 
lower than the threshold value (i.e. negative Ct values). Addition of extra, fresh 2x SYBR-Green 
to the hydrogel reaction mixture, pre-containing 2X SYBR-Green, for a final concentration of 4X 
SYBR-Green resulted in favourable Ct values. The hydrogel has been successfully used for the 
detection of other pathogens such as Herpes simplex virus from raw genital swabs, Plasmodium 
falciparum, BK virus, human platelet antigen 1 (HPA1) and fibroblast growth factor receptor 2 
(FGFR2) from unprocessed blood samples (23-25). Furthermore, the <2-hour time frame from 
specimen collection to results makes this test a potentially much simpler and user-friendly second 
molecular POCT. 
 
The genomic targets of three of our primer pairs have partial homology with genomic targets used 
in two commercial assays. Primer pair 2 has partial homology with the genomic region used in the 
Cobas 4800 CT/NG Test (i.e DR-9 region) and primer pairs 8-3 and 13 have partial homology 
with the genomic targets used in the BD ProbeTec GC QX Amplified DNA Assays (i.e. 
chromosomal pilin gene-inverting protein homologue). In our assay, primer pair 2 did not amplify 
one N. gonorrhoeae isolate. Furthermore, cross-reactivity of primer pairs 8-3 and 13 with 3 and 7 
other non-gonococcal Neisseria species respectively was observed. Cross-reactivity with Neisseria 
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subflava and Neisseria lactamica was also reported for the BD ProbeTec GC Qx Amplified DNA 
Assay (8).  
 
2.6 CONCLUSIONS 
The hydrogel method coupled with the primers discussed in this work can meet the ideal rapid test 
(ASSURED) criteria established by WHO for STI diagnosis tests; Affordable, Sensitive, Specific, 
User-friendly, Robust and Rapid, Equipment-free, and Deliverable to end-users (21). Although the 
hydrogel system was evaluated using pure cultures of N. gonorrhoeae, with further optimization 
the hydrogel diagnostic method with these primers can be used as a POCT for diagnosis of 
gonococci from clinical specimens enabling rapid, reliable and efficient diagnosis of N. 
gonorrhoeae. Furthermore, multiplex primer pairs can be integrated into the hydrogel platform 
enabling simultaneous diagnosis of N. gonorrhoeae and characterization of its AMR profile to 
different antimicrobials. 
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3.0 INTERFACE 
In North America, ciprofloxacin is not recommended for the treatment of N. gonorrhoeae 
infections due to a high prevalence of antimicrobial resistance. However, previous research has 
indicated that ciprofloxacin susceptible N. gonorrhoeae isolates exist in some communities. 
Therefore, we designed multiplex primers specific for N. gonorrhoeae, which can also identify a 
gonococcal isolate’s ciprofloxacin susceptibility status, with the long term intention of introducing 
this test as a diagnostic tool to local health communities. This research highlights that ciprofloxacin 
susceptible N. gonorrhoeae isolates can be identified for targeted treatment, and is unique in that 
it emphasizes the importance of looking at mutations in both gyrA S91 and D95 amino acid 
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positions to determine resistance to ciprofloxacin. This chapter was previously published in the 
Journal of Clinical Microbiology, 55(11): 3201-3209, 2017, and is reprinted here with permission. 
The work discussed in this chapter has been presented at the 17th World Congress of the 
International Union against Sexually Transmitted Infections held in Marrakech, Morocco, on May 
9-12th, 2016, and at the Saskatchewan Epidemiology Association 19th Annual Fall Symposium and 
Workshop held in Regina, Saskatchewan, Canada, on October 8-9th, 2019.  
 
Sumudu R Perera carried out laboratory experiments, analyzed data and wrote the manuscript 
Nurul H Khan carried out laboratory experiments and analyzed data 
Irene Martin provided non-gonococcal DNA and performed validation experiments 
Ali Taheri and Anthony Kusalik designed the primers 
Rajinder P Parti performed preliminary laboratory experiments 
Paul N Levett and Greg B Horsman provided gonococcal isolates 
Jo-Anne R Dillon conceptualized the research, provided guidance with the experimental design, 
feedback and editing on the manuscript and held the research grant that supported this work 
 
3.1 Abstract 
A real-time PCR (RT-PCR) assay was designed for the simultaneous identification of N. 
gonorrhoeae and its ciprofloxacin susceptibility status. A SYBR-Green based multiplex RT-PCR 
format was used and comprised of two different forward primers and a common reverse primer to 
detect single nucleotide polymorphisms (SNPs) in gyrA of N. gonorrhoeae. The primer pairs were 
evaluated for their sensitivity and specificity with genomic DNA from 254 N. gonorrhoeae isolates 
(82 ciprofloxacin susceptible and 172 resistant) and 23 non-N. gonorrhoeae species. The 
performance of the primers was validated using genomic DNA from 100 different N. gonorrhoeae 
isolates (46 ciprofloxacin susceptible and 54 resistant) and 52 non-N. gonorrhoeae isolates. This 
latter panel was revalidated by testing 99 of the N. gonorrhoeae isolates (46 ciprofloxacin 
susceptible and 53 resistant) and 23 non-N. gonorrhoeae isolates. These primers detected N. 
gonorrhoeae and its ciprofloxacin susceptibility status with over 99% sensitivity and specificity 
for all panels tested. This assay has the potential to be an inexpensive and rapid test for the 
simultaneous identification of N. gonorrhoeae and its ciprofloxacin susceptibility status.   
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3.2 INTRODUCTION 
Gonorrhea remains an important global public health concern with 78 million new infections 
worldwide each year (1). Cases of gonorrhea are underreported especially because most infections 
(almost half of the women infected) are asymptomatic and such infections can have major long-
term and negative impacts on reproductive health, especially in women (2). Gonococcal infections 
can only be cured with antibiotics; there are no vaccines against this disease (3, 4). Over time, N. 
gonorrhoeae isolates have developed resistance to every class of antibiotic introduced for therapy, 
including the third-generation cephalosporin which was the last class of antibiotic used in single-
dose therapy (3, 5). The recommended treatment in many countries for gonococcal infections now 
comprises co-therapy with two antibiotics, azithromycin coupled with ceftriaxone (6). There is an 
increased urgency for new strategies to treat gonococcal infections, either with new antibiotics, 
antibiotic combinations, or possibly to use older antimicrobials where susceptibility to the agent 
is known. 
 
The identification of N. gonorrhoeae in high-income countries is usually accomplished by nucleic 
acid amplification testing (NAAT; 7, 8, 9, 10). A limitation of NAATs is that susceptibility testing 
cannot be completed at present as such testing requires the pathogen to be cultured, and molecular 
testing for antimicrobial susceptibility is still under evaluation (3, 5, 11, 12). Due to the widespread 
use of NAATs, antimicrobial susceptibility testing of N. gonorrhoeae isolates has significantly 
declined in resource-rich countries (12, 13). Such testing is often beyond the technical capability 
of resource-limited settings. 
 
Ciprofloxacin, a fluoroquinolone antibiotic, was first introduced for the treatment of gonococcal 
infections in 1985; by 2006, in the United States, ciprofloxacin resistance was observed in 13.8% 
of isolates (11, 14). The population-based recommendation of the World Health Organization is 
that when resistance to an antibiotic exceeds 5% of isolates tested, the antibiotic should be 
discontinued for treatment (5, 6). Consequently, from 2007 ciprofloxacin has not been 
recommended for the treatment of N. gonorrhoeae infections in the USA (15). In Canada, between 
2004 and 2014, ciprofloxacin resistance in N. gonorrhoeae isolates increased from 6.3% to 34.0% 
and is no longer recommended for the primary treatment of gonorrhea (16, 17). It is notable, 
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however, that in the United States, ~80% of N. gonorrhoeae isolates are susceptible to 
ciprofloxacin (18). The issue is that individual patients infected with a susceptible isolate must be 
identified before the antibiotic can be considered as a treatment option. Thus, there is a need for a 
point-of-care test (POCT) that might identify those infected with ciprofloxacin susceptible N. 
gonorrhoeae isolates. 
 
Ciprofloxacin resistance in N. gonorrhoeae is caused by single nucleotide polymorphisms (SNPs) 
within DNA gyrase A (gyrA; amino acid positions S91 and D95) and parC (amino acid positions 
S88 and E91) (3, 5, 19, 20). Studies have shown that more than 99% of ciprofloxacin-resistant N. 
gonorrhoeae isolates carry gyrA S91 and/or D95 mutations, making these targets potentially 
diagnostic for resistance (21, 22, 23).  
 
We report on the design and evaluation of a test that can be used simultaneously to identify N. 
gonorrhoeae and to determine its ciprofloxacin susceptibility status in a single multiplex assay. 
Our test was over 99% sensitive and specific for the identification of ciprofloxacin susceptibility 
status of N. gonorrhoeae.  
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3.3 MATERIALS AND METHODS 
3.3.1 Bacterial Strains 
Two different N. gonorrhoeae strain panels were used and comprised of DNA extracted from 
clinically derived cultured specimens. Panel 1 comprised 254 gonococcal and 23 non-gonococcal 
isolates (Table 3.1). Panel 1 N. gonorrhoeae isolates were chosen randomly from the Dillon culture 
collection, which consisted of isolates previously reported by Vidovic et al., 2014 (35) and Liao et 
al., 2009 (36). A core feature of all selections was their different susceptibilities to ciprofloxacin. 
The WHO reference isolates were reported in Unemo et al., 2009 (24). A random collection of 
non-Neisseria and other Neisseria species were obtained from the National Microbiology 
Laboratory (NML), Winnipeg MB, Canada. The second unrelated panel comprised 100 
gonococcal and 52 non-gonococcal isolates from across Canada and was selected at the NML to 
include isolates having different susceptibilities to ciprofloxacin. A subsample of panel 2 (panel 
3) containing DNA from 99 gonococcal and 23 non-gonococcal isolates was used for re-validation. 
One isolate from panel 2 was eliminated in panel 3 due to inconsistent results. WHO N. 
gonorrhoeae reference strains for ciprofloxacin susceptibility determination included strains F, O, 
P, B and C (susceptible), G (intermediate) and M, N, K and L (resistant; 24).  
 
N. gonorrhoeae isolates were stored at -80°C in brain heart infusion medium (Difco BD 
Bioscience) with 20% glycerol. Aliquots from frozen inoculum were cultured on GC medium base 
(Difco BD Bioscience) supplemented with 1% Kellogg’s defined supplement. Plates were 
incubated at 35-37°C with 5% CO2 in a humid environment for 18 to 24h (25). 
 
DNA extraction was performed using a QIAamp DNA Mini kit (Qiagen) according to the 
manufacturer’s protocol. DNA was quantified using a NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific) and 50ng/µl of DNA from each isolate was used for RT-PCR reactions.  
 
3.3.2 Antimicrobial Susceptibility Testing 
The minimum inhibitory concentration (MIC) of all N. gonorrhoeae isolates to ciprofloxacin 
(Sigma-Aldrich) was assessed by the agar dilution method (25). Antimicrobial susceptibility 
criteria recommended by the Clinical and Laboratory Standards Institute (CLSI) were used to   
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Table 3.1 N. gonorrhoeae and non-N. gonorrhoeae isolates used in this research. 
 
Isolate 
selection 
Organisms Geographic source No  References  
Panel 1 Neisseria gonorrhoeae Saskatchewan 110 35, 37 
China 96 36 
WHO 
 
USA 
 
 
South America  
and the Caribbean  
10 
 
13 
 
 
25 
 
24 
 
Dillon Culture 
Collection 
 
Dillon Culture 
Collection 
 
Total 
 
254 
 
Non-N. gonorrhoeaeb Canada 13 NMLa 
Non-Neisseria 
speciesb 
Canada 10 NML 
 Total 23  
Total isolates  278  
Panel 2 N. gonorrhoeae Canada 100 NML 
Non-N. gonorrhoeae 
& non-Neisseria 
speciesc 
Canada 52 NML 
Total isolates  152  
Panel 3 N. gonorrhoeae Canada 99 NML 
 Non-N. gonorrhoeae 
& non-Neisseria 
species.b 
Canada 23 NML 
 Total isolates  122  
 
aNational Microbiology Laboratory 
bN. animaloris, N. elongate, N. flava, N. lactamica, N. meningitides, N. mucosa, N. perflava, N. 
polysacchareae, N. sicca, N. subflava, N. wadsworthii, N. weaverii, N. cinerea, E. faecalis, E. 
faecium, E. coli, K. oxytoca, L. jensenii, M. catarrhalis, P. aeruginosa, S. Typhimurium, S. aureus, 
S. epidermis 
cA. vaginae, B. ureolyticus, C. albicans, C. glucoronolyticum, C.. urealyticum, C. xerosis, C. 
neoformans, E. aerogenes, E. faecalis, E. faceium, E. coli, G. vaginalis, K. oxytoca, L. crispatus, 
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L. gasseri, L. iners, L. jensenii, L. buccalis, L. monocytogenes, M. curtisii, M. catarrhalis, N. 
animalis, N. animaloris, N. cinerea, N. elongate, N. flava, N. flavescens, N. lactamica, N. 
meningitidis, N. mucosa, N. perflava, N. polysaccharea, N. sicca, N. subflava, N. wadsworthii, N. 
weaver, P. niger, P. anaerobius, P. bivia, P. mirabilis, P. aeruginosa, S. Typhimurium, S. aureus, 
S. epidermidis, S. agalactiae, S. gordonii, S. infantis, S. oralis, S. pyogenes, U. urealyticum, U. 
parvum, M. hominis. 
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interpret ciprofloxacin MICs as follows: sensitive (≤ 0.06 µg/mL), intermediate (0.125 to 0.50 
µg/mL) and resistant (≥ 1.0 µg/mL; 25).  
 
3.3.3 Primers and Real-Time (RT) PCR 
Two different forward primers and one common reverse primer with homology to N. gonorrhoeae 
gyrA were designed (United States utility patent #62/088,332) using Primer-BLAST (26). Primer 
pair gyrA-W, for which the forward primer was designed to amplify a conserved region of gyrA, 
comprised forward primer gyrA-W-F (5’GCGATTCCGCAGTTTACGA3’) and the common 
reverse primer gyrA-R (5’CGAAATTTTGCGCCATACGGACGAT3’). Primer pair gyrA-M, for 
which the forward primer was designed to amplify the region containing the gyrA S91 and gyrA 
D95 SNPs associated with ciprofloxacin resistance, comprised forward primer gyrA-M-F (5’ 
TACCACCCCCACGGCGATTT3’) and the common reverse primer gyrA-R.  
 
For panels 1 and 3 RT-PCR was performed using an Applied Biosystems (AB) StepOnePLus RT-
PCR system (Life Technologies) on a 96-well plate (Life Technologies) platform and for panel 2 
using ViiA 7 RT-D2 RT-PCR Instrument (Life Technologies) on a 96-well plate platform with the 
SYBR Select Master Mix reagent kit (Life Technologies). PCR reactions contained 5µl of 2X 
SYBR-Green Master Mix, 0.25µl of each primer (10µM) and 2µl of DNA template (50 ng/µl). 
The final reaction volume was adjusted to 10µl with deionized water. PCR was conducted 
according to the manufacturer’s guidelines with the following modifications: initial holding and 
activation at 50°C for 2min followed by a secondary holding at 95°C for 2 min. PCR was 
performed for 25 cycles at 95°C for 15 sec. and 60°C for 30 sec. The post-PCR melt curve was 
performed between 60°C to 95°C with 0.3°C temperature increments. DNA from WHO strain F 
was used as a positive control and a sample without DNA was used as a negative control. Data 
were collected at 50°C in the holding stage, at 60°C in the annealing stage (for amplification data), 
and during the melt curve process (for melt curve data).  
 
3.3.4 Multiplex RT-PCR Analyses 
For multiplex RT-PCR analyses, reactions contained 5µl of 2X SYBR-Green Master Mix, 0.25µl 
of each of the forward primers (10µM), 0.25µl of the common reverse primer (10µM) and 2µl of 
the DNA template (50ng/µl). The final reaction volume was adjusted to 10µl with deionized water. 
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The method for multiplex RT-PCR was the same as described above. Initially, the sensitivity and 
specificity of the primers were analyzed using purified DNA from 254 N. gonorrhoeae and 23 
non-N. gonorrhoeae isolates (Table 2.1) using single primer pairs and in a multiplex format. These 
tests were validated with the same primers and methods but using panel 2 isolates. A subset of 
DNA from panel 2 isolates was re-validated as panel 3 (Table 2.1). 
 
3.3.5 Calculation of Specificity and Sensitivity 
Specificity and sensitivity were calculated using the formulas described before (27).  
 
3.3.6 DNA Sequencing 
gyrA genomic region of N. gonorrhoeae was PCR amplified with primers gyrA-F 
(ACTGTACGCGATGCACGAGC) and gyrA-R (TCTGCCAGCATTTCATGTGAG)19. Sanger 
sequencing of the amplicon was performed at Eurofins Genomics, Louisville KY, USA. 
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3.4 RESULTS 
3.4.1 Specificity and Sensitivity of gyrA Primers for Identification of N. gonorrhoeae Either 
in Single PCR or Multiplex Formats  
Individually and in multiplex, gyrA-W and gyrA-M primers did not amplify DNA from any of the 
non-N. gonorrhoeae isolates (Table 3.2) indicating 100% specificity. A non-specific melt curve 
was produced by the gyrA-M primer pair for Lactobacillus jensenii that was not reproduced on the 
repeated analyses. Similarly, the gyrA-W primer pair produced non-specific melt curves for N. 
animaloris and N. meningitidis, which were not observed in repeated experiments. Non-specific 
melt curves were considered negative amplification, as these melt curve temperatures fell beyond 
the expected range and do not interfere with the melt curve interpretation of the ciprofloxacin 
susceptibility status of N. gonorrhoeae. The gyrA-W primer pair and gyrA-M primer pair amplified 
57% and 58% of the 254 N. gonorrhoeae isolates respectively (Table 2.2). In the multiplex format 
with three primers (2 forward and a common reverse primer), all 254 N. gonorrhoeae isolates were 
amplified and no non-N. gonorrhoeae isolates were amplified (Table 2.2). Therefore the multiplex 
assay showed 100% sensitivity and specificity for the identification of N. gonorrhoeae.   
 
3.4.2 Multiplex Primers in Ascertaining Ciprofloxacin Susceptibility Status  
94 N. gonorrhoeae isolates (a subset of panel 1) were analyzed by multiplex RT-PCR; where 47 
isolates were previously determined to be ciprofloxacin susceptible (MIC 0.002-0.063ug/mL) and 
another 47 isolates were determined as ciprofloxacin intermediate/resistant (MIC 0.125-64ug/mL). 
Putative ciprofloxacin susceptibility status was precisely ascertained by melt curve analyses, 
which distinctly differentiated between ciprofloxacin susceptible and intermediate/resistant N. 
gonorrhoeae isolates. Susceptible N. gonorrhoeae produced melt curve values ~78.0°C and 
intermediate/resistant N. gonorrhoeae produced melt curves values 80.0-83.0°C. Mutations in the 
gyrA sequence resulting in S91 and D95 amino acid alterations were distinguished using the 
multiplex assay (Figure 3.1A). Further, the multiplex assay performed equally well in 
differentiating WHO N. gonorrhoeae reference strains into ciprofloxacin susceptible and 
intermediate/resistant groups (Figure 3.1B). The gyrA primers in the multiplex format successfully 
identified WHO-B, C, F, O and P strains as ciprofloxacin sensitive (melt curve ~78.0°C), and 
WHO-K, L and M strains as intermediate/resistant (melt curve  80.0-83.0°C).   
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Table 3.2 Sensitivity and specificity of gyrA-W and gyrA-M primer pairs in multiplex format for 
identification of N. gonorrhoeae isolates (Panel 1) and determination of their ciprofloxacin 
susceptibility status 
 
 No isolates 
amplified 
Sensitivity 
(%) 
Specificity 
(%) 
Single gyrA primers    
N. gonorrhoeae amplified with gyrA-W  144/254 57 NA 
Non-N. gonorrhoeae amplified with gyrA-W  0/23 NA 100 
N. gonorrhoeae amplified with gyrA-M  148/254 58 NA 
Non-N. gonorrhoeae amplified with gyrA-M  0/23 NA 100 
Multiplex gyrA-M and gyrA-W 
N. gonorrhoeae  254/254 100 NA 
Non-N. gonorrhoeae  0/23 NA 100 
Ciprofloxacin susceptiblea N. gonorrhoeae  82/82 100 99c 
Ciprofloxacin intermediate/resistanta  
N. gonorrhoeae  
171/172 99 100 
 
aAs per ciprofloxacin MIC analyses of N. gonorrhoeae: 82 isolates susceptible, 7 isolates 
intermediate, and165 isolates resistant.  
bNA - not applicable 
cOne ciprofloxacin-resistant isolate was incorrectly identified as ciprofloxacin susceptible 
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The ciprofloxacin susceptibility status of panel 1 isolates had previously been determined with 
MIC analyses: 82 isolates were susceptible (MIC 0.002-0.063ug/mL), while 172 isolates were 
intermediate (n=7; MIC 0.125-0.5ug/mL) or resistant (n=165; MIC 2-64ug/mL). With multiplex 
RT-PCR, 171/172 isolates were characterized as ciprofloxacin intermediate/resistant and 82/82 
isolates were characterized as ciprofloxacin susceptible (Table 3.2). One resistant isolate was 
incorrectly classified as susceptible after amplification. Thus gyrA primers in multiplex are 100% 
sensitive and 99% specific for the identification of ciprofloxacin susceptible isolates. Similarly, 
the primers are 99% sensitive and 100% specific in the identification of ciprofloxacin 
intermediate/resistant N. gonorrhoeae isolates (Table 3.2).  
 
3.4.3 Validation of RT-PCR Multiplex Tests for N. gonorrhoeae Identification and 
Ciprofloxacin Susceptibility Status Determination 
The gyrA primers were used to ascertain gonococcal identification and susceptibility status with 
panel 2 isolates. Used as single primer pairs, gyrA-W was 94% sensitive and 100% specific for the 
identification of N. gonorrhoeae, and gyrA-M was 100% sensitive and specific for N. gonorrhoeae 
identification (Table 3.3). Some non-specific peaks were observed with the gyrA-M primer pair 
and interpreted to be non-specific amplifications: short peak melt curves with temperatures 
84.12°C, 86.87°C and 87.21°C were observed for Atopobium vaginae, N. animaloris and 
Salmonella Typhimurium, respectively. N. perflava produced a melt curve at 76.65°C for the gyrA-
W primer pair but this observation was not reproduced in repeated experiments (data not shown). 
 
With panel 3, which comprised DNA from isolates in panel 2, primer pair gyrA-W was 93% 
sensitive and 100% specific for N. gonorrhoeae identification while gyrA-M was 99% sensitive 
and 100% specific for N. gonorrhoeae identification (Table 3.3). In multiplex analyses, the primers 
were 100% sensitive and specific for N. gonorrhoeae identification. Amplification of N. 
animaloris and N. meningitides produced melt curves at 76.65°C for gyrA-W but was not 
reproduced on replication and the result was interpreted as negative amplification. 
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Figure 3.1 Multiplex RT-PCR melt curve representation of ciprofloxacin susceptible and 
intermediate/resistant N. gonorrhoeae isolates. (A) Ciprofloxacin susceptible (n=47) and resistant 
(n=47) N. gonorrhoeae isolates (a subset of panel 1). Blue lines represent susceptible isolates, 
orange lines represent intermediate/resistant isolates, and black lines represent no template 
negative control. (B) WHO N. gonorrhoeae reference strains (n=8). Strains B, C, F, O, and P are 
susceptible (melt curve ~78oC) and strains K, L, and M are intermediate/resistant (melt curve 80.0-
83.0oC). 
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Table 3.3 Validation and re-validation of primers gyrA-W and gyrA-M using N. gonorrhoeae and 
non-N. gonorrhoeae isolates in panel 2 and panel 3 by RT-PCR. 
 
 
 
 
        Panel 2           Panel 3a 
No isolates 
amplified 
Senb 
(%) 
Spec 
(%) 
 No isolates 
amplified 
Sen 
(%) 
Spe 
(%) 
Single gyrA primers        
N. gonorrhoeae amplified with 
gyrA-W  
94/100 94 NAd  92/99 93 NA 
Non-N. gonorrhoeae amplified 
with gyrA-W  
0/52 NA 100  0/23 NA 100 
N. gonorrhoeae amplified with 
gyrA-M  
100/100 100 NA  98/99 99 NA 
Non-N. gonorrhoeae amplified 
with gyrA-M  
0/52 NA 100  0/23 NA 100 
Multiplex gyrA-M and gyrA-W        
N. gonorrhoeae  NPe NP NP  99/99 100 NA 
Non-N. gonorrhoeae  NP NP NP  0/23 NA 100 
Ciprofloxacin susceptiblef   
N. gonorrhoeae  
NP NP NP  47/47 100 100 
Ciprofloxacin 
intermediate/resistantf  
N. gonorrhoeae  
NP NP NP  52/52 100 100 
 
aPrimary purpose of Panel 3 was to assess the performance of multiplex primers using a majority 
of Panel 2 isolates; bSen – Sensitivity; cSpe – Specificity; dNA – not applicable; eNP – not 
performed; fAs per ciprofloxacin MIC analyses of N. gonorrhoeae: 47 isolates susceptible, 
52isolates resistant 
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3.5 DISCUSSION 
A method for the simultaneous identification of the pathogen N. gonorrhoeae and its ciprofloxacin 
susceptibility status has been described. Primer gyrA-W forward was designed to include the most 
conserved region in the gyrA sequence that is not common in non-N. gonorrhoeae species. The 
gyrA-M forward primer was designed to include the gyrA sequence harbouring S91 and D95 
mutations. These primers, paired with the common reverse primer, were not anticipated to be 
highly sensitive when used as individual pairs; however, the multiplex test format had high 
sensitivity and specificity (>99%) for detecting N. gonorrhoeae and its ciprofloxacin susceptibility 
status in a single amplification.  
 
The gyrA and parC genomic regions of N. gonorrhoeae are associated with ciprofloxacin 
resistance (19). parC mutations in association with gyrA mutations maintain higher levels of 
overall resistance (MIC ≥1) whereas lower levels of resistance are associated with gyrA mutations 
only. On the other hand, parC mutations alone are not associated with ciprofloxacin resistance (22, 
28, 29). In our research, we considered gyrA mutations alone and identified the ciprofloxacin 
susceptible and resistant isolates in a single multiplex RT-PCR assay. Thus, our results support the 
findings by others and demonstrate that the gyrA region alone is sufficient for the determination 
of ciprofloxacin susceptibility status (13, 18, 22, 30). We determined, through DNA sequencing, 
that the majority of intermediately susceptible isolates in our research carried mutations only at 
the S91 or D95 position, and not both (Table 3.4); one intermediately susceptible isolate in Panel 
2 had mutations both at S91 and D95 positions. Similarly, the majority of resistant isolates carried 
mutations both at S91 (S91F) and D95 positions (D95G, D95A or D95N). One resistant isolate in 
Panel 1 had a mutation only at the D95 position. Thus, we showed that ciprofloxacin resistance 
can arise due to mutations at both S91 and D95 amino acid positions, and analysis of S91 position 
alone is not sufficient for a comprehensive determination of ciprofloxacin susceptibility status. 
 
To our knowledge, this is the first report of simultaneous detection of N. gonorrhoeae as well as 
its ciprofloxacin susceptibility status in a single and simple test that is highly specific, sensitive, 
inexpensive, and rapid. The costs associated with culturing, training of laboratory personnel, as 
well as the current costs of NAATs, are beyond the economic capabilities of many resource-limited 
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settings. The cost/sample in the RT-PCR assay discussed in our test ($11.07) is about two times 
less than the costs/sample incurred by the current N. gonorrhoeae diagnostic NAATs or the costs 
associated with SNP and/or ID testing at the NML, estimated at $75/sample including labour. Thus 
the assay discussed in our work is far more affordable than the current NAATs for N. gonorrhoeae 
diagnosis. One study demonstrated the detection of N. gonorrhoeae and its ciprofloxacin 
susceptibility status, but this assay required three consecutive tests for a clear interpretation (31).  
 
Several recent publications introduced RT-PCR based methods for the detection of mutations at 
the gyrA S91 locus from clinical specimens (18, 30, 32). However, these analyses were restricted 
only to the S91 locus and the assays could be more likely to have errors if ciprofloxacin resistance 
arose through mutations in the D95 locus. In our work, we have observed through amplicon 
sequencing, ciprofloxacin resistance primarily arose due to mutations in both S91 and D95 loci, 
while intermediate resistance mainly arose due to mutations in either S91 or D95 loci. (Table 3.4). 
 
Although the results of this research highlight the utility of this multiplex RT-PCR method in 
identifying N. gonorrhoeae and determining its ciprofloxacin susceptibility status, caution is 
needed as only a very limited number of non-N. gonorrhoeae isolates were tested. In addition, 
further studies are needed to investigate if the assay has clinical applicability by testing clinical 
specimens directly with the aim of personalized care (18).  
 
Our findings show promise for the development of a POCT for the identification of N. gonorrhoeae 
and its ciprofloxacin susceptibility status. POCTs facilitate the diagnosis at the health care 
provider’s office and avoids unnecessary treatment delays. This eliminates the need for patients to 
return for post-diagnosis treatments and prevents unwanted complications and disease 
transmission (31).  Given its probable low cost and relative ease of use, this assay could have major 
implications for resource-poor, high disease burden countries (33, 34). Further, our assay may 
prove helpful to clinicians and laboratories to respond to infectious disease control organizations, 
increase surveillance for ciprofloxacin resistance, and present coherent findings for 
epidemiological and surveillance purposes. With the proper diagnosis of the AMR status, the use 
of ciprofloxacin can be increased from 8% (with NAAT based diagnosis) to over 81% (with gyrA 
based diagnosis), and thereby reduce the use of last resort antimicrobials (18).  Thus, a rapid and   
 8
4
 
Table 3.4 Single Nucleotide Polymorphisms (SNPs) observed at S91 and D95 amino acid positions of N. gonorrhoeae isolates based 
on gyrA amplicon sequencing. 
 
 
 
SNP 
Susceptible Intermediate Resistant  
Total 
Tested S91/D95 S91/D95G S91F/D95 S91Y/D95 S91/D95N S91F/D95G S91F/D95A S91F/D95N 
 
Panel 1a 
No Isolates 35 1 2 2 1 44 56 12 154 
 
 
Susceptibility 
Status 
 
Sb 
 
Ib 
 
I 
 
I 
 
Rb 
 
R 
 
R 
 
R 
 
Panel 2  
No Isolates 46 - 2 1 - 43 5 3 100 
 
 
Susceptibility 
Status 
 
S 
 
- 
 
I 
 
I 
 
- 
 
I, Rc 
 
R 
 
R 
 
agyrA sequencing information from Panel 1 is presented for 154/254 isolates. Sequencing information is not available for older isolates. 
Ciprofloxacin susceptibility status of Panel 1 and Panel 2 isolates was confirmed with MIC testing 
bS – Susceptible; I – Intermediate; R – Resistant 
c1/43 isolate intermediate and 42/43 isolates resistant 
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reliable assay, such as the platform discussed by our work, would improve the understanding of 
the extent of the disease worldwide.  
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CHAPTER 4: ENHANCED SURVEILLANCE OF NEISSERIA GONORRHOEAE AND 
ITS CIPROFLOXACIN SUSCEPTIBILITY PROFILE THROUGH CULTURE 
INDEPENDENT POINT-OF-CARE TESTING 
 
4.0 INTERFACE 
This chapter expands research described in Chapter 3, where a test comprising of multiplex primers 
for the simultaneous identification of N. gonorrhoeae and its ciprofloxacin susceptibility status 
was assessed using DNA from N. gonorrhoeae cultures. In this research, the performance of the 
test was further evaluated using different types of clinical specimens (i.e. remnant Aptima urine 
specimens, DNA from urines and raw urines). Susceptibility testing on remnant Aptima specimens 
will serve as a supplementary test for characterizing the resistance profile of a diagnosed N. 
gonorrhoeae isolate. As the goal is to introduce the test to local health centers, assessment with 
clinical specimens highlights the strengths and weaknesses of the test, and indicate the best 
specimen type for this test. The work undertaken in this chapter was presented at the Saskatchewan 
Epidemiology Association 19th Annual Fall Symposium and Workshop held in Regina, 
Saskatchewan, Canada, on October 8-9th, 2019. 
 
Sumudu R Perera conceptualized the research with guidance from Dr. Dillon, carried out 
laboratory experiments, analyzed data, wrote the manuscript and supervised Kristen M Mitzel, 
who worked on this project as a summer student and an undergraduate honours student. 
Kristen M Mitzel carried out laboratory experiments and analyzed data as part of an 
undergraduate honours project and a Summer research project. 
Jo-Anne R Dillon conceptualized the research, provided guidance with the experimental design, 
feedback and editing on the manuscript and held the research grant that supported this work. 
 
4.1 ABSTRACT 
With the emergence of the post-antibiotic era, multidrug-resistant N. gonorrhoeae has become an 
imminent threat, throughout the world. With time running out on the use of existing antimicrobials, 
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it is of vital importance to find new strategies to combat the emergence and spread of drug-resistant 
N. gonorrhoeae. We developed a PCR assay using multiplex primers (gyrA-W-F, gyrA-M-F, and 
gyrA-R) that are unique for N. gonorrhoeae and can ascertain its ciprofloxacin susceptibility status 
in a single multiplex RT-PCR reaction. In this research, the feasibility of using this molecular test 
on urines and remnant Aptima urine specimens for antimicrobial susceptibility prediction was 
assessed. This test, with remnant Aptima urine specimens (n=83), had an overall 71% sensitivity 
for N. gonorrhoeae identification; where 92% and 53% sensitivities were observed for 
ciprofloxacin susceptible and resistant specimens, respectively. When DNA extracted from urine 
specimens was used, 80% sensitivity and specificity were observed for N. gonorrhoeae 
identification. The primers were also assessed on a hydrogel platform for their ability to identify 
ciprofloxacin susceptibility status of gonococcal isolates in this setup and had demonstrated 100% 
sensitivity and specificity. The development of rapid diagnostic tests for N. gonorrhoeae and more 
importantly for its ciprofloxacin susceptibility prediction will open possibilities of using no-longer 
recommended older antimicrobials in therapy and in-turn promote the preservation of cherished 
last resort antimicrobials. 
 
  
92 
4.2 INTRODUCTION 
N. gonorrhoeae is a significant global public health concern, with 86.9 million reported new 
infections annually (1). Over time, gonococci have developed resistance to every class of antibiotic 
introduced for therapy, including third-generation cephalosporins, the last class of antibiotic used 
in single-dose therapy (2-4). The recommended treatment in many countries now comprises co-
therapy with 1g of oral azithromycin and 250mg of intramuscular ceftriaxone (5). Nonetheless, 
there have been reports of gonococci with decreased susceptibility to azithromycin and/or 
ceftriaxone (6-9), as such many countries in the European Union, only recommend ceftriaxone or 
cefixime for treatment of gonorrhea (10). As we have a limited pool of antibiotics to combat the 
emerging multi-drug resistant N. gonorrhoeae,  there is an increased urgency for new strategies to 
treat gonococcal infections.  
 
Early diagnosis of infection is vital for proper control of gonorrhea (11, 12). The identification of 
N. gonorrhoeae in high-income countries is usually accomplished by nucleic acid amplification 
tests (NAATs; 13). A limitation of NAATs is that the antimicrobial susceptibility (AMS) of N. 
gonorrhoeae positive specimens cannot be completed at present, as such testing requires the 
pathogen to be cultured. Due to the widespread use of NAATs, AMS testing of N. gonorrhoeae 
isolates has significantly declined over the last decade (14). In resource-poor settings, patients are 
treated empirically based on symptoms (15, 16), either due to costs associated with diagnostic tests 
or the unavailability of appropriate laboratory facilities. In these instances, syndromic management 
often fails to identify asymptomatic infections or resistant isolates (17, 18).  
 
An important factor contributing to the rising prevalence of gonorrhea is treatment delay during 
which patients, waiting for a positive diagnosis, can spread the disease to their contacts (19). At 
times, despite the availability of laboratory facilities, the delays in reporting results (which can 
take up to days) severely hinder timely treatment (11). It has been reported that a rapid test with a 
sensitivity as low as 63% can significantly increase the number of patients treated, instead of 
waiting for a highly sensitive, yet slower test (20, 21).  
 
Ciprofloxacin, a fluoroquinolone antibiotic, was widely been used for treating N. gonorrhoeae 
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infections from the mid-1980s onwards (3). The World Health Organization (WHO) recommends 
the discontinuation of an antibiotic when resistance is observed in >5% of isolates tested (5). In 
Canada, between 2004 and 2014, ciprofloxacin resistance in N. gonorrhoeae increased from 6.3% 
to 34% of isolates tested and is no longer recommended for the primary treatment of gonorrhea 
(21). However, in many parts of the world, a high percentage of isolates remain susceptible to 
ciprofloxacin, i.e. Saskatchewan 90%, United States 80.4%, Europe 66%, and Australia 73% (22-
25). Thus if ciprofloxacin susceptible isolates could be identified, ciprofloxacin can be re-
introduced for treatment of these isolates.  
 
Recently a commercial NAAT test ascertaining gonococcal ciprofloxacin susceptibility status was 
licensed in the United States (26). However, this assay only targets the gyrA S91F amino acid 
substitution. Furthermore, many other tests designed to identify ciprofloxacin susceptible N. 
gonorrhoeae isolates have also only focused on the gyrA S91 position (27-31). We and others have 
previously shown that there can be other substations at the S91 position (i.e. S91Y), as well as 
substitutions at the D95 amino acid position which confer resistance to ciprofloxacin (32-34). Thus 
focusing on the S91 position alone may limit the ability to identify all susceptible isolates. 
Consequently, still there is an urgent need for a comprehensive test that can identify those infected 
with ciprofloxacin susceptible N. gonorrhoeae isolates, and preserve vital last resort 
antimicrobials. 
 
A reliable and rapid point-of-care (POC) diagnostic test, capable of AMS testing in N. 
gonorrhoeae would be a critical advancement in the diagnostic capability, especially given the 
limitations of current NAATs for AMS testing (35). Furthermore, it was shown that targeted 
ciprofloxacin therapy may be cost-effective in comparison to current dual drug therapy when the 
frequency of testing and the prevalence of resistance is accounted for (36). Previously with N. 
gonorrhoeae-specific multiplex primers and DNA from N. gonorrhoeae cultures, we obtained over 
99% sensitivity and specificity for identifying ciprofloxacin susceptible isolates (Chapter 3: 31, 
37). In this research, we assessed the efficacy of these multiplex primers in identifying N. 
gonorrhoeae and predicting ciprofloxacin susceptibility from urines and remnant Aptima urine 
specimens.  
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4.3 MATERIALS and METHODS 
4.3.1 Clinical Specimens and Bacterial Strains 
Two types of specimens were used; urines and remnant Aptima urine specimens. The 331 remnant 
Aptima urine specimens were obtained from the Roy Romanow Provincial Laboratory (RRPL), 
Regina SK. The specimens were collected between 2015 and 2016. N. gonorrhoeae was identified 
using the Aptima Combo 2 assay (Hologic Gene-Probe Inc., San Diego CA) at the RRPL. Of the 
331 specimens, 301 were N. gonorrhoeae positive and 30 were N. gonorrhoeae negative. Also, 20 
N. gonorrhoeae positive and 20 N. gonorrhoeae negative urines were obtained from the 
Saskatchewan Health Authority (SHA), Regina region (Regina SK). These specimens had been 
tested for N. gonorrhoeae using the Aptima Combo 2 assay. The DNA extracted from urines and 
raw urines (without DNA extraction) was used in the analyses. For experiments involving urines, 
positive controls consisted of DNA from the WHO N. gonorrhoeae reference isolates F, P, G, K 
and N (38), while the negative controls included DNA from Neisseria weaveri, Neisseria 
wadsworthii, Klebsiella oxytoca, Staphylococcus aureus and Lactobacillus iners, obtained from 
the National Microbiology Laboratory (NML), Winnipeg MB.  
 
The portable hydrogels were manufactured by the Aquila Diagnostic Systems Inc. Edmonton AB, 
Canada. This hydrogel-based diagnostic platform utilizes Real-Time Polymerase Chain Reaction 
(RT-PCR) melt curve analysis to amplify nucleic acids directly from clinical specimens and report 
the presence of specific genetic targets. For experiments using hydrogels DNA from the following 
isolates and specimens were used; N. gonorrhoeae 971008 and N. gonorrhoeae C0910B027331 
(10ng/µl; Dillon culture collection), and DNA from urine #54 (10ng/µl) and urine #55 (2.6ng/ul; 
SHA, Regina Region). DNA concentrations of raw urines were not measured since urines are 
highly diluted. 
 
4.3.2 DNA Extraction 
N. gonorrhoeae isolates were stored at -80°C in brain heart infusion medium (Difco BD 
Bioscience) with 20% glycerol. Aliquots from frozen inocula were cultured on GC medium base 
(Difco BD Bioscience) supplemented with 1% Kellogg’s defined supplement. Plates were 
incubated at 35-37°C with 5% CO2 in a humid environment for 18 to 24h (39).  
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Remnant Aptima urine specimens and urines were shipped on dry ice to the Dillon laboratory. 
Aptima specimens were stored at 4oC for 2-3 days prior to DNA extraction, while the urines were 
stored at -80oC until DNA extraction. 
 
DNA extraction from bacterial cultures and remnant Aptima urine specimens was performed using 
a QIAamp DNA Mini kit (Qiagen) according to the manufacturer’s instructions. DNA from 
bacterial cultures was quantified using NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific) and was normalized to 50ng/µl. Due to their variability, DNA concentrations were not 
standardized for remnant Aptima urine specimens. 
 
Urine specimens were spun at 13,000xg for 10 min. The resulting pellets were treated overnight 
with Proteinase K and ATL buffer. On the following day, DNA was extracted using a QIAamp 
DNA Mini kit (Qiagen) according to the manufacturer’s protocol. DNA was quantified using a 
Qubit 4 Fluorometer (Thermo Fisher Scientific) and was normalized to 50ng/µl for all the positive 
and negative control specimens.  
 
4.3.3 DNA Sequencing 
To determine ciprofloxacin susceptibility status of N. gonorrhoeae, a fragment of the gyrA 
genomic region of N. gonorrhoeae, corresponding to the S91 and D95 amino acid positions, was 
PCR amplified from N. gonorrhoeae cultures, remnant Aptima urine specimens, and urines with 
primers gyrA-F (ACTGTACGCGATGCACGAGC) and gyrA-R (TCTGCCAGCATTTCATG 
TGAG) (40). Sanger sequencing of the amplicons was performed at Eurofins Genomics 
(Louisville KY, USA).  
 
4.3.4 Multiplex Primers  
Two different forward primers and a common reverse primer with homology to N. gonorrhoeae 
gyrA were designed (United States utility patent #62/088,332) using Primer-BLAST as reported 
previously (Chapter 3, 32, 41). Briefly, primer pair gyrA-W, for which the forward primer was 
designed to amplify a conserved region of gyrA, comprised the forward primer gyrA-W-F 
(5’GCGATTCCGCAGTTTACGA3’) and the common reverse primer gyrA-R (5’CGAAATTTT 
GCGCCATACGGACGAT3’). Primer pair gyrA-M, for which the forward primer was designed 
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to amplify the region containing the gyrA SNPs associated with ciprofloxacin resistance, 
comprised the forward primer gyrA-M-F (5’ TACCACCCCCACGGCGATTT3’) and the common 
reverse primer gyrA-R (32).  
 
4.3.5 Real-Time (RT) PCR 
RT-PCR was performed using an Applied Biosystems StepOnePLus instrument (Life 
Technologies) on a 96-well plate platform (Life Technologies) with the SYBR Select Master Mix 
reagent kit (Life Technologies). PCR reactions contained 5µl of 2X SYBR-Green, 3µl of combined 
primer mix (10µM) and 2µl of DNA template (at various concentrations). PCR was performed 
with an initial holding at 50°C for 2min followed by a secondary holding at 95°C for 2 min. PCR 
was performed for 25 cycles at 95°C for 15 sec and 60°C for 30 sec. The post-PCR melt curve was 
determined between 60°C to 90°C, with a 0.3°C temperature increments. Each experiment was 
performed in duplicate. The sensitivity and specificity of the melt curve predicted ciprofloxacin 
susceptibility status was calculated using the formulas described before (40).  
 
For experiments with hydrogels, PCR reactions contained 0.25μl of each primer (which were either 
at 5, 10 or 15μM), and 2μl of DNA template (at various concentrations). The DNA concentration 
was not adjusted to all samples, due to variability in urines. The final reaction volume was adjusted 
to 10μl with deionized water. PCR was conducted as; initial holding at 50°C for 2 min followed 
by a secondary holding at 95°C for 2 min. Amplification was performed for 40 cycles (experiment 
1) or 25 cycles (experiment 2) at 95°C for 15 sec and 60°C for 30 sec. The 25 and 40 PCR cycles 
were determined with preliminary experiments involving urines and previous observations (32). 
The post-PCR melt curve was determined between 60°C to 95°C with 0.3°C increments. All 
experiments were performed in duplicates.  
 
4.3.6 Hydrogels 
Hydrogels were manufactured by Aquila Diagnostic Systems Inc., (Edmonton AB). Different 
SYBR-Green dye concentrations (2X, 3X, 4X, 5X and 6X) were incorporated into the gels before 
shipping to the Dillon laboratory. Primers and DNA were added to the gels immediately before 
PCR amplification.  
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4.4 RESULTS 
4.4.1 Predictability of Ciprofloxacin Susceptibility Status using Aptima Urine Specimens 
From the 301 N. gonorrhoeae positive remnant Aptima urine specimens, 146 (49%) specimens 
were correctly identified as N. gonorrhoeae positive, and from the 30 N. gonorrhoeae negative 
specimens, 21 (70%) were identified as negative. From the 146 specimens identified as N. 
gonorrhoeae positive, RT-PCR based melt curve analyses predicted 105 were ciprofloxacin 
susceptible and 41 were intermediate or resistant.  
 
To ascertain the accuracy of RT-PCR based prediction of ciprofloxacin susceptibility status using 
the gyrA multiplex primers, 83 specimens were amplicon sequenced for the region surrounding 
the gyrA S91 and D95 positions. The results from sequencing were compared to melt curve based 
predictions of ciprofloxacin susceptibility status (Table 4.1). Of the 83 specimens, 54 was 
identified as susceptible and 29 was identified as resistant with melt curve analysis. However, 
sequence analysis indicated that 16 resistant isolates were incorrectly recognized as susceptible 
and these 16 isolates had the S91F/D95G substitutions. Of the 45 resistant isolates, 35 carried the 
S91F/D95G, 9 carried the S91F/D95A, and 1 carried the S91F/D95 substitutions. 
 
These results were indicative that although resistance cannot be predicted with a high sensitivity, 
ciprofloxacin susceptible isolates can be predicted, with over 90% accuracy, using DNA from 
remnant Aptima urine specimens. However, the results should be taken with caution, as 16 
resistant isolates were also identified as susceptible. 
 
4.4.2 Sensitivity of the gyrA Multiplex Primers When Using Urines 
Next, the primers were assessed using urines. When using DNA from N. gonorrhoeae and non-N. 
gonorrhoeae cultures, sensitivity and specificity of 100% were observed (Table 4.2). With DNA 
from N. gonorrhoeae positive urines, 80% sensitivity was observed, while a 15% sensitivity was 
noted with N. gonorrhoeae positive raw urines (i.e. no DNA extraction step was performed). 
Similarly, an 80% specificity was observed with DNA from N. gonorrhoeae negative urines, and 
a 100% specificity was observed with N. gonorrhoeae negative raw urines.  
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Table 4.1 The ciprofloxacin susceptibility status predicted with melt curve analysisa  
 
 No of specimens Susceptibility/Resistance 
based on Sequencing 
SNPs 
Susceptible 54 38 S91/D95 
Resistant 29 45a S91F/D95G – 35 
S91F/D95A – 9 
S91F/D95 – 1  
 
a16 resistant isolates were identified as susceptible. All these isolates had S91F/D95G substitution 
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Table 4.2 Sensitivity and specificity of gyrA multiplex primers for identification of N. 
gonorrhoeae and its ciprofloxacin susceptibility prediction using urine specimens. 
 
  
Sensitivity No. Cipro 
Susceptiblea 
No. Cipro 
Resistanta 
DNA from N. gonorrhoeae cultures (n=5) 100% (5/5) 2/5 3/5 
DNA from N. gonorrhoeae positive urines (n=20) 80% (16/20) 16/20b 0/20 
N. gonorrhoeae positive raw urines (n=20) 15% (3/20) - - 
 Specificity   
DNA from non-N. gonorrhoeae cultures (n=5) 100% (0/5)c - - 
DNA from N. gonorrhoeae negative urines (n=20) 80% (4/20)c - - 
N. gonorrhoeae negative raw urines (n=20) 100% (0/20)c - - 
 
aCiprofloxacin susceptibility status predicted with RT-PCR was verified with gyrA amplicon 
sequencing 
bFour susceptible specimens had non-specific melt curves 
cSpecificity was determined by the number of non-amplified specimens 
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Ciprofloxacin susceptible control strains (WHO F and P) were correctly identified as susceptible 
(2/5; Table 4.2), and the ciprofloxacin intermediate and resistant strains (WHO G, K and N) were 
correctly identified as resistant (3/5). As N. gonorrhoeae positive raw urines and DNA from N. 
gonorrhoeae positive urines represent the same samples, susceptibility status was only determined 
for DNA samples. Here, 16/20 specimens were identified as ciprofloxacin susceptible by melt 
curve analysis and were later confirmed by amplicon sequencing the region surrounding the gyrA 
S91 and D95 positions. The four remaining specimens had non-specific melt curves. Thus, with 
DNA from urines, none of the ciprofloxacin susceptible isolates were incorrectly identified as 
resistant. 
 
4.4.3 Hydrogel Experiments with gyrA Multiplex Primers 
We previously used a hydrogel-based RT-PCR detection platform and a panel of N. gonorrhoeae 
specific diagnostic primers to identify N. gonorrhoeae DNA from cultures (32). To optimize 
conditions in hydrogels for the gyrA multiplex primers, we evaluated DNA from N. gonorrhoeae 
cultures and N. gonorrhoeae positive urines, as well as raw urines using the gyrA multiplex 
primers. The criteria for a positive test consisted of a copy number (Ct) value above the threshold, 
a melt curve (Tm) at the correct temperature (susceptible 77-78oC and resistant 80-82oC) and 
visual inspection of the melt curve for a characteristic peak. 
 
In the first experiment (Exp 1, 40 PCR cycles), the best performance was observed with 10µM 
primer and 2X, 3X, 4X and 5X SYBR-dye, where all 6 N. gonorrhoeae specimens amplified and 
the negative control did not amplify (Table 4.3). DNA from N. gonorrhoeae cultures amplified 
with all SYBR dye and primer concentrations except for two instances; Ng C0910B027331 with 
4X SYBR/5µM primer and Ng 971008 with 3X SYBR/5µM primer. DNA from urine #54 
amplified under all conditions expect with 2X SYBR/5µM primer. DNA from urine 55 failed to 
amplify with 2X SYBR, 3X SYBR, and 6X SYBR when15µM primer was used. However, DNA 
extracted from urine specimens performed best with 4X and 5X SYBR concentrations. The results 
using raw urines were optimal with 3X SYBR and all three primer concentrations. 
 
In the second experiment (Exp 2, 25 PCR cycles), none of the negative controls amplified, as 
expected (Table 4.3). However, none of the raw urines or DNA extracted from the urine specimens   
  
1
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Table 4.3 Summary of the hydrogel-gyrA multiplex primer experiment. Exp 1 – experiment 1 performed with 40 RT-PCR cycles; Exp 
2 – experiment 2 performed with 25 RT-PCR cycles. 
 
aR – ciprofloxacin resistant  
bS – ciprofloxacin susceptible  
 
Primer 
Conc. 
 
SYBR 
Dye 
Conc. 
Isolates/Specimens 
DNA extracted from  
N. gonorrhoeae cultures  
DNA extracted from 
urines 
Raw urines  
N. polysacharea 
(negative control) C0910B027331 
(R)a 
971008  
(S)b   
#54  
(R) 
#55  
(S) 
#54  
(R) 
#55  
(S) 
Exp 1/Exp2c Exp 1/Exp2 Exp 1/Exp2 Exp 1/Exp2 Exp 1/Exp2 Exp 1/Exp2 Exp 1/Exp2 
 
5 uM 
2x +/+ +/- -/- +/- -/- +/- +/- 
3x +/+ -/- +/- +/- +/- +/- -/- 
4x - /+ +/- +/- +/- -/- +/- +/- 
5x +/+ +/- +/- +/- +/- -/- +/- 
6x +/- +/- +/- -/- -/- -/- -/- 
 
 
10 uM 
2x +/+ +/- +/- +/- +/- +/- -/- 
3x +/+ + /+ +/- +/- +/- +/- -/- 
4x +/+ + /+ +/- +/- +/- +/- -/- 
5x +/+ +/- +/- +/- +/- +/- -/- 
6x +/+ +/- +/- +/- -/- +/- +/- 
 
 
15 uM 
2x +/+ + /+ +/- -/- +/- -/- +/- 
3x +/+ + /+ +/- -/- +/- +/- +/- 
4x +/+ + /+ +/- +/- +/- +/- +/- 
5x +/+ + /+ +/- +/- +/- +/- +/- 
6x +/+ + /+ +/- +/- -/- +/- +/- 
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amplified either. Both Ng C0910B027331 and Ng 971008 amplified with 2X SYBR/15µM primer, 
3X SYBR/10µM and 15µM primer, 4X SYBR/10µM and 15µM primer, and 5X SYBR/15µM 
primer concentrations.  
 
Overall, the samples performed the best with 10µM primer concentration, 5X SYBR-Green 
concentration and 40 PCR cycles. Surprisingly, N. polysacharea amplified 9/15 times, and 
irrespective of the SYBR concentration or the primer concentration (Table 4.3). Subsequent testing 
with N. gonorrhoeae and ddH2O from different sources indicated that 40 PCR cycles were causing 
non-specific amplification and was not observed when 25 PCR cycles were used. However, 25 
PCR cycles had compromised the amplification of raw urines and DNA from urine specimens. 
The SYBR dye concentration did not affect the performance of the samples, although 15µM primer 
concentration worked the best with DNA extracted from N. gonorrhoeae cultures (Table 4.3). In 
this preliminary experiment, DNA extracted from N. gonorrhoeae cultures and urines, as well as 
raw urines had 100% sensitivity for N. gonorrhoeae identification and ciprofloxacin susceptibility 
prediction, with 10µM primer, 5X SYBR-Green and 40 PCR cycles, in the hydrogel assay. (Table 
4.3).   
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4.5 DISCUSSION 
This research assesses the feasibility of using urine specimens for the diagnosis of N. gonorrhoeae 
and characterization of its ciprofloxacin susceptibility status with unique multiplex primers (32, 
36). Our results shed light on the limitations associated with using remnant Aptima urine 
specimens for AMS prediction by molecular techniques, as these specimens were not ideal for 
predicting resistance. However, we observed over 90% sensitivity in susceptibility predictions, but 
the specificity was low as 42% resistant isolates were also identified as susceptible. Although N. 
gonorrhoeae was not readily amplified from raw urines, the DNA extracted from urines have 
higher sensitivity for N. gonorrhoeae identification and ciprofloxacin AMS prediction than with 
remnant Aptima urine specimens. Despite the use of N. gonorrhoeae positive remnant Aptima 
specimens in the past for PCR amplification of resistant determinants (42), and evaluation of 
diagnostic assays (28, 43), these experiments were limited in either time for results (41) or 
capability for a comprehensive analysis of all markers associated with ciprofloxacin resistance (27, 
28, 43, 44).  
 
The gyrA and parC loci of N. gonorrhoeae are associated with ciprofloxacin resistance (45). 
Although parC mutations in association with gyrA mutations are implied in higher levels of 
ciprofloxacin resistance (MIC of ≥1), gyrA mutations alone are associated with lower levels of 
resistance. In contrast, parC mutations alone are not associated with ciprofloxacin resistance (31, 
46). Thus, in our research, we have further supported that the characterization of gyrA alone is 
sufficient to identify ciprofloxacin susceptible isolates both using DNA from cultures and urines 
(31, 32, 34, 44, 47). However, in contrary to other PCR based methods for detecting gyrA S91 
substitutions (44, 47, 48), previously we have shown that reduced susceptibility can arise due to 
substitutions either at S91 or D95 amino acid positions (32). Therefore, the analysis of the S91 
position alone is not sufficient for a comprehensive determination of ciprofloxacin susceptibility 
status, and our primers are unique to identify resistance arising through mutations corresponding 
to both S91 and D95 amino acid positions. 
 
Despite the assay’s benefits, this research has limitations. Here we only tested a limited number of 
urine specimens and have not tested other types of clinical specimens, such as swabs. For this 
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assay to be an ideal POCT, the volume of urine and the type of specimen should be optimized such 
that the concentration of N. gonorrhoeae DNA in the final reaction can be increased (27). 
Additionally, the minimum inhibitory concentrations (MICs) were not ascertained for any of the 
specimens because they were derived from remnant Aptima urine specimens. This may be more 
feasible with swab specimens (29). Due to the limited number of samples and replicates involved 
with hydrogel experiments, it was difficult to establish the sensitivity and specificity of the gyrA 
primers in the hydrogel platform. Larger sample sizes would allow for more reliable sensitivity 
and specificity predictions. Furthermore, the number of PCR cycles should be optimized to amplify 
the urine specimens, but not the DNA from commensal Neisseria species.   
 
Despite these limitations, our findings show promise in using DNA extracted from urines to 
diagnose N. gonorrhoeae infections and determine the isolate’s ciprofloxacin susceptibility status. 
Furthermore, this is the first research using direct clinical specimens (i.e. without a DNA extraction 
step) for molecular AMS testing for ciprofloxacin in N. gonorrhoeae; whereas other tests using 
clinical specimens have utilized a DNA extraction step (27-29). Given that local communities exist 
with ciprofloxacin susceptible gonococcal isolates (23), our assay enables rapid (~2h) and timely 
determination of AMS and thereby facilitate the use of no longer recommended antibiotics to treat 
gonorrhea and promote the preservation of last resort antimicrobials such as cephalosporin and 
azithromycin (44). As such, this platform shows promise in the development as a POCT for N. 
gonorrhoeae diagnosis and characterization of its ciprofloxacin susceptibility status. POCTs 
facilitate timely diagnosis at local health clinics and evade unnecessary treatment delays (49). 
Given its probable low cost and relative ease of use, this assay could have major implications for 
resource-limited, high disease burden communities.  
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5.0 INTERFACE 
Although N. gonorrhoeae isolates from different communities can remain susceptible to 
ciprofloxacin, more and more gonococcal isolates are acquiring mutations leading to multi-drug 
resistance. Thus, for antimicrobial stewardship and to help in treatment, it is crucial to characterize 
emerging drug resistance trends and overall resistance prevalence in N. gonorrhoeae isolates. This 
research assessed the use of remnant Aptima urine specimens to characterize eight genes 
associated with antimicrobial resistance in N. gonorrhoeae and to predict antimicrobial 
resistance/susceptibility to six antibiotics. We reported emerging gonococcal resistance, in 
Saskatchewan, to azithromycin and cefixime, two of the last resort antimicrobials presently used 
for gonococcal treatment. Especially, we identified an emerging clone implicated globally in 
cefixime resistance with penA type XXXIV. Thus, this research highlights the importance of 
molecular analysis of clinical specimens for the prediction of present and emerging AMR in 
gonococci. This chapter was previously published in Future Microbiology DOI:10.2217/fmb-
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2019-0161 and is reprinted here with permission. The work discussed in this chapter has been 
presented at the Gordon Research Conference on Drug Resistance held in Smithfield, Rhode 
Island, the United States of America, on July 22-27th, 2018, and at the International Union Against 
Sexually Transmitted Infections (IUSTI) World + European Congress held in Dublin, Ireland on 
June 27-30th, 2018. 
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Jo-Anne R Dillon conceptualized the research, provided guidance with the experimental design, 
feedback and editing on the manuscript and held the research grant that supported this work 
 
5.1 ABSTRACT 
To ascertain antimicrobial resistance and strain types (STs) of Neisseria gonorrhoeae from 50 
remnant Aptima urine specimens using molecular methods, mutations predictive of resistance to 
six antibiotics were identified in eight genes. STs were determined using NG-MAST and NG-
STAR. All eight antimicrobial resistance genes could be characterized in 36 specimens. A total of 
17 specimens were predicted to be susceptible to all antibiotics, including ceftriaxone. Decreased 
susceptibility to cefixime and ciprofloxacin resistance was predicted in 11 specimens (PBP2 type 
34.001). Overall, 38/50 specimens were predicted to be ciprofloxacin susceptible; 3 were 
azithromycin resistant. Nineteen NG-MAST and 21 NG-STAR STs were noted. Molecular 
analysis of remnant Aptima specimens enabled the prediction of emerging gonococcal cefixime 
and azithromycin resistance, which would otherwise have been undetected. 
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5.2 INTRODUCTION 
Gonorrhea, caused by the pathogen N. gonorrhoeae, is the second most common sexually 
transmitted infection (STI) in Canada (1). There are 78 million new infections of gonorrhea per 
year worldwide (2012 estimates) (2). Gonorrhea is managed with a combination of case finding, 
microbiological diagnosis, and treatment with antibiotics. There are no vaccines for this disease. 
N. gonorrhoeae has sequentially developed resistance to every class of antimicrobial agents used 
for treatment since the introduction of sulphonamides in 1935 (3). Because of this resistance, 
treatment options for gonorrhea infections are limited and, in many countries, a combination of 
ceftriaxone, a third-generation cephalosporin and the last class of drug used in monotherapy, with 
azithromycin is recommended for therapy (4). Increasing resistance to both ceftriaxone and 
azithromycin, and documented treatment failures to both antibiotics have further intensified the 
need to find either new treatment modalities, or to steward currently available antibiotics for the 
treatment of gonorrhea more effectively (5, 6). The World Health Organization (WHO) established 
a global action plan to control the emergence and spread of antimicrobial resistance (AMR) in N. 
gonorrhoeae with AMR surveillance being a critical component of the plan (4, 7).  
 
AMR determination of N. gonorrhoeae isolates requires that the microorganism be cultured so that 
its antimicrobial susceptibility (AMS) can be ascertained. This is not performed in many regions. 
Resource-rich settings use nucleic acid amplification tests (NAATs) for the identification of N. 
gonorrhoeae from clinical specimens; the microorganism cannot be cultured for AMR testing from 
such specimens (8). Resource-limited settings often do not culture for N. gonorrhoeae and, in the 
absence of adequate laboratory facilities, patients rely on syndromic management and empiric 
treatment of gonococcal infections (3). Thus, the true extent of AMR in N. gonorrhoeae is 
unknown in many areas. One solution to this challenge would be to devise reliable molecular 
methods for AMR determination or prediction.  
 
Resistance to antibiotics in N. gonorrhoeae isolates is caused by mutations in various genes and/or 
horizontal gene transfer (9). For example, penicillin resistance can be mediated by a plasmid-
encoded TEM β-lactamase (blaTEM) or by mutations in several chromosomal genes (10). The 
stepwise acquisition of mutations in genes such as penA (encodes PBP2), mtrR (encodes MtrR), 
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and porB (encodes PIB) lead to a reduced affinity for penicillin by PBP2, increased efflux pump 
activity and membrane impermeability (10). These mutations, with an additional mutation in ponA 
(encodes PBP1), contribute to stepwise increases in the Minimum Inhibitory Concentration (MIC) 
and ultimately chromosomally-mediated penicillin resistance (10). In addition to these mutations, 
mosaic patterns (~60 mutations) in the transpeptidase domain of PBP2 can lead to reduced 
susceptibility or resistance to extended-spectrum cephalosporins (ESCs) (11-14). Resistance to 
tetracycline is conferred by a mutation in ribosomal protein S10 (encoded by rpsJ), which 
increases gonococcal MICs to tetracycline (MIC = 1 mg/L), and, in combination with the 
mutations in porB and mtrR, contributes in the development of chromosomal resistance (MIC >2 
mg/L) (15). High-level tetracycline resistance (MIC >16 mg/L) is plasmid-mediated and caused 
by the presence of the tetM determinant (3). Mutations in gyrA and parC, that encode DNA gyrase 
A and topoisomerase IV, respectively, are correlated with ciprofloxacin resistance (16). Resistance 
to macrolides, such as azithromycin, is caused by mutations in 23S r-RNA, coupled with mutations 
in mtrR (17, 18).  
 
In Saskatchewan (SK), more than 95% of N. gonorrhoeae cases are diagnosed by NAAT using 
the Health Canada approved Aptima Combo 2 Assay (19, 20). Thus, there is no information on 
the AMS of these gonococcal specimens. Only two investigations have tested remnant Aptima 
specimens to predict AMR and strain types (STs) of N. gonorrhoeae using molecular methods (21, 
22). Pabbaraju et al. purified DNA from 34 N. gonorrhoeae positive Aptima specimens, followed 
by PCR and DNA sequencing, to determine mutations in PBP2 (penA) linked with resistance to 
cefixime, and to ascertain STs using the N. gonorrhoeae multi-Antigen Sequence Typing (NG-
MAST) method (21). Melendez et al. purified DNA from 552 remnant Aptima swabs positive for 
N. gonorrhoeae and used qPCR to predict resistance to ciprofloxacin (gyrA and parC), penicillin 
(blaTEM plasmid-mediated penicillin resistance), and ESCs – cefixime and ceftriaxone (penA) 
(22). The present research aimed to predict susceptibility based on the molecular characterization 
of AMR genes by utilizing remnant Aptima urine specimens. We isolated DNA from 50 N. 
gonorrhoeae positive remnant Aptima urine specimens to predict AMR to six antibiotics. We 
amplified and sequenced penA, porB, mtrR, ponA, rpsJ, gyrA, parC, and 23S r-RNA from these 
specimens to ascertain the mutations linked with different AMRs and characterized AMR STs 
using the Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) 
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program (23). We also ascribed STs by NG-MAST, which characterizes two hypervariable loci, 
tbpB and porB (24). These analyses allowed us to generate insights into the emerging resistance 
and STs of N. gonorrhoeae in SK that would otherwise not have been possible. 
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5.3 MATERIALS AND METHODS 
5.3.1 Specimen Collection 
N. gonorrhoeae was identified from urine specimens submitted to the Roy Romanow Provincial 
Laboratory (RRPL, Regina, SK) using the Aptima Combo 2 assay (Hologic Gene-Probe Inc., CA, 
USA). Information such as place and date of collection, age, and sex of the patients was also 
collected. Fifty N. gonorrhoeae positive remnant Aptima urine specimens (40 were collected in 
June/July 2017 and 10 in November 2017) were transported to the University of Saskatchewan on 
dry ice and stored at -20°C. Patient ages ranged from 15-59; 20 were male, 30 were female.  
 
5.3.2 DNA Extraction & Amplification of AMR Genes from Remnant Aptima Urine 
Specimens 
DNA from specimens collected during June/July 2017 (n=40) was isolated using the QIAamp 
DNA Mini kit (Qiagen, Ontario; method 1) as per the manufacturer’s instructions. For method 1, 
Taq polymerase was used to amplify (55°C annealing temperature) eight (penA, porB, mtrR, ponA, 
gyrA, parC, rpsJ and 23S r-RNA) AMR determinants and two NG-MAST loci (tbpB and porB). 
However, due to difficulties in the amplification of AMR determinants in many specimens from 
method 1, DNA from all 50 specimens was purified using the QIAamp Viral RNA Mini kit 
(Qiagen, Ontario; method 2). For method 2, 400µl of the Aptima specimen was spun at 3000g for 
1 min and the supernatant was processed using the manufacturer’s instructions. Phusion High 
fidelity DNA polymerase (New England Biolabs, NEB) was used to amplify various genes (that 
were not previously amplified) from the DNA obtained using method 2. Here, AMR determinants 
were amplified using the following annealing temperatures: penA-A1/penA-B1 62oC; penA-
A2/penA-B2 55oC; penA-A3/penA-B3 58oC; mtrR1/mtrR2 58oC, por-NGMAST-F/por-
NGMAST-R 58oC; ponA1-F/ponA1-R 65oC, GYRA-1/GYRA-2 68oC; parC-F/parC-R 62oC; 
gonrRNAF/gonrRNAR2 55oC; tbpB-F/tbpB-R 69oC; and rpsJ-F/rpsJ-R 55oC.  
 
For both methods, DNA concentrations were measured by using NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific, Ontario) and 260/230 and 260/280 ratios were 
recorded. Primer sequences (Table 5.1) for rpsJ (25) and other AMR determinants 
(https://ngstar.canada.ca/) were synthesized at Thermo Fisher Scientific. Amplicons were 
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confirmed for the correct size (https://ngstar.canada.ca/) by agarose gel electrophoresis and were 
sequenced by Sanger sequencing (Eurofins Genomics, Ontario). Amplicon products with distinct 
bands were directly submitted for sequencing. Only amplicons containing primer-dimers or 
nonspecific amplification were purified, using the QIAquick PCR Purification Kit (Qiagen), and 
subsequently sequenced. Differences in DNA concentration for each specimen and 260/230 ratios 
obtained by the two methods were evaluated using the paired t-test in GraphPad Prism 6.0 
(GraphPad Software, Inc., San Diego, CA).  
 
5.3.3 DNA Sequence Analysis & Strain Typing 
penA sequences were assembled using Clone Manager 9 Professional (Scientific & Educational 
Software, NC, USA). Nucleotide sequences of all genes (except for 23S r-RNA) were translated 
into protein sequences and mutations implicated in AMR were identified by manually aligning to 
the reference sequences downloaded from NG-STAR (https://ngstar.canada.ca/). The reference 
sequence for rpsJ was retrieved from NCBI (N. gonorrhoeae FA19 - GenBank: EEZ46595.1). The 
manual alignment of each nucleotide and protein sequence to reference sequences was carried out 
using CLC Genomics Workbench (Qiagen). The allele numbers for each AMR determinant were 
obtained and NG-STAR STs were assigned. NG-MAST STs were obtained by aligning DNA 
sequences to the ST database at the NG-MAST website (www.ng-mast.net/). The phylogenetic 
tree was constructed using the maximum likelihood method in MEGA7 after concatenating each 
AMR determinant.  
 
5.3.4 Prediction of AMR 
AMR was predicted according to criteria reported in the literature. Reduced susceptibility to 
cefixime (MIC ≥0.25 mg/L) can be associated with non-mosaic PBP2 (penA) types such as 13.001 
(A501V substitution) or mosaic PBP2 (penA) types such as 10.001 and 34.001 with associated 
I312M, V316T, G545S, A501V, and N512Y substitution (12, 14, 26, 27). In addition, isolates with 
reduced susceptibility to cefixime also carry mutations in MtrR (mtrR, e.g. A-; A38T; G45D) and 
PIB (porB, e.g. G120K; A121N/S/G; 12).  
 
Mosaic PBP2 (penA) types coupled with the substitution G542S and P551S/I are associated with 
elevated MICs (MIC ≥0.016 mg/L) to ceftriaxone (28). Also, substitution such as A311V and  
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Table 5.1 List of primers used to amplify N. gonorrhoeae AMR markers. 
 
  
AMR marker Primer name Primer sequence (5’ to 3’) Product size 
(bp) 
Reference 
penA PenA-A1(forward)  
PenA-B1(reverse) 
 
PenA-A2(forward)  
PenA-B2 (reverse) 
 
PenA-A3(forward)  
PenA-B3 (reverse) 
 
PenA-A4 (forward) 
CGGGCAATACCTTTATGGTGGAAC 
AACCTTCCTGACCTTTGCCGTC 
 
AAAACGCCATTACCCGATGGG 
TAATGCCGCGCACATCCAAAG 
 
GCCGTAACCGATATGATCGA 
CGTTGATACTCGGATTAAGACG 
 
AATTGAGCCTGCTGCAATTGGC 
669 
 
 
581 
 
 
863 
23 
mtrR MTR1(forward) 
MTR2 (reverse) 
CA GCAT CT ATTTCA  
TTAGAAGAATGCTTTGTGTC 
916 23 
porB1b por-NGMAST-F (forward)  
por-NGMAST-R (reverse) 
CAAGAAGACCTCGGCAA 
CCGACAACCACTTGGT 
737 23 
ponA ponA1-f (forward)  
ponA1-r (reverse) 
CGCGGTGCGGAAAACTATATCGAT 
AGCCCGGATCGGTTACCATACGTT 
1240 23 
gyrA GYRA-1(forward)  
GYRA-2 (reverse) 
AACCCTGCCCGTCAGCCTTGA 
GGACGAGCCGTTGACGAGCAG 
270 23 
parC parC F (forward) 
parC R (reverse) 
GTTTCAGACGGCCAAAAGCC 
GGCATAAAATCCACCGTCCCC 
332 23 
23S rRNA gonrRNAF (forward) 
gonrRNAR2 (reverse) 
ACGAATGGCGTAACGATGGCCACA 
TTCGTCCACTCCGGTCCTCTCGTA 
712 23 
rpsJ RPS-for 
RPS-rev 
GTGCTGTTGTAAAAGGCCCG 
CGGCCGGCAAATCCAGCTTC 
186 25 
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T483S in mosaic PBP2 type 60 confer reduced susceptibility to ceftriaxone (29). Some reports 
suggest that MtrR (mtrR), PIB (porB) and other novel genes are implicated in reduced 
susceptibility to ceftriaxone (MIC ≥0.125 mg/L) (27, 30, 31).  
 
Resistance to azithromycin is conferred by A2059G (high level) and C2611T (low level) in all 
four alleles of 23S r-RNA (32). Mutations in MtrR (i.e. A-; A38T; G45D) are also implicated in 
high-level resistance of N. gonorrhoeae to azithromycin (18). Several substitutions at positions 
S91 (e.g. S91F) and D95 (e.g. D95G/A/N) of GyrA (gyrA), and positions D86, S87 and S88 of 
ParC (parC, e.g. D86N; S87R/N; S88P; and E91K) are associated with resistance to ciprofloxacin 
(MIC ≥1 mg/L) (33-35). The step-wise acquisition of mutations in penA, mtrR, porB and ponA 
confers stepwise increases in MIC to penicillin (10, 36). Insertion of aspartic acid at position 345 
in PBP2, together with an additional four and/or eight substitutions (e.g. F504L, A510V, A516G, 
H541N and/or P552V, K555Q, I556V, and I557V) in any non-mosaic PBP2 (penA) confer an 
intermediate MIC to penicillin (MIC = 0.12 mg/L) (10). Mutations (i.e. A-; A38T; G45D) in MtrR 
(mtrR) do not elevate penicillin MICs alone but in combination with G120K/N and A121N/S/G 
substitutions in PIB (porB) are associated with a penicillin MIC of 1 mg/L (10). The further 
addition of substitution L421P in PBP1 (ponA) confers resistance to penicillin (MIC ≥2 mg/L; 10).  
 
For tetracycline, mutations in MtrR (mtrR, A-; A38T; G45D), PIB (porB, G120K:A121N; A121S; 
G120N:A121G) and S10 (rpsJ, V57M) can produce chromosomal resistance (MIC ≥ 2 mg/L) (15). 
The V57M substitution in S10 (rpsJ) must be present as mutations in mtrR or mtrR/porB do not 
confer high-level chromosomally-mediated resistance to tetracycline (15). 
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5.4 RESULTS 
5.4.1 Assessment of DNA Extraction Methods for Amplification 
DNA concentrations and 260/230 ratios were compared from the DNA of 40 Aptima urine 
specimens extracted using methods 1 and 2. Specimens processed with the Viral RNA Mini kit 
(method 2) exhibited significantly (P < 0.01, paired t-test; Figure 5.1) higher DNA concentrations 
(96.21±2.683 ng/µl) as compared with specimens processed using the DNA Mini kit (30.58±3.919 
ng/µl; method 1). It should be noted that some carryover absorption of RNA using the Viral RNA 
Mini kit might have increased the apparent DNA concentration. We also observed that the 260/280 
ratio was higher than 2 in >60% of the specimens processed with the Viral RNA Mini kit, which 
was probably caused by the carrier RNA added as recommended by the manufacturer. 
Furthermore, 85% (34/40) of the specimens processed by method 2 had better 260/230 ratios 
(1.9±0.11) as compared to specimens prepared using method 1 (0.58±0.02; P < 0.01, paired t-test; 
Figure 5.1).  
 
If 100% amplification of the 8 AMR genes for each of the 50 specimens was achieved, 400 
amplicons would have been generated. We obtained 397 amplicons when both methods 1 and 2 
were combined (3 amplicons were not obtained due to insufficient specimen volumes). With 
method 1, only 146 of 320 (45.6%) amplicons were generated and 251 amplicons of 397 (63.2%) 
were produced using method 2. With method 1, the sequences of 97.2% (142/146) of the amplicons 
were characterized (i.e. defined allele numbers upon complete alignment with the reference NG-
STAR database). With method 2, 91.2% (229/251) of the DNA sequences were assigned to NG-
STAR alleles (data not shown). 
 
5.4.2 Mutations Observed in 8 AMR Genes of N. gonorrhoeae Positive Aptima Urine 
Specimens 
Overall, the sequences of AMR determinants PBP1, GyrA, ParC and 23S r-RNA, were 
characterized for 96, 98, 100 and 100% of the specimens, respectively. The sequences of PBP2, 
PIB, MtrR, and S10 were characterized for 94, 90, 82, and 86% of the specimens, respectively. 
Sequence analysis of PBP2 (penA) revealed that 47/50 specimens which were 
characterized, carried 2 mosaic (34.001 and 67.001), 2 semi-mosaic (91 and 80) and 6 non-mosaic  
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Figure 5.1 DNA purification from remnant Aptima urine specimens using DNA Mini kit and Viral 
RNA Mini kit. A) Comparison of 260/230 ratios of DNA. X-axis: Name of kit; Y-axis: 260/230 
ratio. B) Comparison of DNA concentrations. X-axis: Name of extraction kit; Y-axis: 
Concentration of DNA (ng/µl). 
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(1.001, 2.001, 12.001, 14.001/14.002, 22.001 and 61.001; Table 5.2) PBP2 types. Mosaic PBP2 
(penA) patterns 34.001 (20%, 10/50) and 67.001 (4%, 2/50) comprised 24% of the specimens, and 
semi-mosaic PBP2 patterns 91.001 (8%, 4/50) and 80 (2%, 1/50) comprised 10% of the specimens. 
Non-mosaic PBP2 patterns 14.001/14.002 (40%, 20/50), 12.001 (12%, 6/50), 2.001 (2%, 1/50), 
22.001 (2%, 1/50), 61.001 (2%, 1/50) and 1.001 (2%, 1/50) comprised 60% (30/50) of the 
specimens. PBP2 sequences in 3 specimens could not be characterized due to their poor 
quality. 
 
A high percentage (18%, 9/50) of the specimens could not be characterized for mutations in MtrR 
(mtrR) due to the poor quality of the sequences. 28% (14/50) carried wild-type sequences of the 
MtrR (mtrR) repressor and upstream region, while 24% (12/50) carried an A- deletion in the 
promoter region, and 20% (10/50) carried an A39T substitution in MtrR (mtrR) (Table 
5.2). Mutation combinations such as A-; A39T (10%, 5/50) and A-: G45D (2%, 1/50) were also 
noted.  
 
For PIB (porB), 90% of the alleles could be characterized (45/50) (Table 5.2). Wild-type 
sequences of PIB (porB) comprised 22% (11/50) of the specimens. Substitutions such 
as G120K:A121N (34%, 17/50), A121S (20%, 10/50) and G120N:A121G (6%, 3/50) were 
also identified in PIB (Table 5.2). porB1a alleles were observed in 10% (5/50) of the specimens. 
Wild-type sequences of PBP1 were observed in 66% (33/50) of the specimens and an L421P 
substitution was noted in 30% (15/50) (Table 5.2). PBP1 (ponA) sequences in 4% (2/50) of the 
specimens could not be characterized. Only 8% (4/50) of S10 (rpsJ) sequences were wild-type, 
78% (39/50) carried a V57M substitution (Table 5.2). S10 (rpsJ) sequences in 8% (4/50) could 
not be characterized, and 6% (3/50) could not be tested due to insufficient specimen volume.  
 
All but one of the GyrA (gyrA, 49/50) and all ParC (parC, 50/50) sequences were 
ascertained (Table 5.2). High percentages of wild-type DNA sequences of gyrA (74%, 37/50) and 
parC (74%, 37/50) were observed. Some specimens carried GyrA substitutions S91F;D95G (24%, 
12/50) and S87R (26%, 13/50) in ParC. Since substitutions in GyrA are predictive of resistance 
to ciprofloxacin, these results predict that three-quarters of the specimens were susceptible to this 
antibiotic. All specimens could be characterized for potential substitutions in the peptidyl-   
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Table 5.2 Prevalent mutation patterns of chromosomal AMR determinants identified from 
remnant Aptima urine specimens. 
AMR markers 
(n = 50) 
Allele type Pattern/Mutations n (%) 
PBP2 (penA) 
npenA =47 
Non-mosaic 
 
14.001/14.002 20 (40) 
12.001 6 (12) 
2.001 1 (2) 
22.001 1 (2) 
61.001 1 (2) 
1.001 1 (2) 
Mosaic 
34.001 10 (20) 
67.001 2 (4) 
Semi-mosaic 
 
91.001 4 (8) 
80.001 1 (2) 
Unable to characterize - 3 (6) 
MtrR (mtrR) 
nmtrR = 41 
Wild type WT 14 (28) 
Mutated 
A- 12 (24) 
A39T 10 (20) 
A-, A39T 5 (10) 
A-, G45D 1 (2) 
Unable to characterize - 9 (18) 
PIB (porB) 
nporB = 45 
Wild type 
WT 11 (22) 
porB1a 5 (10) 
Mutated 
G120K; A121N 17 (34) 
A121S 10 (20) 
G120N; A121G 3 (6) 
Unable to characterize - 5 (10) 
PBP1 (ponA) 
nponA= 48 
Wild type WT 33 (66) 
Mutated L421P 15 (30) 
Unable to characterize - 2 (4) 
S10 (rpsJ) 
nrpsJ= 43 
Wild type WT 4 (8) 
Mutated V57M 39 (78) 
Unable to characterize - 7 (14) 
GyrA (gyrA) 
ngyrA= 49 
Wild type WT 37 (74) 
Mutated S91F; D95G 12 (24) 
Unable to characterize - 1 (2) 
ParC (parC) 
nparC = 50 
Wild type WT 37 (74) 
Mutated S87R 13 (26) 
Unable to characterize - - 
23S r-RNA 
n23S rRNA= 50 
Wild type WT 47 (94) 
Mutated A2059G 3 (6) 
Unable to characterize - - 
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transferase loop region in domain V of 23S r-RNA; 94% (n=47/50) of the specimens carried a 
wild-type 23S r-RNA whereas 6% (n=3/50) had A2059G substitution in 23S r-RNA (Table 5.2). 
Therefore, these results indicate that 94% of the specimens could be predicted as being susceptible 
to azithromycin. As only one allele was sequenced, the identification of 3 specimens as 
being resistant is presumptive. 
 
5.4.3 Prediction of AMR in N. gonorrhoeae Remnant Aptima Specimens 
The 8 AMR determinants tested could be characterized completely in 36/50 specimens (Table 5.3, 
Figure 5.2). As the characterization of multiple genes (penA, mtrR, porB, rpsJ, ponA) is 
required to predict susceptibility to cefixime, penicillin, and tetracycline, the denominator used 
for these antibiotics was 36. However, the denominator used to predict ciprofloxacin and 
azithromycin resistance was 50, reflecting the high number of relevant genes characterized. A 
phylogenetic tree, constructed by concatenating the sequences of these genes (Figure 5.2), showed 
that specimens were clustered based on similar NG-STAR profiles. Two major clusters 
were observed. Cluster-A was distinguished by semi-mosaic (cluster A1) and mosaic (cluster 
A2) PBP2 patterns. Cluster-B comprised non-mosaic PBP2 types with Cluster B1 specifying 
PBP2 types 14.001/14.002 and 22.001 and Cluster B2 specifying PBP2 types 2.001, 12.001, and 
61.001.  
 
The 3 specimens in cluster A1 carried a novel PBP2 pattern 91.001, identified in this research 
(similar to PBP2 pattern 39.001 with additional substitutions N512Y, G545S, T550A, and V566I; 
Figure 5.2; sequence available at https://ngstar.canada.ca/). Substitutions such as N512Y/G545S, 
in association with I312M, V316T, are implicated in elevated MICs to cefixime (12). However, 
specimens in Cluster A1 did not carry I312M, V316T substitutions and hence these specimens 
were predicted to be susceptible to cefixime (Figure 5.2). Specimens in cluster A2 carried mosaic 
PBP2 types 67.001 (n=1) and 34.001 (n=10; Figure 5.2). These specimens (11/36, 30.5%) carried 
PBP2 substitutions (I312M, V316T, N512Y, and G545S) implicated in reduced susceptibility to 
cefixime. None of the Cluster B specimens, which comprised non-mosaic PBP2 types (1.001, 
2.001, 12.001, 14.001, 22.001 and 61.001; Figure 5.2), was predicted to be resistant to cefixime. 
Overall, 30.5% (11/36) of the specimens were predicted to possibly have reduced susceptibility to 
cefixime. None of the specimens was predicted to have reduced susceptibility to ceftriaxone since 
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the documented substitutional combinations such as A311V;T483S (in PBP2 pattern 60.001) 
associated with reduced susceptibility (MIC ≤ 0.125 mg/L) and G542S;P551L/S (in any PBP2 
patterns) associated with elevated MICs to ceftriaxone (MIC ≤ 0.016 mg/L) were not observed in 
this research. However, 3 specimens in cluster B2 (nos. 13, 17, and 9) with PBP2 pattern 12.001 
carried a P551S substitution (Figure 5.2). These specimens were considered to be susceptible to 
ceftriaxone as an additional G542S substitution is associated with elevated MICs (MIC 0.016 
mg/L) to ceftriaxone (28).  
 
In Cluster A, two specimens (nos. 42 and 45) carried the substitution A2059G in 23S r-RNA 
predictive of resistance to azithromycin (Figure 5.2). One specimen from Cluster B (no. 47) also 
carried an A2059G substitution in 23S r-RNA predictive of high-level resistance to azithromycin.  
 
Eleven specimens in Cluster A carried substitutions in both GyrA and ParC and were predicted to 
be resistant to ciprofloxacin. None of the specimens in cluster B had substitutions in GyrA or ParC 
(Figure 5.2). However, one additional specimen, which was partially characterized, was 
also predicted to be resistant to ciprofloxacin (Table 5.3). In total, 24% (12/50) of the specimens 
were predicted to be ciprofloxacin-resistant. 
 
In Cluster A, eight of 11 specimens (nos. 24, 42, 45, 2, 29, 34, 18, and 36) had mutations PBP2, 
MtrR, PIB and PBP1 (PBP2/MtrR/PIB/PBP1), which are associated with the sequential 
acquisition of chromosomal resistance to penicillin. In Cluster B, two specimens (nos. 9 and 10) 
had mutations in PBP2/MtrR/PIB/PBP1 predictive of resistance to penicillin (Figure 5.2). A total 
of 90.9% (20/22) of the specimens did not have mutations in all AMR determinants 
(PBP2/MtrR/PIB/PBP1), which are associated with the development of resistance to penicillin and 
hence these specimens were predicted to be susceptible or have intermediate MICs (<2 mg/L) to 
penicillin. Overall, 27.7% (10/36) of the specimens were predicted as being penicillin-resistant. 
Nine specimens (i.e. nos. 38, 24, 31, 42, 45, 2, 29, 18, and 36) in Cluster A carried mutations in 
MtrR, PIB and S10 predictive of chromosomally mediated resistance to tetracycline (Figure 5.2). 
In Cluster B, six specimens (nos. 23, 47, 27, 50, 9 and 10) carried such mutations (Figure 5.2). 
Overall, 41.6% (15/36) of the fully characterized specimens were predicted as being tetracycline 
resistant. 
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Figure 5.2 Phylogenetic tree of the Aptima urine specimens clustering based on their allelic profiles of 8 AMR determinants; AMR 
prediction based on the association of mutations with respective antibiotics. Columns indicate the mutation patterns for each molecular 
determinant. ¥ indicates possibly decreased susceptibility to cefixime. The complete profile of 14/50 samples could not be ascertained. 
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Table 5.3 Mutations in chromosomal AMR determinants, NG-STAR and NG-MAST STs from 50 remnant Aptima urine specimens. 
 
Specimen 
no, % 
Penicillin  Ciprofloxacin Azithromycin Strain Types (STs) 
(n=50) 
ESCs  Tetracycline   
NG-
STAR 
NG-MAST (n) 
 penA* ponA mtrR porB rpsJ (n) gyrA parC 23S r-RNA   
8 (16%) 14.002a WTd WT WT 
V57M(6), 
- (2) 
WT WT WT 160 
7638 (5), 11933 
(1), 14878 (1), 
14537 (1) 
5 (10%) 34.001c L421P A- G120K; A121N 
V57M(4), 
na (1) 
S91F; D95G S87R WT 90 
10451 (1), 10956 
(1), 16196 (1), 
11299 (1),  - (1) 
2 (4%) 34.001c L421P A- G120K; A121N V57M S91F; D95G S87R A2059G 1018† 10451 (2) 
2 (4%) 14.001a WT WT A121S V57M WT WT WT 191 800 (1), - (1) 
2 (4%) 14.001 WT A39T porB1a V57M WT WT WT 289 - 
2 (4%) 14.001 WT A39T A121S V57M WT WT WT 42 6968 (1), 5985 (1) 
1 (2%) 34.001 L421P WT G120K; A121N V57M S91F; D95G S87R WT 88 4951 
1 (2%) 34.001 L421P A- WT V57M S91F; D95G S87R WT 89 11691 
1 (2%) 2.001a L421P A- WT - WT WT WT 442 5441 
1 (2%) 14.001 WT A39T A121S V57M WT WT WT 1021† 5985 
1 (2%) 14.001 WT A39T A121S V57M WT WT A2059G 1017† 5985 
1 (2%) 22.001a WT WT A121S V57M WT WT WT 1016† 5985 
1 (2%) 12.001a L421P A-; A39T G120K; A121N V57M WT WT WT 1024† 3912 
1 (2%) 61.001a L421P A-; A39T G120K; A121N V57M WT WT WT 1023† 3912 
1 (2%) 12.001 WT WT G120K; A121N V57M WT WT WT 1022† 17008‡ 
1 (2%) 91.001b† L421P A-; A39T G120N; A121G V57M WT WT WT 1398† 17005‡ 
1 (2%) 34.001 WT A39T G120K; A121N V57M S91F; D95G S87R WT 1019† 17006‡ 
1 (2%) 91.001 WT A-; A39T porB1a V57M WT WT WT 1397† - 
1 (2%) 91.001 WT A-;G45D G120N; A121G V57M S91F; D95G S87R WT 1396† - 
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1 (2%) 12.001 WT WT A121S V57M WT WT WT 1025† - 
1 (2%) 67.001c WT A39T porB1a V57M WT WT WT 1020† - 
1 (2%) 12.001 - - G120K; A121N - WT WT WT - 3912 
1 (2%) 12.001 WT - G120K; A121N WT WT WT WT - - 
1 (2%) 12.001 WT - G120K; A121N WT WT WT WT - - 
1 (2%) 14.002 WT - G120K; A121N V57M WT WT WT - - 
1 (2%) 14.002 WT - WT WT WT WT WT - - 
1 (2%) - L421P A- G120K; A121N V57M S91F; D95G S87R WT - - 
1 (2%) 67.001 L421P A- - WT WT WT WT - - 
1 (2%) 1.001a WT A- - WT WT WT WT - - 
1 (2%) 14.002 WT - - V57M - WT WT - - 
1 (2%) - WT A39T - V57M WT WT WT - - 
1 (2%) 80.001b WT - A121S V57M WT WT A2059G - - 
1 (2%) 14.002 WT - - V57M WT WT WT - - 
1 (2%) 91.001 WT - porB1a na WT WT WT - - 
1 (2%) - - A39T A121S na WT S87R WT - - 
 
*penA types (NG-STAR numbers): anon-mosaic, bsemi-mosaic and cmosaic  
dWild type allele 
†New penA and new STs for NG-STAR 
‡New ST for NG-MAST 
-uncharacterized alleles and STs (NG-MAST and NG-STAR)  
naspecimens were not amplified due to insufficient volume
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5.4.4 NG-MAST & NG-STAR STs & Demographics 
NG-STAR STs could be assigned to 72% (n=36/50) of the specimens that were fully 
characterized for all AMR determinants (Table 5.3). A total of 21 different NG-STAR STs were 
assigned to 36 specimens (Table 5.3). NG-STAR STs such as 160 (22.2%; 8/36), 90 (13.8%; 5/36), 
191 (5.5%; 2/36), 289 (5.5%; 2/36), and 42 (5.5%; 2/36) were predominantly observed (Table 5.3). 
We also observed new allelic combinations in 13/36 specimens and they were assigned to STs 
such as 1018, 1021, 1017, 1016, 1024, 1023, 1022, 1398, 1019, 1397, 1396, 1099, and 1020 (Table 
5.3).  
 
Successful strain typing by NG-MAST was achieved for 66% (n=33/50) of the specimens (Table 
5.3, Figure 5.3), which comprised 19 different NG-MAST STs (Table 5.3). NG-MAST STs such 
as 7638 (15.1%; 5/33), 5985 (12.1%; 4/33), 3912 (9.09%; 3/33), and 10451 (9.09%, 3/33) 
predominated (Table 5.3). Three of 33 specimens had new allelic combinations of porB and tbpB  
(i.e. NG-MAST STs ST-17005, ST-17006, and ST-17008; Table 5.3).  
 
There was mostly no association between NG-STAR and NG-MAST STs. However, 2 specimens 
(Figure 5.3, cluster A2) with NG-MAST ST-10451 were also NG-STAR ST-1018. Both specimens 
were isolated from males but from different geographic areas (Figure 5.3). In cluster B1, 5 
specimens (4 female and 1 male) that were NG-STAR ST-160, were also NG-MAST ST-7638 
(Figure 5.3). Two specimens with NG-STAR ST-191 also carried NG-MAST ST-800 and were 
collected from different regions. These limited data indicate potentially linked isolates. 
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Figure 5.3 Phylogenetic tree of the Aptima urine specimens describing the strain types and their 
demographic details. New Allelic Combinations (NAC) for NG-STAR and NG-MAST STs are 
indicated with “a” and “b”, respectively. Dash “-” indicates uncharacterized STs. Common NG-
MAST and NG-STAR STs are coloured red in cluster A and blue in cluster B.  
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5.5 DISCUSSION 
The extensive use of NAATs for the identification of N. gonorrhoeae from clinical specimens 
has significantly reduced the availability of cultured isolates for AMS testing. Thus, there is an 
urgent need for a validated molecular approach for the characterization of AMR determinants 
in N. gonorrhoeae positive NAAT specimens to predict AMS and/or AMR (37). In the present 
research, we used PCR and DNA sequencing approaches to characterize eight different genes 
implicated in gonococcal AMR from N. gonorrhoeae positive remnant Aptima urine specimens to 
predict the AMS. 
 
The present research describes emerging resistance in N. gonorrhoeae from SK to antibiotics such 
as cefixime and azithromycin. Mosaic PBP2 type 34.001, which carries key substitutions such as 
I312M, V316T, N512Y, and G545S is associated with reduced susceptibility to cefixime 
(38). We predicted 30.5% (11/36) of the specimens would carry reduced susceptibility to cefixime 
due to these substitutions. Although the MIC cut-off for cefixime reduced susceptibility is 0.25 
mg/L (27), the gonococcal isolates with PBP2 type 34.001 may have a range of MICs (MIC = 0.06 
– 0.250 mg/L) to cefixime (39). Treatment failure to cefixime with the MIC of 0.125 mg/L has 
also been reported (40). Thus, our predictions are cautionary and imply a need for further 
surveillance of emerging resistance. A previous report from SK indicated that only 1 of 146 
cultured isolates carried a mosaic penA allele with PBP2 type 34.001, and had a MIC of 0.125 
mg/L for cefixime (41). PBP2 type 34.001 was first reported in the USA (42) and has spread 
worldwide (43, 44). In Canada, a study of gonococcal isolates (n=169) with reduced susceptibility 
to ESCs reported an increase in isolates with PBP2 type 34.001 from 2005 (25%, n=2/8) to 2010 
(33%, n=14/43), with the highest prevalence in 2012 (50%, n=12/24) (45). We also determined, 
as in other studies, that gonococcal specimens with PBP2 type 34.001 were also resistant to 
ciprofloxacin due to predictive substitutions in GyrA and ParC (23, 46). 
 
In the present research, none of the N. gonorrhoeae positive Aptima urine specimens was 
predicted to carry mutations implicated in reduced susceptibility to ceftriaxone. However, 
in Canada, a recent report showed two travel-related cases of ceftriaxone-resistant strains of 
N. gonorrhoeae which were genetically linked with N. gonorrhoeae strain FC428 identified in 
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Japan (2015) (47). In the NG-STAR database, PBP2 type 60.001 is associated with ceftriaxone 
resistance and carries A311V and T483S substitutions. 
 
Three specimens (6%; 3/50) carried an A2059G substitution in the 23S r-RNA gene predictive 
of the development of high-level resistance to azithromycin. Although the substitution was 
observed in a single allele of 23S r-RNA, isolates with a substitution in just one allele are capable 
of rapidly acquiring the substitutions in all four alleles (48). Increasing rates of azithromycin 
resistance have been reported nationally (49) and globally in N. gonorrhoeae (50). In Canada, 
between 2010 and 2016, the proportion of azithromycin-resistant N. gonorrhoeae increased from 
1.3% to 7.2% (49). The WHO indicated that 17 of 42 countries reported (2012-2013) azithromycin 
resistance in 5% or more of isolates (50). Such a high rate of azithromycin resistance is of 
concern as it is recommended for combination therapy with ceftriaxone. 
 
In the present research, we predicted that 27.7% (10/36) of the specimens would be penicillin-
resistant. In Canada, 6% of N. gonorrhoeae isolates were reported as being resistant to penicillin 
in 2004 and this increased to a high of 25.1% in 2010 (it was 18.2% in 2014) (51). In SK, penicillin 
resistance from 2006 to 2012, and in 2015, was observed in <5% of the population (a cut -off 
determined by WHO, above which an antibiotic should not be used for treatment). Reported 
penicillin resistance in SK between 2013 and 2014 was 27.5% and 13.5% respectively (20). 
 
This research predicted that 41.6% (15/36) of the specimens were tetracycline resistant. The 
Public Health Agency Canada (PHAC) reported that between 2013 and 2015, tetracycline 
resistance in Canada, increased from 33% to 56.4% due to increases in both plasmid-mediated and 
chromosomal tetracycline resistance (51). Similarly, between 2003 and 2015, 11.8 to 89.1% 
of gonococcal isolates from SK were tetracycline resistant (20). In the present research, we did 
not test for plasmid-mediated tetracycline resistance (tetM), which is important in the 
determination of an accurate rate for overall tetracycline resistance in SK. In SK, 16.8% and 
17.5% of N. gonorrhoeae isolates carried plasmid-mediated tetracycline resistance in 2014 and 
2015, respectively (20). 
 
Several studies have reported the correlation of substitutions in GyrA with resistance to 
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ciprofloxacin (52-54). In our research, 74% (37/50) of the specimens did not have substitutions in 
GyrA and ParC and were identified as susceptible. A higher number of specimens showing 
ciprofloxacin susceptibility also suggests that an effective, rapid molecular test predicting 
susceptibility could be used to direct individualized treatment, potentially sparing the use of 
ESCs (55). The implementation of such an approach has been reported in the United States, 
where the results obtained using GyrA diagnostic assay were 100% concordant with the 
susceptibility test results (53). The most prevalent NG-MAST ST in our research was ST-7638 
(15.1%; 5/33). Previous NG-MAST typing of N. gonorrhoeae isolates (n= 85; 2016) in SK showed 
that STs 7638 (20%, 17/85), 11933 (13%, 11/85), 11299 (10%, 8/85), 5985 (8%, 7/85) and 10451 
(7%, 6/85) were predominant (51). A recent report from Alberta also indicated that ST-7638 was 
a predominant ST comprising 12.7% (367/2891) of the gonococcal isolates screened, with a higher 
proportion observed in female patients (56). In the present research, four of five specimens with 
ST-7638 were from female patients. 
 
Although we were able to predict resistance to several antibiotics from Aptima urine specimens 
using molecular methods, this research has several limitations. The method of DNA purification 
impacted the amplification of antibiotic resistance genes in the specimens. We determined 
that the Viral RNA Mini kit coupled with Phusion high fidelity DNA polymerase was a better 
method to amplify genes from these specimens. There might have been a carryover of RNA in the 
DNA extracted using the Viral RNA Mini Kit, and this increased the total nucleic acid 
concentration and 260/280 ratio. We did not consider this to be a major issue as targeted amplicon 
sequencing was performed and the Viral RNA Mini kit performed better for our purposes. The 
purpose of describing DNA methods in detail was to give an insight into some of the issues 
regarding DNA extraction from such specimens. There may be other approaches that are better 
and more cost-effective. Another limitation is that there were differences in the success with which 
different genes that could be fully characterized for mutations (i.e. ponA, gyrA, parC, and 23S r-
RNA sequences were determined in more than 95% of the specimens, while penA, mtrR, porB, 
and rpsJ were characterized in 82% to 94% of the specimens). Other studies have reported lower 
detection of markers such as penA, mtrR, and porB in clinical specimens using qPCR assays (38, 
57, 58). In one study, 18.8–31.2% of the NAAT positive clinical specimens (n=1629) remained 
uncharacterized for markers such as mtrR, porB, gyrA, and 23S r-RNA (58). A second study 
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noted false-positive results in detecting of the Asp345del in penA from pharyngeal 
specimens using a qPCR assay (57). Additionally, cross-reactivity of penA, mtrR, porB, and ponA 
with similar genes from commensal Neisseria isolates has been reported in PCR assays using 
clinical specimens (38).  
 
Furthermore, penC, ermA, 16S r-RNA, tetM, blaTEM and several other genes predictive of 
resistance to penicillin, azithromycin, and spectinomycin were not assayed in our research due to 
logistical and cost issues. Historically, SK has a low prevalence of penicillinase-producing 
(0.15%) or plasmid-mediated tetracycline resistant Neisseria gonorrhoeae isolates (5.8%), but it 
would have been useful to ascertain the percentage of isolates carrying blaTEM and tetM (20). It 
should be noted that the prediction of resistance, based on molecular profiles of AMR genes, does 
not always align with MICs indicative of resistance and therefore carry an implicit error factor. 
The approach used by us is useful to monitor trends in emerging resistance given that over 
90% of cases of N. gonorrhoeae in the province are not tested for AMR. We wish to highlight 
two other factors. The present research analyzed only remnant Aptima urine specimens 
(predominant specimen type collected in the province). Moreover, the utilization of costlier 
and labour-intensive first-generation sequencing, such as Sanger sequencing, limits the 
application of this AMR prediction approach in routine diagnostics. 
 
A better approach for gonococcal AMR prediction and strain relatedness determination in clinical 
specimens would be whole-genome sequencing (WGS) as it could potentially provide 
comprehensive information regarding AMR genes and STs and allow for more rapid selection of 
appropriate antimicrobial therapy. This approach has been used for AMS surveillance using 
cultured N. gonorrhoeae isolates (59-63). Although WGS from Aptima urine or other clinical 
specimens identified by NAATs would be rapid and of great advantage, the extraction of DNA 
from such specimens presents notable challenges. For example, Aptima buffer is a transportation 
buffer which lyses all cells (human and bacterial) in the specimen, making it very difficult to 
enrich N. gonorrhoeae and other bacterial DNA (64, 65, unpublished observations). A few studies 
have performed bacterial enrichment (Chlamydia trachomatis and other bacteria) for WGS from 
urine specimens (64, 66). Only one study reported the enrichment of N. gonorrhoeae from urine 
specimens (67). 
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5.6 CONCLUSION 
The molecular approach used in this research for the prediction of AMS in N. gonorrhoeae positive 
remnant Aptima urine specimens has the potential to preclude the culture-based AMS testing. 
However, the recovery of the sequences of substandard quality for some of the markers from such 
specimens limits their use to predict AMR. Furthermore, such an approach is costly, time -
consuming and requires considerable expertise. The WGS analysis of such specimens would 
provide the advantage of covering an array of genes to characterize AMR and N. gonorrhoeae 
strain relatedness simultaneously. The development of methods to enable the WGS approach 
from clinical specimens is urgently needed. 
 
5.7 SUMMARY POINTS 
 The DNA sequences of ponA, gyrA, parC and 23S r-RNA alleles were determined in more 
than 95% of the remnant Aptima urine specimens, while penA, mtrR and porB were 
characterized in 86–94% of the specimens. 
 The emergence (30.5%, 11/36) of N. gonorrhoeae with PBP2 type 34.001, which is 
associated with reduced susceptibility to cefixime, was observed and these specimens 
were also resistant to ciprofloxacin. These results reflect the expansion of this clone in 
Canada. 
 No mutations indicative of reduced susceptibility to ceftriaxone were identified.  
 NG-MAST ST-7638 is a circulating strain in western Canada and is associated with NG-
STAR ST-160. 
 A total of 47.2% (17/36) of the specimens were predicted as being fully susceptible to 
all antibiotics indicating that a molecular test to predict susceptibility would enhance 
the stewardship of antibiotics. When the determinants specifying ciprofloxacin 
resistance alone are considered, 76% (38/50) of the isolates were susceptible. 
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6.0 INTERFACE 
As discussed in Chapter 5, mutations in both the chromosome and plasmids can lead to drug 
resistance in N. gonorrhoeae. In Chapter 5, we mainly focused on mutations in the chromosome 
leading to resistance. In this research, we characterized a β-lactamase producing plasmid from N. 
gonorrhoeae with a novel 6 bp deletion in the ATG start codon of blaTEM-1. This highlights the 
importance of extended monitoring for β-lactamase activity, as slow β-lactamase producing 
gonococcal strains could be easily misdiagnosed as non-PPNG isolates. Findings of plasmids 
harbouring blaTEM variants, such as pJRD20, is of critical importance for the proper control and 
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management of antibiotic resistance in N. gonorrhoeae. This chapter was previously published in 
The Journal of Antimicrobial Chemotherapy, 74(10): 2904-2912, 2019, and is reprinted here with 
permission. The findings of this research have been presented at the International Union Against 
Sexually Transmitted Infections (IUSTI) World + European Congress held in Dublin, Ireland on 
June 27-30th, 2018, and at the Protein Structure, Function and Malfunction (PSFaM) 7th Annual 
Meeting held in Saskatoon, Saskatchewan, Canada on June 20-21th, 2019. 
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6.1 ABSTRACT 
Seven structurally related β-lactamase-producing plasmids have been characterized in 
penicillinase-producing Neisseria gonorrhoeae (PPNG) isolates. We characterized a variant (i.e. 
pJRD20, Canada-type) of the Africa-type (pJD5) plasmid isolated from N. gonorrhoeae strain 
8903. The objective of this research was to compare the DNA sequence of pJRD20 with pJD5 and 
pJD4 (Asia type) and their TEM-1 β-lactamases. N. gonorrhoeae 8903 was identified as part of 
the Gonococcal Antimicrobial Surveillance Program in Canada. β-lactamase production was 
assessed using nitrocefin. MICs were determined by agar dilution and Etest methods (CLSI). The 
DNA sequences of pJRD20, pJD5 and pJD4 were assembled and annotated. The structure of TEM-
1 and its penicillin-binding properties were determined by in silico molecular modelling and 
docking. TEM-1 proteins were characterized by Western blot, mass spectrometry and ampicillin 
hydrolysis assays. N. gonorrhoeae 8903 exhibited intermediate susceptibility to penicillin with 
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slow β-lactamase activity (i.e. 35 min to hydrolyze nitrocefin). Except for a novel 6 bp deletion 
starting at the G of the ATG start codon of blaTEM-1, the DNA sequence of pJRD20 was identical 
to pJD5. The TEM-1 β-lactamase produced by pJRD20 is 24 KDa and hydrolyzes ampicillin only 
after several hours. This unusual PPNG isolate might have been characterized as a non-PPNG due 
to its low MIC to penicillin and its very slow hydrolysis of nitrocefin. Given the unusual nature of 
its TEM-1 β-lactamase, laboratories might consider extending the length of time for nitrocefin 
hydrolysis assays. 
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6.2 INTRODUCTION 
β-lactamase producing plasmids were first isolated from N. gonorrhoeae in 1975 and are one of 
the main causes of penicillin resistance in this organism (1). Penicillinase-producing plasmids of 
N.gonorrhoeae (PPNG) are named according to their first source of geographic isolation; i.e. Asia 
(7,426 bp), Africa (5,599 bp), Toronto/Rio (5,154 bp), Nimes (6,798 bp), New Zealand (9,309 bp), 
Johannesburg (4,865 bp) and Australia (3,269 bp) plasmid types (2, 3). Asia, Africa and 
Toronto/Rio plasmid types have been associated with epidemic outbreaks while the other plasmid 
types have been isolated sporadically (4). The structural diversity of β-lactamase-producing 
plasmids of N. gonorrhoeae is attributed to the presence of repeat sequences involved in DNA 
rearrangements, such as duplications and deletions (5). The plasmids are all related structurally to 
the Asia-type plasmid, with Africa-, Toronto/Rio-, and Johannesburg-types being unique deletion 
derivatives, the New Zealand-type plasmid an insertion derivative, and the Nimes-type plasmid 
both a deletion and insertion derivative (6-9).  
 
In N. gonorrhoeae, most penicillinase-producing plasmids carry a blaTEM-1, with blaTEM-135 being 
the most common variant (1, 2, 7, 10-14). blaTEM-1 is found in the ancestral Asia-type plasmid, 
while some strains of Asia-, Africa-, Toronto/Rio- and Australian-type plasmids can carry 
blaTEM-135 (7, 15, 16). Diversity in TEM-1 β-lactamases arises through SNPs (14). TEM-135 differs 
from TEM-1 by one SNP (M182T, position 539 in the blaTEM gene) (15, 16). TEM-220, isolated 
from Toronto/Rio-type plasmids, differs from TEM-135 by one additional SNP (A185T, position 
547 in the blaTEM gene) (3, 17). In addition, four novel amino acid substitutions (P14T, P14S, 
E110K, and G228S) have been identified in TEM of Asia- and Africa-type β-lactamase producing 
plasmids; however, allele numbers have not been assigned (7). With the selective pressure exerted 
by the use of extended-spectrum cephalosporins (ESC) to treat gonococcal infections, a concern is 
that blaTEM-135  or blaTEM-220  may acquire additional mutations thereby evolving to encode an ESBL 
(3, 17). Such an enzyme would be capable of hydrolyzing all ESC, including ceftriaxone, 
potentially leading to untreatable gonorrhea infections (7, 11, 14, 18, 19).  
 
We have characterized a novel β-lactamase-producing plasmid from a strain of N. gonorrhoeae 
(i.e. 8903) with an intermediate MIC to penicillin and in which β-lactamase production is delayed 
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significantly. We compared the DNA sequence of this plasmid, which we named pJRD20 (Canada-
type), to that of pJD4 (Asia-type) and pJD5 (Africa-type) and determined that pJRD20 is identical 
to pJD5 except for a 6 bp deletion starting at the G of the ATG start codon of blaTEM-1 (2, 5). The 
DNA sequence of blaTEM-1 and the structural features of the TEM-1 β-lactamase were investigated 
to ascertain the effects of the 6 bp deletion on protein expression and β-lactamase activity. We 
confirmed that a truncated 24 KDa TEM-1 penicillinase using an alternative downstream ATG 
start site was produced (i.e. TEM-1S-ATG; where ‘S’ stand for short) and that this protein hydrolyzed 
ampicillin more slowly than the TEM-1 β-lactamase. 
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6.3 MATERIALS AND METHODS 
6.3.1 Bacterial Strains and Plasmids  
N. gonorrhoeae 8903 was isolated in 1992 as part of the Gonococcal Antimicrobial Surveillance 
Program (GASP) in Canada. WHO strains O and F were used as positive and negative controls for 
β-lactamase production respectively. N. gonorrhoeae  F62 (20), WHO O and F were cultured on 
GC medium base (BD Bioscience, Mississauga ON, Canada) supplemented with 1% Kellogg’s 
defined supplement (GCMBK) and incubated at 35-37°C with 5% CO2 in a humid environment, 
for 18–24 h (21, 22). N. gonorrhoeae 8903 was grown on GCMBK supplemented with 0.125 mg/L 
ampicillin. E. coli strains DH5α (pJD4) and C600 (pJD5), previously transformed with pJD4 and 
pJD5, respectively, were grown overnight at 37oC on LB agar with 10 mg/L ampicillin (23). 
 
6.3.2 MIC Determination and Detection of β-Lactamase Activity 
MICs and breakpoint interpretations of penicillin, tetracycline, spectinomycin, ceftriaxone, 
ciprofloxacin, erythromycin, gentamicin and azithromycin (Sigma-Aldrich, Milwaukee WI, USA) 
were ascertained using agar dilution and Etest (Biomerieux, St Laurent QC, Canada) as described 
by the CLSI (22). β-lactamase production was detected using nitrocefin discs (Sigma-Aldrich) and 
a liquid assay using nitrocefin powder (Sigma-Aldrich), as described by the manufacturer. The red 
colour indicated positive activity as compared to the control.  
 
6.3.3 Plasmid Isolation and Sequencing 
Plasmid DNA from N. gonorrhoeae 8903, grown overnight on GCMBK supplemented with 0.125 
mg/L ampicillin, and E. coli strains DH5α (pJD4) and C600 (pJD5), which were grown overnight 
on LB agar in the presence of 10 mg/L ampicillin, was isolated using the GeneJET Plasmid 
Miniprep Kit (Thermo Fisher Scientific, Edmonton AB, Canada). Plasmid content was verified by 
agarose gel electrophoresis and DNA concentration was measured using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific). Plasmid DNA sequencing and assembly were 
performed at the CCIB (Center for Computational and Integrative Biology) DNA Core Facility at 
the Massachusetts General Hospital (MGH), Cambridge MA, USA. Briefly, Illumina compatible 
adapters with unique barcodes were ligated onto the sample during library construction. Libraries 
were sequenced on an Illumina MiSeq platform with 2x150 run parameters.   
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6.3.4 Transformation of N. gonorrhoeae and E. coli with pJRD20 
For N. gonorrhoeae F62 transformations, pJRD20 DNA (1 µg) was mixed with recipient cells and 
liquid transformations were performed as described previously (24). E. coli DH5α transformations 
were modified as follows (25). Circular pJRD20 DNA was mixed with E. coli DH5α competent 
cells and heat-shocked at 42oC for 30 seconds. Transformants were grown overnight at 37oC on 
LB agar supplemented with 0.125 mg/L ampicillin. Plasmid DNA was extracted from N. 
gonorrhoeae and E.coli transformants as described above. The blaTEM genes were PCR amplified 
using tem1 primers (synthesized at Invitrogen, Carlsbad CA, USA) (26) and amplicons were 
sequenced (Eurofins Genomics; Toronto ON, Canada) using the same primers.  
 
6.3.5 DNA Sequence Analysis 
Plasmids were assembled using MGH CCIB's de novo assembler UltraCycler v1.0. (Brian Seed 
and Huajun Wang, unpublished). Once the assembly outputs were manually inspected and passed 
quality control standards, results were downloaded. Full-length genomic sequences of pJD4, pJD5 
and JRD20 assembled plasmids were aligned in Jalview (27) using the ClustalW algorithm (with 
default parameters) (28). The complete nucleotide sequence of E.coli KWB5 blaTEM-1 
(KY466951.1) was downloaded from the NCBI nucleotide database using the search term “blaTEM-
1”. This sequence was aligned against pJD4 and pJD5 nucleotide sequences using the blastn 
program in NCBI-blast v2.6.0+ (default parameters) (29). The blaTEM-1 hit regions from pJD4, 
pJD5 and pJRD20 were extracted using the extractseq command from EMBOSS-6.6.0 (30). 
Multiple sequence alignments for pJD4, pJD5 and pJRD20 blaTEM-1 were performed in jalview 
using the ClustalW algorithm with default parameters.  The aligned nucleotide sequences also 
included 100 bp upstream of blaTEM-1. The blaTEM-1 sequences on pJD5 and pJRD20 were 
examined both computationally and manually with DNAMAN software (v9 [with default 
parameters], Lynnon Corp). Computational prediction (31) identified an alternative GTG start 
codon (position 179; translated as fMet) (32) that would encode a truncated TEM. Since automatic 
genome annotations and gene prediction have limitations (33), the sequence was also examined 
manually and a second possible start codon, ATG at position 290 in pJRD20 blaTEM-1 was 
identified and curated (34). The DNA sequences of pJD5 and pJRD20 with annotations have been 
submitted to Genbank under accession numbers MH140435 and MH140434 respectively. 
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ORFs were predicted using the getorf (with parameters “-table 11” and “-minsize 150”) command 
from EMBOSS-6.6.0 (30). Functional annotations of predicted ORFs were performed using 
Blast2GO standalone version (35). To confirm the novelty of the 6 bp deletion in pJRD20, its 
TEM-1 β-lactamase sequence was aligned against all available (total 215) TEM β-lactamases 
(TEM numbers were matched with the list present at the Lahey website https://www. 
lahey.org/Studies/temtable.asp and at the NCBI ftp://ftp.ncbi.nlm.nih.gov/pathogen/betalac 
tamases/Allele.tab). Allele sequences for all TEM β-lactamases were downloaded from the Pasteur 
database (http://bigsdb.pasteur.fr; last updated on 2013) and the NCBI protein database 
(https://www.ncbi.nlm.nih.gov/protein; accessed 2018_12). 
 
6.3.6 Structural Analysis and Molecular Docking 
Three-dimensional homology models of TEM-1 β-lactamase from pJD5 and pJRD20 were built 
using modeller v9.19 (36). For homology modelling, the best suitable template protein, 1esu (53) 
(E. coli TEM-1 β-lactamase mutant with a mutation at position 235 where Alanine replaces Serine 
[S235A]) was selected over other possible templates because of its better crystallographic 
resolution (2Å) and R factor (0.162). The TEM-1 sequences were used as queries against the 
Protein Databank (pdb) using blastp at the NCBI blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi?). 
The top hits showing more than 90% sequence identity with the TEM-1 β-lactamase were used to 
build a profile (build_profile.py) in modeller.  
 
After examining the profile build outputs, the best template was selected based on the quality of 
crystallographic resolution. Following the construction of target-template alignments, homology 
models were built in modeller and the resulting structures were evaluated based on the best DOPE 
(Discrete Optimized Protein Energy) score. To assess the effect of novel deletion in pJRD20, the 
protein binding affinity of TEM-1 β-lactamase and molecular docking of the modelled structure 
with penicillin was performed in silico using AutoDockTools 4.2. (37) PubChem database (38) 
was used to download the Penicillin G (PNN) ligand (C16H18N2O4S). For molecular docking, both 
protein and ligand were prepared by adding hydrogens and computing Gasteiger charge. The 
docking parameters used for the docking modelling were Lamarckian genetic algorithm with 
population size (150), gene mutation rate (0.02), crossover rate (0.8) and the total number of runs 
(50). The grid box was centred over the ligand with the number of grid points in x=48, y=50 and 
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z=52 with a grid spacing of 0.375. Best docking pose from a set of predicted docking 
conformations was identified based on lower binding energy and inhibition constant. 
 
6.3.7 Western Blot Analysis 
N. gonorrhoeae 8903 (pJRD20), N. gonorrhoeae FA1090 (negative control), E. coli DH5α (pJD4), 
and E. coli C600 (pJD5) were collected from overnight growth on GCMBK or LB agar and lysed 
with RIPA lysis buffer (Santa Cruz Biotechnology, Mississauga, ON, Canada) in the presence of 
Halt protease and Halt Phosphatase inhibitors (Thermo Fisher). Protein concentrations were 
measured using a Pierce BCA Protein assay kit (Thermo Fisher) and volumes loaded onto 12% or 
15% SDS-PAGE gels were modified accordingly. The membrane was incubated in an anti-β-
lactamase monoclonal mouse primary antibody (specific for TEM β-lactamases; Abcam ab12251, 
Toronto ON, Canada) overnight at 4oC, and subsequently in IRDye 800CW anti-mouse secondary 
antibody (Mandel Scientific LIC926-32210, Guelph ON, Canada) for 1 h. Bands were visualized 
using Odyssey CLX (LI-COR Mandel Scientific).  
 
6.3.8 Protein Identification by Mass Spectrometry (MS) 
Protein identification by mass spectrometry was done as described in Brandt et al. (39) Crude cell 
lysates from N. gonorrhoeae 8903 (pJRD20), E. coli DH5α (pJD4), E. coli C600 (pJD5) and N. 
gonorrhoeae FA1090 (negative control) were boiled with SDS. Proteins were separated on a 12% 
SDS-PAGE and the gel was stained with Coomassie dye. All chemicals for the MS analysis, unless 
noted otherwise, were purchased from Thermo Fisher Scientific. Protein bands corresponding to 
the area of interest were excised from the gel and destained twice with 100 µL of 200 mM 
ammonium bicarbonate (NH4HCO3) in 50% acetonitrile at 30°C for 20 minutes. Gel samples were 
then treated with acetonitrile for 10 minutes and dried with a speed-vac. Proteins were reduced with 
100 µL of 10 mM dithiothreitol (DTT) in 100mM NH4HCO3 and incubated at 56°C for 1 hour. 
DTT was removed and replaced with 100 µL of 100 mM iodoacetamide and incubated at room 
temperature in the dark for 30 minutes. After washing twice with 200 mM NH4HCO3, samples were 
shrunk with acetonitrile, re-swelled with 200 mM NH4HCO3 and re-shrunk with acetonitrile. 
Samples were dried with a speed-vac and sequentially re-swelled in 20 µL trypsin buffer (50 ng/mL 
sequencing grade modified trypsin [Promega] in 1 mM hydrochloric acid and 100 mM NH4HCO3) 
and 30 µL of 200 mM NH4HCO3. Proteins were digested overnight at 30°C with shaking (300 rpm). 
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Trypsin action was quenched with 1% trifluoroacetic acid and tryptic peptides were extracted from 
gel slices in 100µL of 0.1% trifluoroacetic acid in 60% acetonitrile and stored at -80°C until MS 
analysis. 
 
Extracted tryptic peptides were dried with a speed-vac and reconstituted in 12 µL of MS grade 
water:acetonitrile:formic acid (97:3:0.1 v/v). Insoluble material was removed by centrifugation at 
18,000 x g for 10 minutes at 4ºC. A 10 µL aliquot was used for liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis. Mass spectral analyses were performed on an Agilent 6550 
iFunnel quadrupole time-of-flight (QTOF) mass spectrometer equipped with an Agilent 1260 series 
liquid chromatography instrument and an Agilent Chip Cube LC-MS interface (Agilent 
Technologies, Mississauga, ON, CA). Chromatographic peptide separation was accomplished using 
a high-capacity Agilent HPLC-Chip II: G4240-62030 Polaris-HR-Chip-3C18 consisting of a 360 nL 
enrichment column and a 75 µm × 150 mm analytical column, both packed with Polaris C18-A, 
180Å, 3 µm stationary phase. Samples were loaded onto the enrichment column with 0.1% formic 
acid in water at a flow rate of 2.0 µL min-1. After loading onto the analytical column, peptides were 
separated with a linear gradient solvent system consisting of solvent A (0.1% formic acid in water) 
and solvent B (0.1% formic acid in acetonitrile). The linear gradient was 3–25% solvent B for 50 
minutes and then 25–90% solvent B for 10 minutes at a flow rate of 0.3 µL min-1. Positive-ion 
electrospray mass spectral data were acquired using a capillary voltage set at 1900V, the ion 
fragmenter set at 360V, and the drying gas (nitrogen) set at 225°C with a flow rate of 12.0 L min1. 
Spectral results were collected over a mass range of 250–1700 (mass/charge; m/z) at a scan rate of 
8 spectra s-1. MS/MS data were collected over a range of 50–1700 m/z and a set isolation width of 
1.3 atomic mass units. A maximum of 20 precursor ions was selected for auto MS/MS at an 
absolute threshold of 3000 counts and a relative threshold of 0.01% with a 0.25-minute active 
exclusion. 
 
MS/MS spectral data were extracted from raw data and processed against the concatenated 
SwissProt Neisseria gonorrhoeae database (UniProt release 2018_08), using Spectrum Mill 
(Agilent Technologies) as the database search engine. Search parameters included a fragment mass 
error of 50 ppm, a parent mass error of 20 ppm, trypsin cleavage specificity (two missed cleavages 
per peptide), and carbamidomethylation as a fixed modification of cysteine. Oxidized methionine, 
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carbamylated lysine, pyroglutamic acid, deamidated asparagine, phosphorylated serine, threonine, 
and tyrosine and acetyl-lysine were set as variable modifications. Data were also searched using 
semi-trypsin non-specific C- and N-terminus to enhance protein identification. Spectrum Mill 
validation was performed at peptide and protein levels (1% false discovery rate). 
 
6.3.9 Liquid Chromatography (LC) – Mass Spectrometry (MS) Analysis 
To examine ampicillin degradation by truncated TEM-1S-ATG in pJRD20 as compared to pJD5 
TEM-1 β-lactamase, ampicillin hydrolysis assays were performed over a 6 h time course as 
described previously (54). Cleanup of the 20 µL cell supernatants was carried out by passing 
through a pre-conditioned C18 column (100 µL OMIX C18 pipette tip, Agilent Technologies 
Canada) followed by elution with 100 µL acetonitrile:water (50:50 v/v). The eluent was dried in a 
speed vac, reconstituted in 300 µL acetonitrile:water (3:97 v/v), and subjected to mass 
spectrometric analysis on an Agilent 6550 iFunnel quadrupole time-of-flight (QTOF) mass 
spectrometer equipped with an Agilent 1260 series liquid chromatography instrument and an 
Agilent Chip Cube LC-MS interface (Agilent Technologies Canada). Chromatographic separation 
was accomplished using a high-capacity Agilent HPLC-Chip II: G4240-62030 Polaris-HR-Chip-
3C18 consisting of a 360 nL enrichment column and a 75 µm × 150 mm analytical column, both 
packed with Polaris C18-A, 180Å, 3 µm stationary phase. Samples were loaded onto the 
enrichment column with 0.1% formic acid in water at a flow rate of 2.0 µL min-1. Separation 
occurred with a linear gradient solvent system consisting of solvent A (0.1% formic acid in water) 
and solvent B (0.1% formic acid in acetonitrile). The linear gradient was 3–11% solvent B for 15 
min and then 11–20% solvent B for 4 min at a flow rate of 0.3 µL min-1. Positive-ion electrospray 
mass spectral data were acquired using a capillary voltage set at 1750V, the ion fragmenter set at 
360V, and the drying gas (nitrogen) set at 225ºC with a flow rate of 12.0 l min-1. MS spectral data 
were collected over a mass range of 250–1700 (mass/charge; m/z) at a scan rate of 8 spectra s-1. 
MS/MS data were collected over a range of 50–1700 m/z and a set isolation width of 1.3 atomic 
mass units. The collected MS spectral data were analyzed using the MassHunter qualitative 
analysis software (version B.07.00; Agilent Technologies Canada). 
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6.4 RESULTS  
6.4.1 An Intermediate MIC and Slow β-Lactamase Activity Observed in pJRD20. 
The median MICs against N. gonorrhoeae 8903 harboring pJRD20 were (mg/L): penicillin 0.125, 
tetracycline 0.5, ciprofloxacin 0.003, ceftriaxone <0.016, azithromycin 0.047, erythromycin 0.19, 
spectinomycin 12, and gentamicin 4.  
 
The positive control N. gonorrhoeae WHO O produced a proper colour reaction (yellow to red) 
instantaneously when tested for β-lactamase activity using nitrocefin. N.gonorrhoeae WHO F 
(negative control) did not show β-lactamase activity. N. gonorrhoeae 8903 was slowly positive for 
β-lactamase activity, 35 minutes. When E. coli DH5α was transformed with pJRD20, slow β-
lactamase activity (≥4 h) was observed as compared to N. gonorrhoeae 8903. N. gonorrhoeae F62 
transformed with pJRD20 resulted in significantly slower β-lactamase activity (>6 h).  
 
6.4.2 pJRD20 Has a Novel 6 bp Deletion Starting at the G of the ATG Start Codon of 
blaTEM-1  
As compared to pJD4, an identical deletion of 1828bp (co-ordinates 2942–4770 bp in pJD4; Figure 
6.1A) is present in both pJRD20 and pJD5 (5). In addition, pJRD20 has a novel 6 bp deletion from 
position 5389 to 5394 bp (co-ordinates 7225–7230 bp [GAGTAT] in pJD4; encodes Met, Ser, and 
Ile; Figure 6.1). The blaTEM-1 regions were extracted from assembled plasmid sequences and the 
location of the 6 bp deletion was confirmed through multiple sequence alignments of blaTEM-1 from 
the three plasmids. Multiple sequence alignment of the pJRD20 blaTEM-1 sequence with blaTEM-1 
(KY466951.1), blaTEM-135 (GQ896333.1) and blaTEM-220 (KM998962) sequences confirmed that 
pJRD20 carries blaTEM-1 with a 6 bp deletion which starts at the G of the ATG start codon. To 
confirm the novelty of the pJRD20 6 bp deletion at the protein level, the pJRD20 TEM-1 
β-lactamase was compared with the publicly available list of 215 TEM β-lactamase sequences 
(Lahey clinic website and NCBI). The novel 6 bp deletion in pJRD20 TEM-1 β-lactamase has not 
been reported previously in any other TEM β-lactamase. Multiple sequence alignment of the 
pJRD20 TEM-1 β-lactamase with TEM-1 (NP_052173.1), TEM-135 (ACX46122.1) and 
TEM-220 (AIW68620.1)
3 β-lactamases confirmed that pJRD20 encodes TEM-1.  
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Figure 6.1 pJRD20 Canada-type in comparison to other gonococcal β-lactamase producing 
plasmids A) Linear alignment map of the gonococcal β-lactamase producing plasmids. 
Coordinates are based on the Asia-type plasmid pJD4. Deletions are highlighted with dashed lines. 
The novel 6bp deletion within the ATG start-site of pJRD20 blaTEM-1 is highlighted with dashes in 
the pink colour box (pJD5 and pJRD20 alignment). B) Protein multiple sequence alignment of 
pJRD20 TEM-1S-ATG and pJD5 TEM-1 were generated using the Muscle algorithm and visualized 
in Jalview. Truncated N-terminal residues are highlighted in the blue box.  
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A total of 29 direct repeats are present in pJRD20 (13 on the forward strand and 16 on the reverse 
strand; Table 6.1).  The longest direct repeat is 43 bp, followed by two 27 bp repeats, one 22 bp 
repeat, and two 21 bp repeats. The remaining repeats are <20 bp long. Furthermore, 27 inverted 
repeats are present in pJRD20. pJRD20 carries 38 ORFs (both strands) with a minimum of 50 AA 
(150 nucleotides; Table 6.1). Functions were assigned to the putative ORFs by searching the NCBI 
protein database using Blast2GO. ORFs were annotated as DNA strand transferase (2194-686 bp), 
recombinase (487-2 bp), TEM-1 (5398-4535 bp), replication protein (3169-4227 bp), transposase 
for transposon Tn3 (2-166 bp) (1, 5), integrase (170-409 bp) and hypothetical proteins (75-278, 
4929-5102, 5546-5292bp).  
 
6.4.3 The 6 bp Deletion Leads to a Truncated 24 KDa TEM-1S-ATG β-Lactamase With 
Altered Penicillin-Binding Properties 
In silico examination of the pJRD20 blaTEM-1 coding sequence indicated that blaTEM-1 could be 
translated into two different truncated proteins (i.e. TEM-1S-ATG and TEM-1S-GTG; Figure 6.2,). In 
option 1, the first 65 N-terminal residues would be eliminated from TEM-1 (i.e. TEM-1S-ATG) and 
the start codon for translation in blaTEM-1 would be an ATG 663 bp downstream (Figure 6.2A). In 
option 2, 28 residues would be deleted from the N-terminus, with a start codon of GTG (Figure 
6.2B; i.e. TEM-1S-GTG).  
 
Molecular docking studies of the proposed truncated proteins with penicillin indicated altered 
protein-ligand interactions for both truncated proteins as compared to TEM-1. Penicillin binds at 
pJD5 TEM-1 active site by interacting with a serine residue at position 68 by forming hydrogen 
bonds with a distance (and energy) of 1.787 (-0.039), 1.762 (-2.382) and 2.116 (-4.416) with 
arginine at position 241 (Figure 6.3A). Whereas in pJRD20 TEM-1S-ATG, penicillin binds with 
allosteric sites other than the serine active site residues (Figure 6.3B). Arginine at position 124 
interacts with penicillin by making a hydrogen bond with distance 2.106 (and energy -0.991). The 
binding energy and inhibition constant of this truncated protein are smaller (although larger than 
pJD5 TEM-1) as compared to the other hypothetical TEM-1S-GTG in figure 6.3C. In the case of 
TEM-1S-GTG (figure 6.3C), instead of serine, penicillin interacts with lysine at position 185 by 
making a hydrogen bond (distance = 2.064 and energy = -0.161). In the case of pJD5, the penicillin 
ligand binds to the TEM-1 serine active site with binding energy (a lower value indicates stable 
binding) of –6.14 and an inhibition constant (the stronger the protein-ligand interaction, the lower  
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Table 6.1 Comparison of the molecular characteristics of different β-lactamase producing plasmids of N. gonorrhoeae. 
 
 
aThe complete DNA sequences for Nimes8 and New Zealand9 plasmid types are not available at NCBI. 
bThe DNA sequence of pJRD20 was compared with the nucleotide sequences of other N. gonorrhoeae β-lactamase producing plasmids.  
cDirect and inverted repeats in pJD5 and pJRD20 nucleotide sequences were analyzed using RepEx software.52 
aPlasmid Type bGenbank 
Accession Number 
General 
Information 
cRepeats ORFs blaTEM variants Ref 
  Length (bp) %GC Direct Inverted >=50   
Asia U20374 7427 38.35 37 50 50 blaTEM-1 5 
Africa MH140435 5597 39.66 29 (<50bp) 27 38 blaTEM-1 2 
Canada MH140434 5591 39.67 29 (<50bp) 27 38 blaTEM-1S-ATG This research 
Toronto NC_010881 5161 38.35 39 34 35 blaTEM-1 50 
Johannesburg NC_019211 4865 40.55 22 32 31 blaTEM-1 51 
Australia NC_025191 3269 41.69 6 (<=50bp) 8 23 blaTEM-135 15 
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Figure 6.2 Homology modelling for the two predicted truncated TEM-1 proteins named TEM-1S-
ATG and TEM-1S-GTG. A) TEM-1 structure (Helix (red-color), β-sheet (blue color) and coil (dark 
green color)). The missing N-terminal 65 residues (in predicted TEM-1S-ATG) involved in the 
formation of one helix, and two β-sheets and one loop leading into the core helix, are highlighted 
in yellow. B) The missing 28 residues (TEM-1S-GTG) are shown in yellow.  
  
162 
 
Figure 6.3 Protein-ligand interaction residues present at binding sites in pJD5 and pJRD20. The 
green dotted line represents the visible hydrogen bond (highlighted with orange arrows). Penicillin 
G ligand molecule is highlighted in cyan. A) Africa-type (pJD5) TEM-1; B) Canada-type 
(pJRD20) TEM-1S-ATG; and C) Canada-type (pJRD20) TEM-1S-GTG.  
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the inhibition constant) of 31.75 uM (Figure 6.3A).  In the case of proposed truncated TEM-1S-ATG 
of pJRD20, the penicillin ligand would bind at the allosteric site with a binding energy and 
inhibition constant of –5.74 and 61.98 uM, respectively (Figure 6.3B). The proposed truncated 
TEM-1S-GTG would have a binding energy and inhibition constant of –5.3 and 130.52 uM, 
respectively (Figure 6.3C). These results indicated that the TEM-1S-ATG would produce a protein 
with more stable binding with its ligand. Therefore, we hypothesized that TEM-1S-ATG was 
produced from pJRD20. 
 
6.4.4 Confirmation of Production of a 24 KDa TEM-1S-ATG β-Lactamase by Western Blot 
and MS Analyses  
Western blot analysis showed that a truncated protein of 24 KDa (Figure 6.4, i.e. TEM-1S-ATG) was 
produced by pJRD20, as predicted if the downstream ATG start site was used (Figure 6.4). The 
TEM-1 β-lactamase produced by pJD4 and pJD5 were 32 KDa, corresponding to the wild-type 
gonococcal TEM-1 β-lactamase size. These results were confirmed by Mass Spectrometry (MS). 
TEM-1S-ATG (24 KDa) was produced by pJRD20, whereas TEM-1 (32 KDa; wild-type) was 
produced by pJD5 (Table 6.2). The main difference in the peptide sequences of TEM-1 (32 KDa) 
and TEM-1S-ATG (24 KDa) is in the N-terminus sequence region between amino acids 1 and 65, 
which are missing from the latter (Figure 6.5). Four tryptic peptides identified from that region 
were present in the protein band excised from TEM-1 (32 KDa) and absent in the protein band 
excised from TEM-1S-ATG (24 KDa; Table 6.3). All other tryptic peptides identified in the 
TEM-1S-ATG (24 KDa) were identical to those identified in TEM-1 (32 KDa) between amino acids 
70 and 290. 
 
6.4.5 Ampicillin Hydrolysis by pJRD20 TEM-1S-ATG  
The LC-MS analysis of the hydrolysis assay after 6 h incubation showed that ampicillin 
degradation by pJRD20 TEM-1S-ATG was slow as compared to pJD5 TEM-1 (Table 6.4; Figure 
6.6). The peak at approximately 13.5 minutes, in Figure 6.6A-E, corresponds to intact (non-
hydrolyzed) ampicillin ([M+H]+=350.1173). The two peaks at approximately 8.5 and 9.5 minutes 
in Figure 6.6C and 6.6D, respectively have the same mass (m/z 368.1318), which corresponds to 
the hydrolyzed form of ampicillin and also gave identical MS/MS fragmentations (m/z 175.0872, 
m/z 279.1194, m/z 307.1102 and m/z 324.1377; the latter corresponds to the hydrolyzed  
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Figure 6.4 Western blot showing pJD4, pJD5 and pJRD20 TEM-1 proteins. The membrane was 
incubated in an anti-β-lactamase monoclonal mouse primary antibody (speficic for TEM β-
lactamases). 
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Table 6.2 Proposed TEM-1 β-lactamase. 
 
  
TEM-1 type Name Size (KD) Length (AA) Binding Energy 
TEM-1 pJD5 Wild type TEM-1 32 286 -6.14 
TEM-1 pJRD20 (ATG start) TEM-1S-ATG 24 221 -5.74 
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A) pJD5 blaTEM-1 (290 aa, 32.02 KD) 
 
B) pJRD20 TEM-1S-ATG (Start codon – ATG – 221 aa, 24.13 KD) 
 
Figure 6.5 pJD5 TEM-1 (a) and computationally predicted pJRD20 TEM-1S-ATG (b) protein 
sequences.   
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Table 6.3 Tryptic peptides identified in TEM-1 (32 KD) but not in TEM-1S-ATG (24 KDa).  
Sequence Observed Mass Actual MH+ Charge  Peptide Score 
(K)VKDAEDQLGAR(V) 401.210 1201.617 3 11.6 
(K)DAEDQLGAR(V) 487.732 974.454 2 13.8 
(R)VGYIELDLNSGK(I) 654.347 1307.684 2 14.1 
(K)ILESFRPEER(F) 425.897 1275.669 3 9.33 
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Figure 6.6 Total ion chromatograms (TIC), after 6-hour incubation, for ampicillin (A), ampicillin 
+ N. gonorrhoeae WHO-F (B), ampicillin + E. coli c600 containing pJD5  (C), ampicillin + N. 
gonorrhoeae 8903 containing pJRD20 (D) and ampicillin + N. gonorrhoeae F62 containing 
pJRD20 (E) 
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decarboxylated form of ampicillin). These two peaks were identified as isomers of hydrolyzed 
ampicillin. Products of hydrolyzed ampicillin were only observed in E. coli c600 containing pJD5 
and N. gonorrhoeae 8903 containing pJRD20. While pJD5 TEM-1 hydrolysis of ampicillin was 
instantaneous, even partial hydrolysis (~50%) by pJRD20 TEM-1S-ATG took up to 6 h (Table 6.4). 
N. gonorrhoeae F62 transformed with pJRD20 took upwards of 6 h for β-lactamase production, 
as measured by the ampicillin hydrolysis assay (Figure 6.6; Table 6.4) and nitrocefin degradation.  
 
 
  
1
7
0
 
Table 6.4 LC-MS analysis of cell supernatant from the ampicillin hydrolysis assay. 
 
Experiment Hydrolysis assay of ampicillin Ampicillin Status 
 (after 6 h incubation) 
Mass of intact ampicillin and/or its hydrolysis 
products detected in the supernatant 
A Ampicillin (10µg/µL, Positive 
control) 
Not hydrolyzed 
(≈ 0%) 
[M+H]+= 350.1173 
B Ampicillin + N. gonorrhoeae WHO-F 
(Negative control) 
Not hydrolyzed  
(≈ 0%) 
[M+H]+= 350.1173 
C Ampicillin + E. coli c600 (pJD5) Completely hydrolyzed 
(100%) 
[Mhyd +H]
+= 368.1318,  
[Mhyd/decarb+H]
+= 324.1388 
D Ampicillin + N. gonorrhoeae 8903 
(pJRD20) 
Partially hydrolyzed  
(≈ 50%) 
[M+H]+= 350.1173,  
[Mhyd +H]
+= 368.1318,  
[Mhyd/decarb+H]
+= 324.1388 
E Ampicillin + N. gonorrhoeae F62 
transformed with pJRD20 
Not hydrolyzed  
(≈ 0%) 
[M+H]+= 350.1173 
F H2O (control) + N. gonorrhoeae 8903 
(pJRD20)  
- - 
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6.5 DISCUSSION 
A novel β-lactamase producing plasmid, pJRD20, from N. gonorrhoeae strain 8903 was sequenced 
and assembled. This plasmid was found to be identical to the Africa-type plasmid, pJD5, from N. 
gonorrhoeae, except for a 6 bp deletion starting at the G of the ATG start codon of blaTEM-1. An 
intermediate MIC to penicillin and slow hydrolysis of ampicillin were characteristic of N. 
gonorrhoeae 8903. 
 
Functional analysis of the putative ORFs of pJRD20 indicated their involvement in biological 
functions such as DNA-directed DNA polymerase, lyase, β-lactamase and recombinase activities. 
Similar to pJD5, the Africa-type plasmid, pJRD20 has one replication protein, indicative of one 
origin of replication (ori1) (2). Previous research (2) indicated that pJD4, the Asia-type plasmid, 
contains three distinct origins of replication (ori1, ori2, and ori3), whereas the pJD5 has a single 
origin of replication (ori1).  
 
We hypothesized that the 6 bp deletion starting at the G of the ATG start codon of blaTEM-1 in 
pJRD20 altered the final protein structure. This novel deletion led to the formation of a truncated 
TEM-1 (TEM-1S-ATG) with an alternate ATG start site. In screening TEM-1S-ATG from pJRD20 
against all listed TEM β-lactamases, we determined that the 6 bp deletion has not been reported 
previously. Based on our molecular modelling and docking studies, we proposed that the 6bp 
deletion in pJRD20 blaTEM-1 would lead to the loss of critical residues from the N-terminus but not 
the active site of the truncated TEM-1S-ATG (Figure 2). This would alter the penicillin-binding 
pattern of the protein. This hypothesis was supported by Western blot and mass spectrometry 
analyses, which indicated that a 24 KDa truncated protein (i.e. TEM-1S-ATG) is produced by 
pJRD20. Furthermore, the β-lactamase hydrolysis assay confirmed the slow hydrolysis pattern of 
ampicillin. 
 
This is the first report confirming that a 6 bp deletion starting at the G of the ATG start codon of 
blaTEM-1 shifted the start codon to an alternate downstream ATG in N. gonorrhoeae. The examined 
truncated protein has a traditional ATG start codon and better binding affinity than the predicted 
truncated TEM-1S-GTG with a putative GTG start codon. This second protein was not produced. 
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Other proteins have been expressed from alternative start codons in truncated forms. One example 
is the translation of xopAE (encodes E3 ubiquitin ligase; translated using ATG) into a truncated 
protein using an alternate downstream ATT start codon in Xanthomonas euvesicatoria (40). 
Plasmids carrying infB (IF2α and IF2ß) (41), clpB (ClpB) (42), and folC (Folylpolyglutamate 
Synthetase–Dihydrofolate Synthetase) (43) genes with alternative downstream GTG start sites 
were constructed to measure the expression of the respective truncated proteins. These genes were 
translated into two proteins, a fully mature product encoded from “ATG” start codon and a 
truncated form-encoded from a downstream in-frame “GTG” start site. Truncated proteins in these 
studies showed varying functionality as compared to the mature protein. Rodas et al (44) reported 
that the translation of N. gonorrhoeae narE from a downstream GTG codon resulted in a truncated 
protein carrying a 49 amino acid deletion at the N-terminal. NarE shared 100% similarity with the 
NarE of N. meningitis (protein translated using ATG start codon). Furthermore, alternative 
downstream ATG start sites can be used to form truncated proteins (45, 46). Loh et al. described 
the formation of one mature NolA1 and two N-terminally truncated functional proteins (NolA2 and 
NolA3) from nolA, thereby describing translation using three different ATG start codons in 
Bradyrhizobium japonicum (45). The TipAS  (144 aa) is translated from an alternative ATG start 
site within tipA in Streptomyces lividans (46). Ours is the first report of a truncation in the TEM-1 
β-lactamase with an alternative ATG start site downstream of the original start site in N. 
gonorrhoeae. 
 
The β-lactamase is exported through the cytoplasmic membrane into the periplasm using its 
N-terminus signal peptide (47). In E. coli deletion mutants lacking the TEM signal sequence, the 
“RTEM” β-lactamase was maintained in the cytoplasm but not secreted (48). The excision of the 
signal sequence of bla did not affect the catalytic activity of “RTEM” β-lactamase (48). A 28 KDa 
truncated blaTEM-1 lacking its signal sequence was constructed to study protein export in a mutant 
strain of M. tuberculosis and β-lactamase activity was detected using nitrocefin (49). β-lactam 
resistance was conferred when this truncated blaTEM-1 was fused with either Sec or Tat export signal 
sequences (49). In the present research, the slow β-lactamase activity and protein expression 
detected using Western blotting indicated that pJRD20 is producing a 24 KDa truncated TEM-1S-
ATG. We suggest that the truncated TEM-1S-ATG (lacking the signal peptide) remains mostly in the 
cytoplasm, resulting in the loss of export to the periplasm and delayed hydrolysis of 
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penicillin/ampicillin. Interestingly, this isolate did not confer elevated resistance to penicillin, 
typical of β-lactamase-producing gonococci. However, further research will confirm whether the 
truncated protein is present in the cytoplasm or uses a novel mechanism to be exported across the 
membrane. Alternatively, the TEM-1S-ATG β-lactamase may be released from gonococci upon cell 
lysis. 
 
In conclusion, we identified and characterized an Africa-type pJD5 variant plasmid, Canada-type 
pJRD20, with a 6 bp novel deletion starting at the G of the ATG start codon of blaTEM-1. The 
plasmid showed an intermediate MIC to penicillin and slow β-lactamase production. In silico 
analysis showed the effects of the 6 bp deletion on the 3D TEM-1 structure and penicillin-binding 
patterns. Western blot and mass spectrometry analyses confirmed the production of a truncated 
TEM-1S-ATG sequence. This research highlights the importance of extended monitoring for β-
lactamase activity when using nitrocefin, as these slow β-lactamase producing PPNG strains could 
easily be overlooked. Findings of novel plasmids harbouring blaTEM variants, such as pJRD20, is 
of critical importance for the proper control and management of global antibiotic resistance in N. 
gonorrhoeae.  
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CHAPTER 7: CONCLUSIONS AND FUTURE CONSIDERATIONS 
7.0 THE NEED FOR A RAPID DIAGNOSTIC TEST  
N. gonorrhoeae surveillance calls for increased attention for early detection and screening 
strategies (especially in asymptomatic cases), partner management and development of new 
diagnostics to achieve a 90% reduction in gonorrhea incidence by 2030 as compared to the number 
of cases in 2018 (2). Molecular surveillance can enhance gonococcal diagnosis, monitor AMR, 
improve treatment capabilities and strengthen the knowledge gap in antimicrobial use and AMR 
mechanisms, leading to effective use of antimicrobials, increasing their longevity and the global 
control of AMR in gonococci (1, 3). 
 
For my research, I developed a multiplex real-time PCR assay for the simultaneous identification 
of N. gonorrhoeae and its ciprofloxacin susceptibility status. Such a test could re-introduce 
ciprofloxacin for the treatment of susceptible gonococcal isolates. In addition, I evaluated a 
commercial hydrogel platform for the diagnosis of N. gonorrhoeae by using N. gonorrhoeae 
specific diagnostic primers and multiplex primers discriminating ciprofloxacin susceptible and 
resistant isolates. Preliminary results from these tests will lay the basis for commercial 
development of a portable diagnostic test for N. gonorrhoeae, possibly for use in resource-limited 
settings. Furthermore, I used molecular techniques and predicted trends of AMR in N. 
gonorrhoeae isolates from Saskatchewan. This showed emerging resistance to cefixime and 
azithromycin in Saskatchewan. Finally, I characterized a novel resistance-conferring mutation in 
a β-lactamase (bla) producing plasmid of an N. gonorrhoeae isolate, leading to slow β-lactamase 
production. This finding highlights the importance of continuous surveillance for bla plasmids and 
novel AMR mechanisms in N. gonorrhoeae.   
 
7.1 SIMULTANEOUS IDENTIFICATION OF N. GONORRHOEAE AND ITS 
CIPROFLOXACIN SUSCEPTIBILITY PROFILE  
Historically, a majority of N. gonorrhoeae isolates in Saskatchewan have been susceptible to 
ciprofloxacin and resistance has remained below 10% for many years (4). Due to the high 
prevalence of ciprofloxacin susceptible isolates in Saskatchewan, this antibiotic could be re-
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introduced for treatment of susceptible isolates, provided that the susceptibility status of the isolate 
is known. In fact, the current treatment guidelines in the United Kingdom recommend 
ciprofloxacin therapy for susceptible N. gonorrhoeae isolates (5). Both commercial (6) and 
experimental (7-11) molecular tests have been implemented in the United States and elsewhere, in 
clinical settings, with high success rates. However, such a test is still needed in Canada and for 
resource-constrained settings. 
 
For my research objective to develop rapid techniques for N. gonorrhoeae diagnosis, three primers 
were designed to work in multiplex to identify N. gonorrhoeae along with SNPs in its gyrA locus 
encoding S91 and D95 amino acid substitutions. These primers are unique in their capability to 
simultaneously identify N. gonorrhoeae and predict an isolate’s ciprofloxacin susceptibility 
profile. For the first part of the research (Chapter 3), gryA multiplex primers were tested using N. 
gonorrhoeae cultures and were over 99% sensitive and specific. Subsequently, the performance of 
the primers using DNA from clinical specimens (urines, raw urines and remnant Aptima urine 
specimens) was assessed (Chapter 4). Although the sensitivity and specificity were not as high as 
with cultures, the gyrA multiplex primers had 80% sensitivity with DNA extracted from urine 
specimens. As the ultimate goal of this research is to develop rapid diagnostic tools for N. 
gonorrhoeae identification, these multiplex primers were incorporated into a portable hydrogel-
based RT-PCR platform (Chapter 4). Despite the limited number of specimens, this preliminary 
test shows future potential in the amalgamation of the gryA multiplex primers on to the hydrogel 
system to develop a portable diagnostic platform for N. gonorrhoeae. 
 
The low sensitivities observed with raw urine specimens could be due to a variety of contributing 
factors. Modification of the PCR parameters (i.e. SYBR concentration, number of cycles, the 
volume of sample, etc.) to better suit the given specimen (i.e. raw urine) may prove more useful. 
RT-PCR conditions were initially validated with N. gonorrhoeae cultures. However, in hindsight, 
we used the same conditions to test clinical specimens and did not perform extensive validation 
on urines or remnant Aptima urine specimens prior to experiments with these specimens. 
Therefore, re-validating the PCR conditions for urines and changing one parameter at a time to 
better adapt the RT-PCR protocol to our sample would provide promising results. Furthermore, 
diluting the urine specimens may abrogate PCR inhibition by various substances present in urine 
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specimens (12). However, this may further dilute the urine and result in no amplification. 
Alternatively, urine specimens can be stored at 4oC, instead of -20oC, prior to DNA extraction, as 
this method has shown to improve PCR amplification of urine specimens (12). 
 
The use of gyrA multiplex primers can facilitate real-time analysis of ciprofloxacin susceptibility 
in N. gonorrhoeae and thereby enable informed use of ciprofloxacin to treat susceptible infections. 
With optimization, these primers can be integrated into a POCT for simultaneous identification of 
N. gonorrhoeae and its ciprofloxacin susceptibility status in less than 2h (if DNA extraction is not 
required). Such a test, especially with a low cost (i.e. ~$11/sample), could have major implications 
for resource-poor, high disease burden communities (13, 14). Furthermore, this test could prove 
useful for re-introducing ciprofloxacin for treatment if susceptibility is indicated. Additionally, 
this test could help increase surveillance for ciprofloxacin susceptibility, and present coherent 
findings for surveillance purposes and fill an urgent need, as susceptibility status is not determined 
with current NAATs. With the proper diagnosis of AMR status and with the use of ciprofloxacin, 
the use of cephalosporins might be prolonged.  
 
7.2 DIAGNOSIS OF N. GONORRHOEAE INFECTIONS 
The timely diagnosis of gonorrhea is crucial for proper control of the infection (15). However, an 
important factor contributing to the rising prevalence of gonorrhea is treatment delay where a 
patient waits for days for a diagnosis before treatment is initiated (15, 16), and during this time the 
infection could be passed along to their contacts. The development of POCTs for N. gonorrhoeae 
is recognized as a vital approach to improve timely diagnosis (17-21).  
 
To address this need, a panel of primers unique to N. gonorrhoeae was developed and evaluated 
using DNA from N. gonorrhoeae cultures (Chapter 2). Nine of the eleven primer pairs showed 
100% sensitivity for N. gonorrhoeae. Subsequently, to meet the objective of delivering a 
diagnostic tool for N. gonorrhoeae, these primers were incorporated into the hydrogel platform 
and assessed using DNA from gonococcal cultures (Chapter 2). Subsequently, the single primer 
pairs were combined for improved sensitivity with clinical specimens. These newly developed 
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primer combinations were 100% sensitive with DNA from N. gonorrhoeae cultures. Although the 
primer combinations had lower sensitivities with DNA extracted from remnant Aptima urine 
specimens (39-64%) and raw urines (0%), promising results were observed with DNA extracted 
from urine specimens (90-95%). Despite the availability of commercial NAATs with high 
sensitivities for N. gonorrhoeae, the uniqueness of our test is that the results can be provided in 
real-time and can be a cost-effective tool for resource-constrained settings. If the hydrogel platform 
can be optimized with these primers, the platform would be a useful tool to introduce as a portable 
alternative to empirical treatment in resource-limited settings.  
 
7.3 CHARACTERIZATION OF AMR IN N. GONORRHOEAE USING REMNANT 
APTIMA URINE SPECIMENS 
NAAT-based N. gonorrhoeae diagnosis has resulted in a substantial decline in AMS testing 
of gonococcal isolates. Thus, it would represent a significant advancement to find a strategy 
to characterize the AMS status of N. gonorrhoeae from positive commercial NAATs (22). 
Such a strategy would not only allow rational treatment of gonorrhea but would facilitate 
trend tracking, especially for emerging resistance in gonococci. Thus for my research eight 
AMR determinants in N. gonorrhoeae were assessed using remnant Aptim urine specimens 
(Chapter 5). These determinants are implicated in resistance to six antibiotics.  
 
With PCR amplification and amplicon sequencing, we observed emerging resistance to cefixime 
and azithromycin in Saskatchewan. This is highly significant as elevated MICs to azithromycin 
has prompted the United Kingdom to remove azithromycin from the primary treatment of 
gonorrhoeae (5). Since azithromycin coupled with ceftriaxone is recommended for gonorrhea 
treatment in Canada, vigilant and continuous monitoring of emerging resistance is crucial. These 
findings highlight that valuable information regarding gonococcal AMR can be obtained from 
characterizing resistant determinants. However, the approach used by us is labour-intensive, time-
consuming and costly; therefore a more efficient and user-friendly approach would be valuable for 
health regions, especially if an isolate’s AMS status can be predicted prior to treatment.  
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7.4 A TRUNCATED TEM-1 AND DELAYED AMPICILLIN HYDROLYSIS 
With the worldwide use of ESCs to treat gonococcal infections, a growing concern is that blaTEMs 
could acquire mutations leading to the evolution of an extended-spectrum β-lactamase (ESBL), 
which would be able to hydrolyze all ESC antibiotics making gonorrhea an untreatable infection 
(23-26). We characterized a novel β-lactamase-producing plasmid, pJRD20, from N. gonorrhoeae 
8903, with an intermediate MIC to penicillin and in which β-lactamase production is significantly 
delayed (Chapter 6). This finding highlights that although susceptibility to penicillin is not 
routinely performed, it is useful to monitor penicillinase-producing plasmids of N. gonorrhoeae. 
Characterizing AMR in N. gonorrhoeae, especially emerging resistance mechanisms is crucial to 
managing the spread of AMR globally. 
 
DNA sequencing and structural analyses indicated pJRD20 contains a 6 bp deletion starting at the 
G of the ATG start codon of blaTEM-1 and in turn formed a truncated TEM-1 (TEM-1S-ATG) from a 
downstream ATG start site. Based on molecular docking studies we proposed the pJRD20 TEM-
1 would primarily remain in the cytoplasm, as the N-terminal signal sequence required for 
periplasmic transportation is absent in this truncated TEM-1. Western blot analysis confirmed 
these presumptions showing that the resulting protein is a 24 KDa TEM-1 penicillinase, and Mass 
Spectrometry analysis indicated slow β-lactamase hydrolysis, which supports the hypothesis that 
the TEM-1 remains in the cytoplasm.  
 
Although N. gonorrhoeae 8903 did not confer elevated resistance to penicillin, typical of β-
lactamase-producing gonococci, further research is needed to confirm whether the truncated TEM-
1 remains in the cytoplasm and is released from gonococci upon cell lysis or uses a novel 
mechanism to be exported across the cytoplasmic membrane. Our findings highlight the 
importance of extended monitoring for β-lactamase activity, as these slow β-lactamase producing 
N. gonorrhoeae strains could be easily overlooked. Findings of novel plasmids, such as pJRD20, 
harbouring blaTEM variants is crucial for the control and management of AMR in N. gonorrhoeae.  
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7.5 CHARACTERIZATION OF AMR DETERMINANTS USING WGS 
Whole-genome sequencing has gained widespread popularity as an alternative tool to characterize 
mutations present in the N. gonorrhoeae genome leading to AMR (27-30). In one research study, 
we demonstrated that WGS based analyses of SNPs in genes attributed to AMR can be a powerful 
tool to predict gonococcal resistance, in the absence of MIC testing. Furthermore, this research 
showed that WGS analyses enabled the characterization of strain relatedness and isolate spreading, 
along with their AMR mechanisms. Although studies have performed WGS using cultures, 
research is limited in the use of clinical specimens, especially remnant Aptima urine specimens, 
to characterize AMR in N. gonorrhoeae. Therefore, with the use of DNA from Aptima urine 
specimens and in silico generated synthetic datasets, in a different research we showed that a 
minimum percentage of N. gonorrhoeae DNA is required to be present in the sequencing reads to 
identify an AMR status using WGS. This finding is significant, in that it shows WGS is a powerful 
tool to extract novel resistance mutations from the N. gonorrhoeae genome, however only if a 
sufficient concentration of nucleic acid is present.  
 
7.6 FUTURE DIRECTIONS  
I hypothesized that real-time molecular diagnostic platforms will allow timely diagnosis of N. 
gonorrhoeae and information on its resistance to various antimicrobials used for treatment. 
Additionally, I proposed that the molecular characterization of resistance determinants would 
provide a perspective of the spread of AMR and the emergence of resistance in gonococci in local 
communities. My research supports these presumptions and lays the foundation for preliminary 
work to develop PCR based diagnostic platforms for N. gonorrhoeae and shows emerging AMR 
trends in Saskatchewan and new AMR determinants.  
 
The goal of my research was to introduce the developed diagnostic tests (i.e. gyrA multiplex 
primers and N. gonorrhoeae diagnostic primers) for clinical use. Therefore, to make these tests 
more user-friendly and rapid, these assays need to be optimized, such that the DNA extraction 
step could be either automated or not required. To this end, PCR conditions and reagent 
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concentrations need to be enhanced for each specimen type (i.e. urine, vaginal and urethral 
swabs) separately. As discussed before, both gyrA multiplex primers and N. gonorrhoeae 
identification primers work optimally with DNA from N. gonorrhoeae cultures. Therefore, the 
tests should be optimized to account for low concentrations of DNA in raw urine specimens. To 
establish this, spiked urine samples could be used at differing concentrations. Alternatively, 
urine specimens from patients with symptomatic infections (i.e. men are preferred since women 
tend to have fewer or less prominent symptoms) could be compared to those from patients with 
asymptomatic (yet Aptima Combo 2 confirmed) gonococcal infections. Asymptomatic ‘patients’ 
would ideally be contacts of those who have an Aptima Combo 2 confirmed N. gonorrhoeae 
infection. Once this is established, these tests would be suitable for the introduction into clinical 
laboratories.  
 
Additionally, the conditions in the hydrogel should be optimized to the primers discussed in this 
research, such that a portable version of the tests can be evaluated in resource-constrained 
settings. Once the PCR conditions and specimen concentrations are optimized, these tests could 
be expanded to assess gonococcal resistance to other antimicrobials. This would allow the 
creation of an RT-PCR based test panel, where resistance to multiple antimicrobials would be 
assessed simultaneously and provide important information to clinicians.   
 
The presence of genetic mutations does not always coincide with MIC values indicating 
resistance, especially when resistance arises through multiple mutations in different genes. 
Therefore, the prediction of resistance based on molecular analyses should be undertaken with 
caution. As PCR amplification of single resistance determinants is time-consuming and costly, 
perhaps the use of WGS may alleviate this problem, as it would provide a comprehensive analysis 
of the entire genome of the pathogen and would be less expensive and ‘rapid’ compared to 
amplicon sequencing. Furthermore, WGS derived results will provide information regarding new 
and known mutations in genes implicated in AMR and facilitate strain tracking, contact tracing for 
epidemiological purposes, and the strategic implementation of measures to control the spread of 
gonococcal AMR.  
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APPENDIX A: PERFORMANCE OF NEISSERIA GONORRHOEAE SPECIFIC 
MULTIPLEX DIAGNOSTIC PRIMERS 
 
INTERFACE 
This research was carried out using the N. gonorrhoeae diagnosis primers discussed in Chapter 2. 
The primers performed with 100% sensitivity and specificity singly. However, the performance of 
the single primer pairs was suboptimal with DNA from remnant Aptima urine specimens. In this 
research, we proposed that by multiplexing the single primer pairs, an improved sensitivity can be 
achieved with clinical specimens. These new primer combinations were tested first using DNA 
extracted from N. gonorrhoeae cultures and subsequently with DNA from remnant Aptima urine 
specimens and raw urines. My contribution to this research included conceptualization of the 
research with guidance from Dr. Dillon, performing laboratory experiments, analyzing data, report 
writing, and supervising Kristen M Mitzel, who worked on this project as a summer student. 
 
INTRODUCTION 
The prevalence of gonorrhea is rising both nationally and globally (1). Treatment costs and 
associated lost productivity due to the infection are a severe burden to health care systems and 
economies worldwide (1). Currently, there are no vaccines to prevent N. gonorrhoeae infections 
and diagnosis is mainly based on nucleic acid amplification tests (NAATs) or culture and 
biochemical characterization of specimens. However, the current costs of commercial NAATs, are 
beyond the economic capabilities of many resource-limited settings. As such, patients receive 
empirical treatment. Thus, there is an urgent need to develop an efficient, rapid and cost-effective 
identification platform for N. gonorrhoeae diagnosis. We developed novel primers for the 
diagnosis of N. gonorrhoeae (2; Chapter 2) and have used these primers singly in an RT-PCR 
platform to identify N. gonorrhoeae from DNA extracted from cultures. Our primers showed 100% 
sensitivity for the identification of N. gonorrhoeae. In this research, we explore the utility of these 
primers in multiplex format to identify gonococcal DNA extracted from cultures, remnant Aptima 
urine specimens and from raw urines. 
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MATERIALS AND METHODS 
Bacterial Cultures and Clinical Specimens 
To determine the sensitivity and specificity of N. gonorrhoeae diagnostic primer pairs with clinical 
specimens, 331 remnant Aptima urine specimens, collectd between 2015 and 2016, were obtained 
from the Roy Romanow Provincial Laboratory (RRPL), Regina, SK. N. gonorrhoeae positive 
specimens were identified using the Aptima Combo 2 for CT/NG Assay (Hologic Gene-Probe 
Inc., San Diego CA) at the RRPL. Of the 331 specimens, 301 were N. gonorrhoeae positive and 
30 were N. gonorrhoeae negative. For experiments involving multiplex primer validation, 100 N. 
gonorrhoeae cultures collected from patients in 2018 were obtained from the RRPL. In addition, 
20 N. gonorrhoeae positive and 20 N. gonorrhoeae negative raw urine specimens, collected in 
2019, were obtained from the Saskatchewan Health Authority (SHA), Regina region (Regina, SK). 
These specimens had been tested for N. gonorrhoeae with the Aptima Combo 2 assay. 
 
For experiments involving urine specimens, the positive controls consisted of DNA from WHO N. 
gonorrhoeae reference isolates F, P, G, K and N (3), while the negative controls included DNA 
from Neisseria weaveri, Neisseria wadsworthii, Klebsiella oxytoca, Staphylococcus aureus and 
Lactobacillus iners (obtained from the National Microbiology Laboratory (NML), Winnipeg, 
MB). For validation of multiplex primer combinations, DNA from an additional 15 positive and 
15 negative control isolates was used. Here the positive control DNA was extracted from N. 
gonorrhoeae isolates FA19, F62, HongKong-986002, St. Vincent-97606, SK-7461, SK-1902, SK-
33414, SK-32318, SK-32420, SK-34638, SK-31352, SK-26539, SK-35426, SK-3542, and SK-
31355, from the Dillon culture collection. The negative controls consisted DNA from Neisseria 
animaloris, Neisseria mucosa, Neisseria elongate, Neisseria cinereal, Neisseria meningitides, 
Neisseria subflava, Neisseria polysaccharea, Escherichia coli BL21, E. coli V831, Salmonella 
Typhimurium, Staphylococcus epidermis, Lactobacillus jensenii, Lactobacillus gasseri, 
Moraxella catarrhalis, Enterococcus faecium, Enterococcus faecalis, Pseudomonas aeruginosa, 
and pJRD20 (4). DNA from non-N. gonorrhoeae isolates were obtained from the NML. 
 
DNA Extraction 
This procedure is as discussed in Chapter 4. Briefly, N. gonorrhoeae isolates were cultured on GC 
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medium base (Difco BD Bioscience) supplemented with 1% Kellogg’s defined supplement. Plates 
were incubated at 35-37°C with 5% CO2 in a humid environment for 18 to 24h (5). DNA extraction 
from bacterial cultures, remnant Aptima urine specimens, and raw urines was performed using a 
QIAamp DNA Mini kit (Qiagen) according to the manufacturer’s instructions. DNA 
concentrations from bacterial cultures and remnant Aptima urine specimens were quantified using 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). DNA concentrations from remnant 
Aptima urine specimens varied significantly (Table A.1). However, the amplification in RT-PCR 
was unrelated to DNA concentrations. DNA from raw urines were quantified using a Qubit 4 
fluorometer (Ther Fisher Scientific) and was normalized to 50ng/µl. Due to variability, DNA 
concentrations were not standardized for raw urines. 
 
Multiplex Primers  
N. gonorrhoeae diagnostic primer pairs were designed as described previously (1; Chapter 2). 
Primer sequences used in this research are presented in Table A.2. Multiplex primer combinations 
1 (P3 and P17-1), 2 (P8-4 and P16), and 5 (P3 and P16) consisted of two different primer pairs, 
while multiplex primer combinations 3 (P3, P16 and P21-5), 4 (P3, P16 and P31-2) and 7 (P3, P16 
and P17-1) consisted of three different primer pairs. Primer combination 6 (P3, P8-4, P16 and P17-
1) included four different primer pairs (Table A.3). Targets for all primer pairs are present in 
multiple copies in the N. gonorrhoeae FA1090 genome (NCBI RefSeq NC_002946.2) and in turn, 
increase the sensitivity of detection (Figure A.1). 
 
Real-Time (RT) PCR 
RT-PCR was performed using an Applied Biosystems StepOnePLus instrument (Life 
Technologies) in a 96-well plate platform (Life Technologies) with SYBR Select Master Mix (Life 
Technologies). PCR reactions contained 5µl of 2X SYBR-Green, 3µl of combined primer mix 
(10µM) and 2µl of DNA template (at various concentrations). PCR was initiated with a primary 
holding and activation at 50°C for 2min, followed by a secondary holding at 95°C for 2 min. PCR 
was performed for 30 cycles: 95°C for 15 sec and 60°C for 30 sec. The post-PCR melt curve was 
performed between 65oC to 95oC, with 0.3°C temperature increments for primer combinations 1-
5, and 0.1oC temperature increments for primer combinations 6 and 7. Each experiment was 
performed in duplicate.  
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Table A.1 DNA concentration variability of remnant Aptima urine specimens.  
 
DNA Concentration Number of 
 N. gonorrhoeae Positive 
Specimens (n=301) 
Number of  
N. gonorrhoeae Negative 
Specimens (n=30) 
<10 ng/µL 173 25 
10-50 ng/µL 128 5 
50-100 ng/µL 15 0 
>100 ng/µL 10 0 
  
  
1
9
5
 
Table A.2 Primer sequences used in this research for detection of N. gonorrhoeae, their respective targets and copy numbers.  
 
Primer ID  
(Product Length) 
Sequence (5'->3')a Target Geneb No Targets in Ng 
FA1090 
Primer 3 (139bp) NGO05940, NGO06090, 
NGO06650, NGO1642 
4 
Forward  TATGGGGGTTCCTTCGCACC  
Reverse CAGACGGTTGCGGGTTCTTG  
Primer 8-4 (180bp) NGO0773, NGO1200, 
NGO1703, NGO1137, 
NGO1164, NGO1262, 
NGO1641 
7 
Forward  TCACGGATGACCGCAGCATA  
Reverse  AGACGCTTCACGCCTTCCTT  
Primer16 (93bp) 
 
NGO1131, NGO1209 2 
Forward  CGGAACAAGCGTTTTTCAGCG  
Reverse  TCTTTGGCTTGTCCGGGTGT  
Primer 17-1 (73bp) 
 
NGO1638, NGO0487, 
NGO1108 
3 
Forward  TCCGAAACACGCAAACCGAAA  
Reverse  TAGCCCGGGTTGGTATTGCC  
Primer 21-5 (101bp) 
 
NGO1085, NGO1652 2 
Forward  GCACGAAACCCGTCCAATCC  
Reverse  CAAGACATGCGGCTATGCGG  
Primer 31-2 (188bp) 
 
NGO0480, NGO1113, 
NGO1631 
3 
Forward  AAAATCGCGCCGGGTTTGAA  
Reverse  AGCTTATCCGCAGCGGTTCT  
aThe primer sequences presented in this manuscript are the subject of a United States utility patent (#62/088,332) 
bLocus Tag ID in the NCBI database  
196 
Table A.3 Primer combinations used in this research and primer pairs involved.  
 
Multiplex Primer 
Combination 
Primer Pairs Involved Melt Curve Temperature 
Combination 1 P3 and P17-1 80oC and 86oC 
Combination 2 P8-4 and P16 83oC and 88oC 
Combination 3 P3, P16, and P21-5 80oC, 88oC, 85.5oC 
Combination 4 P3, P16, and P31-2 80oC, 88oC, 83oC 
Combination 5 P3 and P16 80oC and 88oC 
Combination 6 P3, P8-4, P16 and P17-1 80oC, 83oC, 88oC and 86oC 
Combination 7 P3, P16 and P17-1 80oC, 88oC and 86oC 
 
 
 
  
1
9
7
 
 
Figure A.1 Representative map of the diagnostic primer binding regions in the N. gonorrhoeae FA1090 genome. The starting base 
pair location of the primer annealing site is indicated beside the primer name (5’ to 3’) and the PCR product size is indicated within 
brackets. 
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RESULTS 
Performance of Multiplex N. gonorrhoeae Diagnostic Primers  
We developed seven different multiplex diagnostic primer combinations from a pool of six 
different single primer pairs (1; Table A.3). These combinations were created to provide a unique 
set of melting temperatures for each primer combination. Primer combination 2 was eliminated 
due to low sensitivity (Table A.4), while the combinations 3 and 6 were eliminated due to 
overlapping melt curves (Figure A.2). Overlapping melt curves could lead to false-negative 
identification. Primer combination 4 was eliminated both due to low sensitivity and overlapping 
melt curves (Figure A.2; Table A.4). The final panel consisted of primer combinations 1, 5 and 7.  
 
These three multiplex primer combinations were further tested with DNA from 100 N. 
gonorrhoeae cultures, and all three combinations had 100% sensitivity (Table A.5). Combination 
7 performed the best with having 96% specificity with non-N. gonorrhoeae DNA, while 
combination 1 and 5 exhibited 61% and 74% specificity respectively. Although some non-N. 
gonorrhoeae strains were amplified with these primer combinations (Combination 1 - N. 
Animaloris, N. weaverii, S. epidermis, E.  coli BL21, L. jensenii, S. aureus, L. iners, L. gasseri, 
and E. faecalis; Combination 5 - N. Animaloris, N. elongate, E. coli V831, S. aureus, M. 
catarrhalis, and L. gasseri; Combination 7 - S. aureus), no non-specific amplification was 
observed in preliminary tests with single primer pairs (Chapter 2). Similarly, no cross-reactivity 
was found when single primer pairs were BLAST searched with these non-N. gonorrhoeae strains 
(Chapter 2).   
 
Sensitivity and Specificity of Diagnostic Primer Combinations with Urine Specimens 
All three primer combinations (i.e. 1, 5 and 7) had 100% sensitivity and 80% specificity with DNA 
from positive and negative control isolates (Table A.6). Although 100% specificity was observed 
previously (1) with single primer pairs, DNA from S. aureus was amplified by all primer 
combinations reducing the specificity. However, when a BLAST search was performed with the 
primer sequences discussed in this research, cross-reactivity with S. aureaus was not observed. A 
similar search was previously performed for the single primer pairs and was discussed in Chapter 
2, Table 2.3.   
  
1
9
9
 
Table A.4 Sensitivity and specificity of multiplex N. gonorrhoeae diagnostic primer combinations with DNA extracted from N. 
gonorrhoeae and non-N. gonorrhoeae cultures. 
 
Number of 
Cultures 
Tested 
Primer 
Combination 
#1 #2 #3 #4 #5 #6 #7 
Primer pairs P3, P17-1 P8-4, P16 P3, P16, 
P21-5 
P3, P16, 
P31-2 
P3, P16 P3, P8-4, 
P16, P17-1 
P3, P16, 
P17-1 
N=5 Sensitivity  100% 60% 100% 20% 100% 100% 100% 
N=10 Specificity 90% 100% 100% 100% 90% 95% 95% 
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Figure A.2 RT-PCR melt curves for N. gonorrhoeae diagnostic primer combinations 1 to 7.  
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Table A.5 Multiplex N. gonorrhoeae diagnostic primer combinations 1, 5 and 7 with DNA from 
a N. gonorrhoeae test panel and control isolates. 
 
 Positive controls 
(n=20) 
Sensitivity 
Negative controls 
(n=23) 
Specificity 
DNA from 
N. gonorrhoeae 
cultures (n=100) 
Sensitivity 
Primer combo #1 100% 55%a 100% 
Primer combo #5 95% 70%b 100% 
Primer combo #7 100% 95%c 100% 
Non-Neisseria gonorrhoeae species amplified: aN. Animaloris, N. weaverii, S. epidermis, E.  coli 
BL21, L. jensenii, S. aureus, L. iners, L. gasseri, and E. faecalis; bN. Animaloris, N. elongate, E. 
coli V831, S. aureus, M. catarrhalis, and L. gasseri; cS. aureus 
  
  
2
0
2
 
Table A.6 Sensitivity and specificity of N. gonorrhoeae diagnostic primer combinations 1, 5 and 7 with DNA extracted from urines 
and raw urine specimens. 
 
  Primer Combination 
#1 #5 #7 
Sensitivity 
DNA from N. gonorrhoeae cultures (n=5) 100% 100% 100% 
DNA from N. gonorrhoeae positive urines (n=20) 90% 95% 95% 
N. gonorrhoeae positive raw urines (n=20) 0% 0% 0% 
 Specificity 
DNA from non-N. gonorrhoeae cultures (n=5) 80% 80% 80% 
DNA from N. gonorrhoeae negative urines (n=20) 25% 35% 25% 
N. gonorrhoeae negative raw urines (n=20) 100% 100% 100% 
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Primer combination 1 had 90% sensitivity while the primer combinations 5 and 7 each had 95% 
sensitivity with DNA from N. gonorrhoeae positive urines (Table A.6). None of the primer 
combinations was able to amplify directly from N. gonorrhoeae positive raw urines (i.e. urines 
with no DNA extraction step). Primer combinations 1 and 7 had 25% specificity with DNA from 
N. gonorrhoeae negative urines, while the primer combination 5 had 35% specificity. All three 
primer combinations had 100% specificity with N. gonorrhoeae negative raw urines.  
 
As discussed above, the N. gonorrhoeae diagnostic primer combinations had 100% sensitivity 
with DNA from cultures and demonstrated high sensitivities with DNA extracted from urines. 
Thus in this research, we utilized the diagnostic primer combinations 1, 5 and 7 to test the primers 
with DNA from Aptima urine specimens. For this, DNA from N. gonorrhoeae positive (n=36) and 
negative (n=36) remnant Aptima urine specimens was tested (Table A.7). A 94% specificity was 
observed for all three primer combinations. Although relatively low, primer combination 5 had the 
highest sensitivity at 64%. Primer combination 1 had 61% and combination 7 had 39% sensitivity 
respectively. Due to the low sensitivity, these results were indicative that DNA from remnant 
Aptima urine specimens was not ideal for N. gonorrhoeae diagnosis. This finding supported our 
previous observations where we noticed low amplification success both with PCR (Chapter 5) and 
with whole-genome sequencing (Appendix C) approaches using DNA from remnant Aptima urine 
specimens. 
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Table A.7 Performance of N. gonorrhoeae diagnostic primer combinations 1, 5 and 7 with DNA 
from remnant Aptima urine specimens. 
 
Primer 
Combination 
N. gonorrhoeae positive 
specimens (n=36) 
Sensitivity 
N. gonorrhoeae negative 
specimens (n=36) 
Specificity 
#1 61% 94% 
#5 64% 94% 
#7 39% 94% 
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DISCUSSION 
The N. gonorrhoeae diagnostic primer combinations have high sensitivities and specificities with 
DNA extracted from N. gonorrhoeae cultures and urine specimens. This is promising, as the 
current costs associated with culturing and training of laboratory personnel, as well as the cost of 
commercial NAATs, are beyond the economic capability of many resource-limited settings. The 
extremely low sensitivity (0%) observed with N. gonorrhoeae negative raw urine specimens 
(Table A.6) may be attributed to relatively low concentrations of overall DNA in the specimen, 
and this may in turn account for the extremely high specificity (i.e. 100%) with positive urine 
specimens. As such, the use of DNA extracted from urines may be a better alternative to using raw 
urines (i.e. urines without DNA extraction) in RT-PCR based diagnostic assays. However, it is 
important to note that we have only tested a limited number of urine specimens and have not tested 
other types of clinical specimens such as cervical, urethral, pharyngeal and rectal swabs, which 
may prove more effective without a DNA extraction step. However, such specimens first need to 
be evaluated with these primer combinations. Despite the limitations, our findings show promise 
in using the multiplex N. gonorrhoeae diagnostic primers and DNA extracted from urine 
specimens to identify N. gonorrhoeae. Thus, the RT-PCR based platform discussed in our work 
can be a rapid, user-friendly and more affordable alternative for the more expensive commercial 
NAATs for N. gonorrhoeae diagnosis. 
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APPENDIX B: PRELIMINARY ANALYSIS OF NEISSERIA GONORRHOEAE STRAINS 
FROM A LOCAL “OUTBREAK” 
 
INTERFACE 
This research was conducted to characterize known antimicrobial resistance (AMR) determinants 
from a collection of N. gonorrhoeae strains identified as being similar using several different 
typing schemes. DNA from twenty strains were sent for whole-genome sequencing (WGS). 
However, only five strains remained viable. Therefore, only the results from PCR amplification 
with NG-STAR primers for these five strains are presented in this appendix. My contribution to 
this research included DNA extraction from gonococcal cultures, analysis of amplicon sequencing 
reads, and supervision of the technician (Jin Wang) working on the research. WGS reads were 
subsequently analyzed by Dr. Reema Singh. The manuscript for this research is in preparation. 
 
MATERIALS AND METHODS 
Bacterial Cultures and DNA Extraction 
Five different N. gonorrhoeae isolates from two different outbreaks were used in this research  
(isolates 3644, 3648, 5707, and 6525 from outbreak 1, and isolate 883511 from outbreak 2; Dillon 
Culture Collection). N. gonorrhoeae isolates were stored at -80°C in brain heart infusion medium 
(Difco BD Bioscience) with 20% glycerol. Aliquots from frozen inoculum were cultured on GC 
medium base (Difco BD Bioscience) supplemented with 1% Kellogg’s defined supplement. Plates 
were incubated at 35-37°C with 5% CO2 in a humid environment for 18 to 24h (1). Cells were 
collected from agar surfaces with a sterile loop and DNA extraction was performed using a 
QIAamp DNA Mini kit (Qiagen) according to the manufacturer’s instructions. DNA was 
quantified using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). 
 
PCR Amplification and DNA Sequencing 
DNA was PCR amplified using Taq polymerase and primer pairs recommended by the N. 
gonorrhoeae Strain Typing for Antimicrobial Resistance (NG-STAR) typing scheme 
(https://ngstar.canada.ca/alleles/query?lang=en; Table B.1). Primer sequences were synthesized at 
208 
Thermo Fisher Scientific. Amplicons were confirmed for the correct size by agarose gel 
electrophoresis and were sequenced in both forward and reverse directions by Sanger sequencing 
(Eurofins Genomics, Louisville KY, USA). Point mutations in penA (M32091.1), mtrR 
(Z25796.1), porB1b (M21289.1), ponA (AB727718.1), gyrA (U08817.1), parC (U08907.1) and 
23S rRNA (X67293.1) were determined using Clone Manager 8 Professional (Scientific & 
Educational Software, NC, USA). 
 
RESULTS 
Seven different genes implicated in AMR in N. gonorrhoeae were characterized (Table B.2). All 
five isolates carried 345D and F540L substitutions in PenA and a C2605T nucleotide substitution 
in the 23S rRNA. N. gonorrhoeae 883511 had an additional C2599T substitution in the 23S rRNA 
domain. The L421P substitution in PonA was only observed in three isolates. An A- deletion in 
the promoter region of mtrR and G101K, G120K and A121D substitutions in PorB1b were also 
observed in the same three isolates with the PonA substitution (N. gonorrhoeae 3644, 3648 and 
883511). N. gonorrhoeae 5707 and 6525 isolates only contained G101K substitution in PorB1b 
and did not harbour the A- deletion in the mtrR promoter region. Only N. gonorrhoeae 5707 carried 
a D86N substitution in ParC and none of the isolates carried GyrA substitutions.  
 
  
2
0
9
 
Table B.1 List of primers used to amplify N. gonorrhoeae AMR markers (2). 
AMR marker Primer name Primer sequence (5’ to 3’) Annealing 
Temperature  
Product size (bp) 
penA PenA-A1(forward)  
PenA-B1(reverse) 
 
PenA-A2(forward)  
PenA-B2 (reverse) 
 
PenA-A3(forward)  
PenA-B3 (reverse) 
CGGGCAATACCTTTATGGTGGAAC 
AACCTTCCTGACCTTTGCCGTC 
 
AAAACGCCATTACCCGATGGG 
TAATGCCGCGCACATCCAAAG 
 
GCCGTAACCGATATGATCGA 
CGTTGATACTCGGATTAAGACG 
62oC 
 
 
55oC 
 
 
58oC 
669 
 
 
581 
 
 
863 
mtrR MTR1(forward) 
MTR2 (reverse) 
AACAGGCATTCTTATTTCAG 
TTAGAAGAATGCTTTGTGTC 
58oC 916 
porB1b por-NGMAST-F (forward)  
por-NGMAST-R (reverse) 
CAAGAAGACCTCGGCAA 
CCGACAACCACTTGGT 
58oC 737 
ponA ponA1-f (forward)  
ponA1-r (reverse) 
CGCGGTGCGGAAAACTATATCGAT 
AGCCCGGATCGGTTACCATACGTT 
65oC 1240 
gyrA GYRA-1(forward)  
GYRA-2 (reverse) 
AACCCTGCCCGTCAGCCTTGA 
GGACGAGCCGTTGACGAGCAG 
68oC 270 
parC parC F (forward) 
parC R (reverse) 
GTTTCAGACGGCCAAAAGCC 
GGCATAAAATCCACCGTCCCC 
62oC 332 
23S rRNA gonrRNAF (forward) 
gonrRNAR2 (reverse) 
ACGAATGGCGTAACGATGGCCACA 
TTCGTCCACTCCGGTCCTCTCGTA 
55oC 712 
  
2
1
0
 
Table B.2 Characterization of point mutations in known AMR determinants in N. gonorrhoeae using NG-STAR primer pairs. 
 
Isolate ID PenA MtrR PorB1b PonA GyrA ParC 23S rRNA MIC
c Range 
3644a 
345D 
F504L 
A- 
G101K 
G120K 
A121D 
L421P WT WT C2605T 
Penicillin: 0.25-256 mg/L 
Tetracycline: 0.25-16 mg/L 
Erythromycin: ≤0.063-0.125 mg/L 
Spectinomycin: 16-32 mg/L 
Ceftriaxone: 0.001-0.004 mg/L 
3648a 
345D 
F504L 
A- 
G101K 
G120K 
A121D 
L421P WT WT C2605T 
5707a 
345D 
F504L 
WT G101K WT WT D86N C2605T 
6525a 
345D 
F504L 
WT G101K WT WT WT C2605T 
883511b 
345D 
F504L 
A- 
G101K 
G120K 
A121D 
L421P WT WT 
C2599T 
C2605T 
Penicillin: 2-4 mg/L 
Tetracycline: 2-4 mg/L 
Erythromycin: 2-4 mg/L 
Spectinomycin: 16-32 mg/L 
Ceftriaxone: 0.016-0.032 mg/L 
 
aIsolates from outbreak 1 
bIsolates from outbreak 2 
cMinimum inhibitory concentrations. MICs were reported as a range for all the isolates from the outbreak. 
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DISCUSSION 
Specific mutations in penA, mtrR, porB, and ponA are indicative of resistance to penicillin, while 
mtrR and porB mutations are indicative of reduced susceptibility to tetracycline. Thus based on 
our analysis, all five isolates are chromosomally resistant to penicillin and isolates 3644, 3648 and 
883511 have low-level chromosomal resistance to tetracycline. Although substitutions in RpsJ are 
associated with high-level tetracycline resistance, rpsJ was not characterized in this research. 
Isolates 5707 and 6525 have wild-type mtrR promoter sequences and a G101K substitution in 
PorB1b. Therefore these isolates are intermediately susceptible to penicillin and likely susceptible 
to tetracycline. As the ParC substitutions alone do not confer ciprofloxacin resistance, all five 
isolates are deemed ciprofloxacin susceptible. Mutations in 23S rRNA are indicative of reduced 
susceptibility to azithromycin. Therefore, all five isolates could be predicted to have elevated MICs 
to azithromycin. However, it is important to note as only one of the four alleles of the peptidyl-
transferase loop region in domain V of 23S rRNA was sequenced with these primers, the 
identification of elevated MICs to azithromycin is presumptive. Additionally, all five isolates are 
susceptible to cefixime and ceftriaxone. The predicted susceptibilities are in agreement with the 
reported MIC ranges for these isolates. However, since MICs were reported as a range for all the 
isolates from the outbreak, it was difficult to do a direct comparison between predicted 
susceptibility and observed MICs for a given isolate.  
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APPENDIX C: IS WHOLE GENOME SEQUENCING AN EFFECTIVE TECHNIQUE 
FOR THE IDENTIFICATION AND CHARACTERIZATION OF NEISSERIA 
GONORRHOEAE IN APTIMA URINE SAMPLES? 
 
INTERFACE 
With the use of DNA from Aptima urine specimens and in-silico generated synthetic datasets, this 
research shows that a minimum percentage of N. gonorrhoeae DNA to be present in the sequencing 
reads is critical, to ascertain an isolate’s antimicrobial susceptibility (AMS) status using whole-
genome sequencing (WGS). My contribution to this preliminary research included extracting DNA 
from remnant Aptima urine specimens. Bioinformatics analyses were performed by Dr. Reema 
Singh. The manuscript for this research is in preparation. 
 
ABSTRACT  
WGS as a molecular diagnostics tool is gaining widespread interest in clinical microbiology.  
However, this technique is not always directly applicable to clinical specimens due to various 
limitations. This research evaluated the performance of bioinformatics analysis of N. gonorrhoeae 
WGS data from 99 artificial datasets and 9 remnant Aptima urine specimens. The 99 artificial 
datasets were generated by mixing N.gonorrhoeae and human WGS read sets using the “Reservoir 
Sampling” algorithm. Using simulated data, it was found that when the amount of human reads in 
the sample increase, the average percentage of the GC content of each sample decreases, while the 
total number of contigs per assembly increases. Synthetic dataset results were verified by 
analyzing nine remnant Aptima urine specimens. We showed that at least 5% of reads from N. 
gonorrhoeae should be present in the total WGS read datasets to determine an isolate’s 
antimicrobial susceptibility pattern.  
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INTRODUCTION 
Although nucleic acid amplification tests (NAATs) are widely used to confirm gonorrhea 
infections, an isolate’s antimicrobial susceptibility (AMS) status (1-3) is not predicted using 
current NAATs. To address this limitation, WGS, especially using gonococcal cultures, has gained 
widespread popularity (3-7). However, despite the use of WGS techniques for strain typing and 
characterization of resistance determinants from N. gonorrhoeae (6-8), research is limited in the 
use of WGS from N. gonorrhoeae positive clinical specimens, such as remnant Aptima urine 
specimens, for characterizing gonococcal AMS status. The main limitation is that the extraction 
of DNA from remnant Aptima specimens (i.e. remaining specimen following N. gonorrhoeae 
identification with Aptima Combo 2 assay) presents significant challenges. For example, Aptima 
buffer is a transportation medium that lyses all cells (human and bacterial) in the specimen, 
making it extremely difficult to enrich N. gonorrhoeae and other bacterial DNA (9, 10). 
Nonetheless, several studies have utilized remnant Aptima urine specimens for PCR amplification 
of known AMR determinants (2, 11, 12). In the present research, we evaluated the performance of 
bioinformatics analysis on WGS reads from 99 in-silico generated datasets and 9 remnant Aptima 
urine specimens.  
 
MATERIALS AND METHODS 
Artificial Dataset Generation 
Synthetic datasets were prepared by mixing N. gonorrhoeae and human WGS read datasets at 
several (10%-90%) combinations. The WGS paired-end datasets generated using MiSeq platforms 
(600 chemistry used for sequencing) were downloaded from the NCBI SRA repository (13; Table 
C.1). To make Dataset-1, 10% (35,976) of the total reads (sample no 27931), the same set of pair-
end reads were replaced with 35,976 paired-end reads from a human WGS dataset (sample no 
ERR3181737). A random set of read-pairs were extracted by using “seqtk sample” 
(https://github.com/lh3/seqtk) command from N. gonorrhoeae and human read sets. The algorithm 
used for random sampling is “Reservoir Sampling”. Similarly, Datset-2 was created by replacing 
20% (71,952) of the total reads with 71,952 paired-end reads from a human WGS dataset using 
“seqtk random sampling”. Various combinations of synthetic datasets generated using Pair1 are 
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shown in Table C.2. Similarly, a total of 99 different combinations were generated using dataset 
pairs given in Table C.1. Synthetic datasets were generated using in-house Perl scripts. De-novo 
assemblies were generated from each dataset by using SPAdes (14) v 3.10.1 (--k 21, 33, 55, 77, 
99, 127, --pe1-1, -- pe1-2, --careful and –cov-cutoff auto) implemented in Gen2Epi (15). Resulting 
contigs were searched for AMR genes. 
 
DNA Extraction and Whole Genome sequencing 
DNA from nine remnant Aptima urine specimens was extracted using QIAamp DNA Mini kit 
(Qiagen) according to manufacturer instructions. The DNA concentration was measured using 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) and 5ng/µl of DNA from each 
isolate was used for whole genome sequencing (The Donnelley Sequencing Center, University of 
Toronto, Toronto ON, Canada). Paired-end reads (35-301 bp in length) were generated on the 
Illumina Miseq platform using the Nextera XT library preparation kit with 100X coverage.  
 
Bioinformatics Analysis 
Raw reads were trimmed using Trimmomatic v 0.36 (16) with a Phred quality score of < 20. De-
novo assemblies were obtained using Spades v 3.10.1 (parameters “--k 21, 33, 55, 77, 99, 127, --
pe1-1, -- pe1-2, --careful and –cov-cutoff auto”) (12). Contamination with human DNA and DNA 
from urogenital bacterial species are the main problems in samples collected from patients with 
sexually transmitted infections. Therefore, taxonomic labels were assigned to raw reads using 
Kraken v 1.1 (17). Kraken libraries for bacteria, archaea, fungi, human, plasmid, protozoa, and 
virus were used to create a database for read binning. Read binning results were confirmed by 
aligning the raw reads to the reference N. gonorrhoeae FA1090 genome (NC_002946.2). 
Assembled contigs were further searched for sequences of known antimicrobial resistant 
determinants: porB (Z69259.1), porB1b (EU719207.1), tbpB (U65219.1), penA (M32091.1), mtrR 
(KT954119.1), ponA (AB727718.1), gyrA (U08817.1), parC (U08907.1), and 23S rRNA 
(X67293.1) downloaded from the NCBI nucleotide database (https://www.ncbi.nlm.nih.gov/ 
nucleotide).  
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Table C.1 N. gonorrhoeae and Human WGS datasets used in this research. 
 
N. gonorrhoeae 
Sample 
Total 
Reads 
Read 
Size (bp) 
Human Total 
Reads 
Read 
Size (bp) 
Combinationa 
27931 359,760 39-301 ERR3181737 535,527 35-250 Combination1 
28861 581,813 35-251 ERR3181738 726,987 35-250 Combination2 
33679 504,310 35-251 ERR3181740 606,080 35-250 Combination3 
34106 458,761 35-251 ERR3181730 721,803 35-250 Combination4 
34108 733,738 35-251 ERR3181731 756,895 35-250 Combination5 
34442 718,889 89-301 ERR3181714 878,519 35-250 Combination6 
34688 664,878 72-301 ERR3181719 744,968 35-250 Combination7 
35476 611,542 35-301 ERR3181732 953,472 35-250 Combination8 
36090 567,537 127-301 ERR3181723 817,848 35-250 Combination9 
aEach combination has 11 samples  
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Table C.2 Bioinformatics analysis of N. gonorrhoeae datasets. 
 
N. gonorrhoeae Sample % GC Total contigs 
27931 52.71 89 
28861 52.44 110 
33679 52.53 147 
34106 52.54 179 
34108 52.53 159 
34442 52.51 112 
34688 52.49 108 
35476 52.68 110 
36090 52.5 128 
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RESULTS 
Synthetic Datasets 
A total of 99 artificial datasets were generated from different N. gonorrhoeae and human read set 
combinations (Table C.1). First, to identify how in silico generated datasets differ from in vitro 
generated N. gonorrhoeae reads, we compared the average GC content of all 99 synthetic WGS 
datasets. The average GC content of N. gonorrhoeae and the human genome is 52.4% and 39%, 
respectively. As shown in Figure C.1, the average GC percentage drops 38% as the number of 
human-read sets increases in each dataset. Second, the distribution of the total number of 
assembled contigs is shown in Figure C.2. The assemblies vary in size ranging from the smallest 
contigs of 128 bp to the largest of 278,679 bp. We observed that the total number of contigs 
increase per assembly with the increase of human reads in each dataset. However, to measure the 
completeness and authenticity, these contigs generated from human contaminated reads require 
additional analysis such as annotation and quality check.  
 
Finally, we observed that all AMR determinants (porB, porB1b, tbpB, penA, mtrR, ponA, gyrA, 
parC, and 23S rRNA) were present in the contig assemblies generated from all 99 artificial 
datasets. The only exception was the artificial dataset 11, with 1% N. gonorrhoeae reads, where 
most of the AMR determinant is either missing or partially present. For example, AMR 
determinants missing in data combinations include; porB and porB1b in combination 6, mtrR and 
parC in combination 4, tbpB in combination 3, gyrA in combination 2, and penA and ponA in 
combination 1. In combinations, 7, 8 and 9 artificial datasets assembled all nine AMR 
determinants.  
 
Validation of synthetic datasets results 
To validate the results obtained from synthetic WGS dataset analysis, we performed WGS analysis 
on N. gonorrhoeae positive nine remnant Aptima urine specimens. The detailed bioinformatics 
analysis results are shown in Table C.3. Read binning results provided a thorough insight into the 
overall organism distribution in remnant Aptima urine specimens (Table C.4). Here we   
  
2
1
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Figure C.1 Comparison between 99 synthetic datasets based on average % GC.  
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Figure C.2 Comparison between 99 synthetic datasets based on the total number of assembled 
contigs.  
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Table C.3 Summary of bioinformatics analysis of WGS reads from nine N. gonorrhoeae 
positive remnant Aptima urine specimens. 
 
 
 
 
 
 
 
 
 
 
  
Samples Total Reads  Alignment to  
N. gonorrhoeae 
FA1090 genome 
Number of contigs 
   Raw Reads Trimmed Reads 
U205 1,272,329 0.16% 28,572 272 
U215 1,581,119 0.21% 864 207 
U238 1,308,487 0.09% 1,045 336 
U244 1,431,331 0.22% 25,179 186 
U281 1,460,481 0.11% 1,140 243 
U283 1,174,304 0.11% 27,601 274 
U35 1,406,793 0.14% 861 218 
U2 1,142,161 0.11% 18,365 204 
U30 1,905,260 0.07% 1,214 332 
  
2
2
1
 
Table C.4 Read binning results of WGS read sets from nine remnant Aptima urine specimens.  
 
Samples Human Reads N. gonorrhoeae 
Reads 
Other Species (Number of reads) 
U205 1,267,783 (99.64%) 2,639 N. lactamica (2), N.meningitidis (16), Neisseria_sp_KEM232 (2), Human 
polyomavirus (20) 
U215 1,572,138 (99.43%) 3,707 N. lactamica (4), N. meningitidis (19), N.sicca (2), Cutibacterium acnes (18), 
Sphingobium yanoikuyae (12) 
U238 1,304,818 (99.72%) 1,617 N. meningitidis (5), Cutibacterium acnes (30), Escherichia coli (25) 
U244 1,423,503 (99.45%) 5,137 N. meningitidis (17), Cutibacterium acnes (9) 
U281 1,422,629 (97.41%) 2,200 N. meningitidis (10), Mycoplasma hominis (286), Cutibacterium acnes (54), 
Gardnerella vaginalis (6283), Mobiluncus curtisii (86), Mageeibacillus indolicus 
(102), Porphyromonas gingivalis (75), Porphyromonas asaccharolytica (242), 
Prevotella ruminicola (26), Prevotella denticola (86), Prevotella intermedia 
(1277), Prevotella melaninogenica (136), Prevotella dentalis (55), Prevotella 
enoeca (98), Prevotella fusca (125), Prevotella scopos (185), 
Prevotella_sp_oral_taxon_299 (216),  Sneathia amnii (3396), Fusobacterium 
nucleatum (294), Pseudomonas fluorescens (32) 
U283 1,170,719 (99.69%) 1,821 N. meningitidis (14), Cutibacterium acnes (24), Human polyomavirus (10) 
U35 1,401,771 (99.64%) 2,751 N. meningitidis (17), Cutibacterium acnes (12) 
U2 1,138,707 (99.70%) 1,657 N. meningitidis (12), Cutibacterium acnes (14), Klebsiella pneumoniae (17), 
Klebsiella variicola (22) 
U30 1,897,433 (99.59%) 1,832 N. meningitidis (6), Gardnerella vaginalis (1539), Cutibacterium acnes (35), 
Lactobacillus crispatus (52), Lactobacillus jensenii (54), Pseudomonas 
fluorescens (16) 
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identified other bacterial species such as Gardnerella vaginalis, Prevotella intermedia, and 
Sneathia amnii along with several other low abundant species in 2/9 specimens. A large number 
of reads (99%) belonged to the human, while only <1% reads resulted from N.gonorrhoeae, and 
as such is insufficient to characterize the pathogen (Table C.3).  
 
DISCUSSION 
We evaluated the performance of WGS on clinical specimens using bioinformatics analysis of 
remnant Aptima urine specimens and found the minimum amount of DNA required to identify 
N.gonorrhoeae from such specimens. We first analyzed 99 in-silico generated datasets by mixing 
human and N.gonorrhoeae WGS read datasets at different percentages. Subsequently, WGS data 
from nine remnant Aptima urine specimens was analyzed to reveal that only <1% N. gonorrhoeae 
reads were present following WGS of these specimens. This was indicative that a threshold 
quantity of N. gonorrhoeae DNA in Aptima specimens is key to the efficient use of WGS on these 
specimens. This finding is in agreement with two previous studies (18, 19) that describe the 
limitations of extracting DNA for WGS from remnant Aptima specimens in the case of N. 
gonorrhoeae and C. trachomatis.  
 
The other key concern when performing WGS from remnant Aptima specimens is the presence of 
reads from other microbial species and contamination with host (i.e. human) DNA (20). A large 
number of human reads (i.e. 99%) in all 9 remnant Aptima specimens indicate the need to develop 
more efficient methods to extract human DNA prior to genome sequencing. The screening of AMR 
determinants against assembled contigs indicated that at least 5% reads from N. gonorrhoeae 
should be present in the WGS data to determine an isolate’s susceptibility profile when using 
remnant Aptima urine specimen. Further studies where WGS data is obtained from other types of 
clinical specimens (i.e. urines, swabs) are needed to validate our findings.  
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